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Historically, women with pre-existing liver disease were advised against pregnancy due to concerns 
regarding the potential for worsening of liver function, hepatic decompensation and death. The available 
literature detailing outcomes of pregnancy in women with liver disease is sparse, combining this with the 
fact that the term “liver disease” incorporates a spectrum of severity from a variety of underlying 
aetiologies means that generic advice regarding pregnancy risk is clearly not appropriate for all women. In 
addition, women with previously normal hepatic function may develop acute liver failure in pregnancy 
which is associated with high morbidity and mortality. Data regarding early identification of women at 
high risk of death from liver failure is lacking. 
   This body of work addresses the paucity of information regarding pregnancy risk in women with 
liver disease. The potential risks related to pregnancy for the mother, baby and graft in the context of 
different diseases and underlying severity are explored and detailed. Pre-conception parameters are 
identified which can predict poor pregnancy outcomes in women with different aetiologies of liver 
disease and severity. The King’s College Hospital poor prognostic criteria in patients with pregnancy 
associated acute liver failure (ALF) are shown not to be applicable to this unique cohort of patients and 
alternative early poor prognostic indicators are suggested. 
 This work should enable individualised advice regarding pregnancy risk to be given to women 
with liver disease who are considering pregnancy, increase our understanding of specific complications a 
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Chapter 1: Introduction 
The effects of a normal pregnancy on the liver from a physiological stand point are well 
understood. In contrast the effects of pregnancy on the outcomes of patients with liver disease 
are poorly understood.  
Historically, women with pre-existing liver disease were advised against pregnancy due 
to concerns regarding the effect of pregnancy on the underlying liver condition. These concerns 
related to the potential for worsening of liver function, hepatic decompensation and death. 
Concerns also existed regarding poor foetal outcomes and the potential risk of congenital 
abnormalities secondary to medication. The available literature detailing outcomes of 
pregnancy in women with liver disease is sparse, and for the majority of women information is 
limited to case reports and small case series only. The available literature is outlined in detail in 
this and subsequent chapters and reports variable outcomes for mother, liver and foetus in 
heterogeneous small cohorts of women with liver disease. This has resulted in women with liver 
disease being given generic advice, with little individual applicability regarding the safety of 
pregnancy.  
This combined lack of information alongside the fact that the term “liver disease” 
incorporates a spectrum of severity ranging from mild abnormalities in liver enzymes to 
cirrhosis and its complications, or acute liver failure adds to the confusion. Moreover, given the 
variety of underlying diseases with their differing pathophysiologies, generic advice regarding 
risk is clearly not appropriate for all women. More information detailing the outcome and risk 
for individualised cohorts of women is therefore required so that appropriate pre-conception 
counselling can be undertaken along with the necessary care throughout pregnancy, delivery 
and the post-partum period.  
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In addition, women with previously normal hepatic function may develop acute liver 
failure in pregnancy which is associated with a high maternal morbidity and mortality. Again the 
published literature regarding poor prognostic outcomes and indications for consideration for 
liver transplantation is extremely limited. 
This thesis aims to address the paucity of information regarding pregnancy risk in women 
with liver disease and hopes to improve preconception counselling, pregnancy management in 
women with liver disease and maternal and foetal outcomes.  
1.1 Normal physiological changes during pregnancy 
The majority of pregnant women are young and healthy and as a result have an uneventful 
pregnancy. When pregnant, many physiological changes and hormonal changes occur within the 
human body, some of which can mimic the signs and symptoms often seen in women with liver 
disease. These normal physiological changes associated with pregnancy need to be recognised 
and understood as no specific treatment or monitoring is required. Furthermore, a good 
understanding of what a normal pregnancy entails allows early detection and access to 
treatment in those who may develop liver disease and a consequence of pregnancy. (1) 
A rise in maternal heart rate and cardiac output along with a fall in blood pressure all occur 
in a normal pregnancy. (2) A physical examination of a pregnant women may show palmer 
erythema and the presence of multiple spider naevi in up to 70%. (3) Spider naevi are angiomas 
which are found in the distribution of the superior vena cava thus commonly seen on the face, 
neck, upper trunk and arms. They occur due to dilatation of the cutaneous arterioles driven by 
increased circulating oestrogen levels. Due to their pathophysiology they are common in 
pregnancy women, those on hormonal contraception and women with liver disease as the liver 
is responsible, in part, for metabolising oestrogen. Palmer erythema is a mottled, red 
colouration mainly over the thenar and hypothenar eminences in the hands occurring 
secondary to cutaneous vasodilatation and a hyper dynamic circulation. It is a clinical sign that is 
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fairly non-specific and seen in heathy individuals. Indeed, any patient that may have a hyper 
dynamic circulation, i.e., those with hyperthyroidism and patients with liver disease. Pregnant 
women have a hyper-dynamic circulation with the plasma volume estimated to increase by 30% 
and the cardiac output by 40%, which peaks at 32 weeks gestation. (4) Despite this, blood flow 
to the liver remains relatively constant during pregnancy and it remains impalpable as it is 
displaced upwards into the thoracic cavity due to the expanding uterus. 
Biochemical and haematological indices taken during pregnancy need to be interpreted in 
light of the normal physiological changes that occur in test results as a consequence of 
pregnancy. (5) The maternal alkaline phosphatase (ALP) can increase 2-4 times the upper limit 
of normal especially in the third trimester where ALP is produced both from the placenta and as 
a result of foetal bone development. The alpha fetoprotein (AFP) level increases in pregnancy as 
AFP is produced by the foetal liver. A marked increase however may reflect an underlying neural 
tube defect of the foetus. Other common biochemical and haematological tests including 
gamma-glytamyl transpepidase (GGY), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), bilirubin, total protein levels, albumin, urea, haemoglobin levels and 
the prothrombin time remain unchanged or slightly reduced due to haemodilution as a 
consequence of increased circulating plasma volume that occurs with pregnancy. (5) Therefore 
elevations in transaminases, bilirubin or the prothrombin time are abnormal and indicate a 
pathological state which requires further assessment. Pregnancy is also recognised as a pro-













1st Trimester 2nd Trimester 3rd Trimester 
ALT (IU/L) 0-40 6-32 6-32 6-32 
AST(IU/L) 7-40 10-28 11-29 11-30 
Bilirubin 
(µmol/L) 
0-17 4-16 3-13 3-14 
GT (IU/L) 11-50 5-37 5-43 3-41 
ALP (IU/L) 30-130 32-100 43-135 133-418 
      Albumin 
(g/L) 
35-46 
28-37 28-37 28-37 
Bile acids 
(µmol/L) 
       0-14 




110-135 103-130 100-130 
 
Small clinically insignificant oesophageal varices can occur in up to 50% of pregnant women 
in the late second and third trimester. These occur due to compression of the inferior vena cava 
by the enlarging uterus and a reduction in venous return. 
Liver biopsy in pregnancy does not carry additional risks. Despite the hyper dynamic 
circulation and increased plasma volume the total blood volume to the liver remains constant, 
with the majority of excess blood shunted through the placenta and the bleeding risk is not 
thought to be increased. Liver histology is practically normal in the pregnant women, however 







1.2 Tolerance of the immune system in pregnancy 
The human immune system has evolved to combat potential foreign pathogens and 
provide protection from disease. The innate immune system recognises “danger” and rapidly 
initiates generic immune responses. The adaptive immune system is provided by T- and B- 
lymphocytes and is characterised by antigen specificity and the generation of memory for a 
heightened specific response to subsequent antigen exposure. 
Pregnancy was historically regarded as an immunological paradox where the maternal 
immune system tolerates the presence of a foetus expressing paternal antigens. (7) This 
phenomenon occurs as several specialised mechanisms have evolved which help the foetus 
evade attack from the maternal immune system. Firstly foetal tissue depletes tryptophan, an 
amino acid which is essential for rapidly dividing cells, and thereby inhibiting T-cell production. 
(8, 9) Secondly the foetal tissue expresses human leucocyte antigen G1, which inhibits natural 
killer cell activation and finally the foetal-maternal interface is a highly organised structure that 
provides an anatomical barrier. (10, 11) 
More recently the up-regulation of regulatory T-cells has been shown to play a pivotal 
role in foetal-maternal tolerance. (12, 13) Regulatory T-cells are required for the maternal 
immune system to tolerate the foetal allograft, and there is an increase in their circulating 
number during pregnancy. (12, 13) The up-regulation of T-cells during pregnancy is thought to 
be hormonally driven. High concentrations of oestrogens are thought to inhibit immune 
activities whilst progesterone promotes T helper 2 cells and in itself had anti-inflammatory 
properties. (14, 15) 
The above concept of tolerance is key to understand the phenomenon of an 
improvement in disease followed by a flare in the post-partum period in many autoimmune 
conditions including autoimmune hepatitis (AIH) and rheumatoid arthritis. (16) The mechanism 
for this phenomenon in autoimmune conditions is incompletely understood. It is likely, in-part, 
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related to the fact that pregnancy induces the temporary development of immunological 
tolerance in order to allow the mother to tolerate the antigens expressed from the father by the 
foetus. Recent advances in the understanding of the aetiopathogenesis of AIH has 
demonstrated that it is an impairment in regulatory T-cells that is key to the loss of immune 
tolerance in AIH and thus the emergence of uncontrolled effector autoimmune responses. (17, 
18) Taking into account the above factors, it becomes clearer why patients with AIH, and indeed 
other autoimmune conditions, may induce remission during pregnancy and then flare in the 
post-partum period, such that when pregnancy ends, tolerance breaks down and flares in 
disease activity occur. Although this hypothesis has never been scientifically proven, it is 














1.3 Pregnancy related liver disease 
The liver diseases specific to the pregnant state are the most frequent cause of liver 
dysfunction in pregnancy and are reported to complicate up to 3% of all pregnancies. (19) 
Severe liver disease occurring in pregnancy is associated with significant morbidity and mortality 
for both the mother and baby. Early recognition, prompt delivery of the foetus and supportive 
care remain the key pertinent areas of management. The liver diseases specific to the pregnant 
state can be classified into those of early pregnancy (hyperemesis gravidarum) and those of late 
pregnancy (acute fatty liver of pregnancy (AFLP), pre-eclampsia with hepatic involvement 
including the haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome, liver 
rupture/infarction and intrahepatic cholestasis of pregnancy).  
1.3.1 Hyperemesis Gravidarum 
Hyperemesis gravidarum is defined as intractable vomiting, resulting in dehydration, 
ketosis and weight loss of greater than 5%. It complicates between 0.3% and 2% of pregnancies 
and symptoms usually but not exclusively begin before 9 weeks gestation. (20, 21) The cause is 
unclear, but it is likely multi-factorial in origin contributed to by the autonomic nervous system 
and altered gastric motility along with high serum concentrations of human chorionic 
gonadotrophin (HCG) hormone and oestrogen. (20) 
Biochemical abnormalities are common and include renal dysfunction secondary to 
dehydration, electrolyte abnormalities including hypokalaemia and hypomagnesaemia 
secondary to vomiting and reduced oral intake. Abnormalities in hepatic enzymes occur in 
approximately 50% of cases that require hospitalisation with serum aminotransferases usually 
2-4 times the upper limit of normal. Jaundice can occur in those patients severely affected but is 
usually mild with bilirubin levels less than 4-times the upper limit of normal. Prompt treatment 
is essential as HG accounts for approximately one maternal death per year in the UK. This 
includes intravenous rehydration, correction of hyponatraemia and hypokalaemia, thiamine 
21 
 
supplementation, thromboprophylaxis and antiemetic treatment to enable slow reintroduction 
of oral fluids and diet. Hepatic biochemical abnormalities more than those outlined above or fail 
to resolve on resolution of the vomiting should raise the suspicion of an alternative cause for 
the abnormal hepatic biochemistry, including viral hepatitis, autoimmune hepatitis and Budd-
Chiari syndrome.   
1.3.2 Intrahepatic cholestasis of pregnancy  
Intrahepatic cholestasis of pregnancy (ICP) is the commonest pregnancy-specific liver 
disease. It is a reversible form of cholestasis characterized by pruritus in pregnancy and elevated 
fasting or post prandial serum bile acids with spontaneous relief of signs and symptoms within 6 
weeks of delivery.(22) ICP has a high recurrence rate in subsequent pregnancies. It has a 
variable incidence, ranging from 3-5% of pregnant women in Chile to 0.7% in the UK; it is rarely 
reported in African countries. (23) ICP typically presents in the third trimester but it can present 
as early as 7 weeks of gestation. It occurs more commonly in multiple pregnancy and in women 
that have received fertility treatment. ICP has a complex aetiology with genetic, endocrine and 
environmental components. It is likely that elevated estrogen (24) and progesterone 
metabolites (25) in pregnancy unmask the disease in genetically susceptible women. The 
alteration in female sex hormones that occur during pregnancy are postulated to have a direct 
inhibitory effect on the bile salt export pump leading to impaired biliary transport across the 
canalicular membrane and thus induction of cholestasis. Approximately 15% of cases have 
genetic variation in one of the hepatocanalicular transport proteins (ABCB11 (bile salt export 
pump) or ABCB4 (phosphatidylcholine floppase). Smaller studies have reported genetic variation 
and/or heterozygous mutations in ABCC2 (conjugated organic anion transporter), (26) ATP8B1 
(FIC1)) (27, 28) and the nuclear bile acid receptor. (farnesoid X receptors) (27, 29) The maternal 
mortality is low however it is a hepatic complication of pregnancy which carries with it a serious 
foetal risk and thus must be correctly identified and managed. 
22 
 
The initial and most characteristic symptom is pruritus which is often worse at night. 
Patients commonly complain of generalised pruritus, but with the palms and soles most 
severely affected. In its severe form, the pruritus can be intractable and intolerable leading to 
insomnia, excoriated skin with secondary infections, depression and in extreme cases, suicidal 
ideation. The only associated rash is secondary to excoriations from scratching. Some women 
also complain of dark urine and pale faeces.  
Laboratory investigations confirm the presence of cholestasis with the key diagnostic 
test being a fasting serum bile acids concentration of >14umol/L. (30) The alkaline phosphatase 
levels are modestly elevated (3-5 times the upper limit of normal) but with a normal or 
minimally elevated gamma glutamyl transpeptidase (GGT) levels. The level of serum 
aminotransferases are often also elevated and, in severe forms can be as high as 1000IU/L, thus 
making the differentiation from other causes of pregnancy associated liver diseases and acute 
hepatitis challenging. Jaundice occurs in about 25% of cases, usually 2-4 weeks after the onset 
of pruritus. The hyperbilirubinemia is predominantly conjugated and levels rarely rise above 
100g/dl. The prognosis is usually favourable for the mother and both the clinical and 
biochemical signs disappear spontaneously after delivery. A liver biopsy is not generally 
required unless the diagnosis is in doubt. Histological findings include dilated bile canaliculi 
containing bile plugs with sparing of the periportal areas. The hepatocellular architecture 
remains unaltered. 
Serum bile acid measurement is the most useful biochemical test as the two largest 
prospective cohort studies of perinatal outcomes in ICP reported an association between the 
maternal serum bile acid concentration and the risk of adverse pregnancy outcome 
(spontaneous and iatrogenic preterm labour, stillbirth and admission to the neonatal unit). (30, 
31) Adverse outcomes are rarely reported in pregnancies where the maternal bile acid level is 
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below 40µmol/L, and the risk of complications increases as the mother’s serum bile acid level 
rises. (30, 31)  
The intense cholestasis which occurs in IHCP can be associated with clinical or sub-
clinical steatorrhoea. This can lead to the development of a deficiency in fat soluble vitamins, in 
particular vitamin K, which in turn can be associated with a prolonged prothrombin time. This 
cause of a prolonged prothrombin time must be identified and differentiated from the 
coagulopathy seen in acute liver failure.  
Management for the mother is centred on symptomatic relief, close monitoring and 
early delivery of the foetus. The first line treatment for ICP is ursodeoxycholic acid ((UDCA, 
(15mg/KG/Day)) which results in improved maternal symptoms and biochemistry in 
approximately 75% of cases. (22, 32-35) In vitro and in vivo experiments demonstrate that UDCA 
enhances trans-placental transport of bile acids from the fetus to the mother and reduces 
placental damage.(23) A meta-analysis (34) and in vitro experiments (36, 37) suggest that its use 
may positively impact on the frequency of preterm labour, neonatal unit admission, placental 
damage and fetal arrhythmias. Rifampicin, is a potent pregnane X receptor (PXR) agonist. In ICP, 
combining rifampicin with UDCA improves the severity of cholestasis in approximately one third 
of women that do not respond to UDCA alone. (38) 
ICP has a high recurrence rate in subsequent pregnancies, although the severity may 
vary from one pregnancy to the next. Affected women also have an increased risk of 
hepatobiliary disease later in life, most commonly gallstones (perhaps due to a common risk 
factor (ABCB4 gene)), hepatobiliary malignancies and immune-mediated and cardiovascular 
diseases.(39-41) A high prevalence of hepatitis C infection in women with ICP has been 
reported, (39) whether this reflects an enhanced susceptibility to Hepatitis C infection in women 




1.3.3 Acute fatty liver of pregnancy 
Acute fatty liver of pregnancy (AFLP) is a medical and obstetric emergency as it can be 
fatal for both the mother and baby without early recognition and appropriate management. 
(42, 43) It is a rare complication of pregnancy, usually occurring in the third trimester, and in the 
UK affects approximately 1 in 20,000 pregnancies, (44) with the true incidence likely however to 
be higher with underreporting of subclinical / milder forms.  Risk factors include nulliparity, 
male infants and twin pregnancies.     
The presentation is similar to that of mitochondrial cytopathies (Reye’s syndrome and 
tetracycline and sodium valproate toxicity) and an abnormality in mitochondrial Beta oxidation 
is a recognised cause of AFLP in a subset of cases. (43, 45). An abnormality in mitochondrial B 
oxidation is the recognised cause of AFLP. The enzyme long-chain 3-hydroxyacyl coenzyme A 
dehydrogenase is a key part of the mitochondrial trifunctional protein (MTP). (45) Neonates 
born to mothers with AFLP have been shown to have defects in B oxidation and to be deficient 
in long-chain 3-hydroxyacyl coenzyme A dehydrogenase due to mutation on one or both alleles 
of the α subunit of the trifunctional protein. Mothers of neonates with a long-chain 3-
hydroxyacyl coenzyme A dehydrogenase deficiency have been shown to have a 79% chance of 
developing ALFP or HELLP. (45) Other reports have shown a 20-fold increased risk of maternal 
liver disease in pregnancy in foetuses with fatty acid oxidation defects. (46) The pathogenesis is 
that of foetal fatty acids accumulating due to the genetic defect and returning to the mother via 
the placenta. They are then deposited in the liver and present phenotypically as maternal liver 
disease.  
The onset is usually between the 30th and 38th gestational week with a varied clinical 
presentation. Presenting features range from non-specific symptoms such as nausea, vomiting 
and abdominal pain to those of acute liver failure including hypoglycaemia, coagulopathy, 
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jaundice and encephalopathy. (19, 46) Pre-eclampsia is common but not invariable. (43) Risk 
factors include nulliparity, male infants and twin pregnancies. (47) 
Biochemical changes include hyperbilirubinaemia, usually 6-8 times the upper limit of 
normal and a moderate transaminitis occurs usually less than 750IU/L. (5) In addition, serum 
ammonia, lactic acid and amino acid levels are increased reflecting mitochondrial failure. Renal 
dysfunction, leucocytosis and thrombocytopenia’s are common. (5) The prothrombin time is 
prolonged and fibrinogen levels are reduced; disseminated intravascular coagulation is seen in 
approximately 10%. Other potential complications include ascites, pleural effusions, acute 
pancreatitis, respiratory and renal failure. Infections are common as is vaginal bleeding or 
bleeding from caesarean section wounds.  
The definitive diagnosis of AFLP is made histologically. The characteristic findings are 
micro and macro vesicular fat droplets with ballooned hepatocytes containing dense central 
nuclei. The periportal areas are often spared. The microvacuoles may be clearly recognised only 
on fresh sections stained for fat with an oil red O stain. In severe cases hepatocytes necrosis can 
be seen. Recently clinical diagnostic criteria have been developed and validated for AFLP aiding 
rapid diagnosis without the need and associated risks of a liver biopsy. (19, 44) 
Early recognition with rapid delivery of the foetus followed by maternal supportive care 
vastly improves prognosis for both the mother and the baby. (48) Maternal mortality rates have 
been reported to be as high as 92% prior to 1970, (49) but subsequently, overall mortality rates 
have improved, with rates of less than 10% reported in 2008. (42) The use of plasma exchange 
following delivery results in improved clinical outcomes including reduced maternal mortality in 
non-randomised clinical trials. (50-52) Successful liver transplantation in this group has been 
sporadically reported, however the indications for liver transplantation in this unique cohort 
















1.3.4 Hypertension related liver disease of pregnancy 
Hypertension in pregnancy is defined as a blood pressure of greater than 140/90 mmHg 
on at least two occasions. The hypertension related complications of pregnancy include pre-
eclampsia, eclampsia, hepatic infarction, hepatic rupture and the HELLP (haemolysis, elevated 
liver enzymes and low platelets) syndrome. Hypertension in pregnancy is associated with 
hepatological involvement ranging from mild abnormalities in the liver function tests to the 





Six or more of features below in the absence of other aetiology 
• Vomiting 
• Abdominal Pain 
• Polydipsia / Polyuria 
• Encephalopathy 
• Bilirubin (>14 µmol/L) 
• Hypoglycaemia (<4 mmol/L)  
• Leucocytosis (>11x10⁶/L) 
• Elevated uric acid (>340 µmol/L) 
• Elevated ammonia (>42IU/L) 
• Ascites or bright liver on USS 
• Elevated Transaminases (>42 IU/L) 
• Renal impairment  (Creatinine > 150 µmol/L) 
• Coagulopathy (PT >14s or APTT >34s)  




1.3.5 Pre-eclampsia and eclampsia 
Pre-eclampsia is a multisystem disorder defined as sustained hypertension after the 20th 
week of pregnancy (BP 140/90 or higher in a previously normotensive woman) and proteinuria 
(greater that 300mg in 24 hours). (55) It can present as late as 4 week’s post-partum. (55) In a 
patient with pre-existing essential hypertension, preeclampsia is diagnosed if systolic blood 
pressure has increased by 30 mmHg or if diastolic blood pressure has increased by 15 mm Hg. 
(55) Pre-eclampsia affects between 3-5% of all pregnancies, and it occurs more commonly in 
women who are primiparous, those with multiple pregnancies and women at extremes of child-
bearing age. (56) It also occurs more commonly in women with pre-existing hypertension, renal 
disease, diabetes mellitus and obesity, and in those with previously affected pregnancy or 
positive family history of pre-eclampsia. (55, 56) The presence of seizures differentiates pre-
eclampsia from eclampsia. Pre-eclampsia and eclampsia were historically termed “toxaemia of 
pregnancy”.  
The aetiology of pre-eclampsia is incompletely understood and is thought to be 
multifactorial with evidence for several mechanisms including; immunological (impaired 
maternal tolerance against paternal and fetal antigens), abnormal trophoblastic invasion (57), 
genetic predisposition (58) and vascular dysfunction with a systemic imbalance between 
prosatcylin and thromboxane. (59-61) The trophoblast fails to invade the uterine lining, 
resulting in defective arterial placental perfusion which worsens as the pregnancy progresses 
and the demand on the placenta increases. (62) Nitric oxide, prostaglandins and endothelin 
from the placental tissue are released which induce platelet aggregation, endothelial 
dysfunction and arterial hypertension. Fibrin released from endothelial damage forms 
crosslinked networks in the small blood vessels resulting in a microangiopathic haemolytic 
anaemia. The pathogenesis of liver involvement is postulated to be secondary to fibrin 
deposition within the hepatic sinusoids resulting in sinusoidal obstruction and subsequent 
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hepatic ischaemia. It is the combination of hepatic sinusoidal obstruction and ischaemia that 
results in the feared complications of subcapsular haematomas, parenchymal haemorrhage and 
ultimately hepatic rupture. (63) 
Clinical features of pre-eclampsia include right upper quadrant pain, headache, visual 
changes, nausea and vomiting. Many women are hyper-reflexic and oedema is common. 
Abnormal liver function tests are seen in about 30% of cases. Thrombocytopenia is also 
common. Liver biopsy is not indicated, but when performed shows characteristic periportal 
changes with haemorrhage, sinusoidal fibril deposition and hepatocyte necrosis. The 
derangement of LFT’s in patients with pre-eclampsia and eclampsia should highlight the 
presence of severe disease and the need for emergency delivery should be considered. Delivery 
will result in resolution of the disease, although some cases worsen for several days 
postpartum. Women should be treated with glucocorticoids to enhance fetal lung maturation if 
the fetus is <34 weeks’ gestation. If rapid hypertensive control and delivery is not achieved, 
women are at risk of renal dysfunction, cerebral haemorrhage, hepatic infarction, haematomas 
or rupture with markedly increased perinatal mortality and morbidity. 
 
1.3.6 HELLP Syndrome 
HELLP syndrome is the most common hepatic manifestation of the hypertensive related 
pregnancy complications. It was first describes by Weinstein in 1982 and occurs in 
approximately 10-20% of women with pre-eclampsia. (64-66) It carries with it a high infant 
mortality rate. (67) Although HELLP is recognised to complicate pre-eclampsia in up to 20% of 




The diagnosis is based mainly on clinical grounds. The presenting symptoms are varied 
and include right upper quadrant or epigastric pain in approximately 65% of cases, nausea and 
vomiting (35% of cases), headache (31% of cases) and rarer complaints including bleeding and 
jaundice. (68) A significant number of patients are asymptomatic. (68) On examination 
hypertension is evident in up to 85% and proteinuria is common. Laboratory investigations 
show elevated transaminases (10-20 times the upper limit of normal), evidence of haemolysis 
with a raised lactate dehydrogenase (LDH), decreased haptoglobin and a mild increase in 
unconjugated bilirubin along with thrombocytopenia (usually less than 100x 10⁹/L). (5) 
Disseminated intravascular coagulation can occur in which case there will be evidence of 
elevated fibrin degradation products, a low fibrinogen and a secondary rise in the prothrombin 
time.  
There have been two classification systems developed for HELLP syndrome, the 
Tennessee and the Mississippi triple classification system. The Mississippi classification was 
initially developed in 1999 and revised in 2006. (65, 69) It classifies HELLP syndrome into 2 
subsets. Class 1 requires the presence of severe thrombocytopenia (platelets ≤50x10⁹/L), 
evidence of hepatic dysfunction (AST and/or ALT ≥70IU/L), and evidence suggestive of 
haemolysis (total serum LDH ≥600IU/L); class 2 requires similar criteria except 
thrombocytopemia is moderate (>50-100x10⁹/L); and class 3 includes patients with mild 
thrombocytopenia (platelets 100-150x10⁹/L), mild hepatic dysfunction (AST and/or ALT 
>40IU/L), and haemolysis (total serum LDH ≥600IU/L). (65) The Tennessee consists of two 
subsets, complete and partial. (70) Complete HELLP consists of demonstration of haemolysis on 
a peripheral blood film with a raised LDH >600 IU/L, thrombocytopenia <100x10⁹/L and 
elevated transaminases AST>70IU/L. Partial HELLP syndrome is characterised by 1 or 2 of the 
above components. (70) 
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Table 1.3.6 Classification systems used in HELLP Syndrome 
 
Imaging of the abdomen should be considered in all women with HELLP and is 
imperative in those with abdominal pain, shoulder tip pain or hypotension. (71) This in to 
investigate for the feared complications of HELLP syndrome including hepatic haemorrhage, 
rupture and infarction which have been reported to occur in up to 45% of women with HELLP 
syndrome. 
Liver biopsy is rarely undertaken as the diagnosis is based on clinical criteria and due to 
the risks of haemorrhage in association with co-existent thrombocytopenia. In cases where liver 
biopsy has been performed, the microscopic findings are similar to those seen in pre-eclampsia 
Tennessee Classification 
 Complete HELLP requires all of 
o Haemolysis on peripheral blood film 
o AST >70 IU/L 
o LDH >600 IU/L 
o Platelets <100 x 10⁹/L 
 Partial HELLP requires 2 of 
o Haemolysis on peripheral blood film 
o AST >70 IU/L 
o LDH >600 IU/L 
o Platelets <100 x 10⁹/L 
 
Mississippi Classification: 
 AST >40 IU/L and LDH > 600 IU/L and 
o Class I: Platelets <50 x10⁹/L 
o Class II: Platelets 50-100 x10⁹/L 
o Class III: Platelets 100-150 x10⁹/L 
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consisting of periportal haemorrhage and fibrin deposition with periportal hepatocyte necrosis. 
Macro and micro vesicular fat is present but is usually modest in comparison to AFLP. (72) 
In the majority of patients the above abnormalities resolve shortly after the delivery of 
the foetus, which is the treatment of choice. Untreated patients however can progress to 
hepatic and renal failure, hepatic rupture and ultimately death. Thus women with HELLP 
syndrome are often monitored in a high dependency unit. The management is supportive, and 
the foetus should be delivered as soon as possible by the safest route, especially if the foetus is 
beyond 34 weeks gestation, foetal distress in evident or there is evidence of maternal 
deterioration. Hypertension should be treated with labetalol. Patients may require coagulation 
support. If gestation is less than 34 weeks, corticosteroids should be given to promote foetal 
lung maturity. Outcomes at the more severe end of the spectrum are difficult to predict and 
prognostic information is limited to small series. (73, 74) 
 
1.3.7 Hepatic rupture, Infarction and Haematoma 
Hepatic haemorrhage and rupture can complicate pre-eclampsia, eclampsia, HELLP 
syndrome and patients with AFLP with a 50% mortality reported. (68) Patients present with 
abdominal pain, pyrexia and if severe hypovolaemic shock and cardiovascular collapse. 
Laboratory investigations reveal transaminases in the several thousands, leucocytosis and 
anaemia. Imaging in the form of computed tomography or magnetic resonance is the 
investigation of choice. (71) Contained haematomas can be managed conservatively with 
aggressive coagulation support, prophylactic antibiotics and transfusion as required. (75) If 
there is any evidence of haemodynamic instability, then urgent angiography with hepatic artery 
embolization and/or surgical intervention is warranted. Surgical intervention includes packing of 
the liver, hepatic artery ligation and resection. (71, 76)  
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Necrotic infarcts can also occur as a complication of pre-eclampsia. Patients often have 
an unexplained rise in their transaminases to several thousand, fever, anaemia and leucocytosis. 
There may be associated signs of liver failure. In the majority of cases the liver recovers 
however with areas of extensive infarct death from multi organ failure or hepatic rupture can 
ensue.  
 
1.3.8 Acute liver failure in pregnancy 
In the pregnancy specific liver diseases outlined above there is a wide spectrum of 
disease severity ranging from minor biochemical abnormalities to severe liver disease resulting 
in acute liver failure (ALF). 
Acute liver failure is a clinical manifestation of a sudden and severe hepatic insult that 
can arise from many different causes. The abrupt loss of the hepatic metabolic and immunologic 
function results in hepatic encephalopathy, coagulopathy and progressive multi-organ failure. 
Acute liver failure in the United Kingdom is classified according to the time from insult to 
hepatic encephalopathy. The terms hyper acute, acute and subacute describe encephalopathy 
within 7 days, 8-28 days and more than 28 days respectively. (77) The natural history is variable 
and survival without liver transplantation (LT) ranges from 10-90% mostly dependent on the 
underlying aetiology, grade of encephalopathy and presence of multi organ failure. (78) Survival 
has been transformed by the introduction of emergency LT, which now forms part of the 
routine care for patients with ALF. 
 
As survival from ALF is variable, identification and selection of those patients with ALF 
who are likely to benefit from emergency LT is crucial. Inaccurate selection criteria will result in 
subjecting a patient that would have recovered with medical management to a life of 
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immunosuppression, its side effects and increased mortality. Furthermore, failing to identify a 
patient with ALF who would survive only with LT, is meaning their death is inevitable.  
Different selection criteria for emergency LT have been developed based on 
multivariate analysis of survival factors from non-transplanted patients with ALF. The original 
King’s College criteria for non-paracetamol acute liver failure, identify patients with ALF early in 
their clinical course that are at high risk of death and thus may benefit from LT. (78) The criteria 
state that death is likely without LT if the patient is encephalopathic (any grade) with an INR of 
greater than 6.5, or any three parameters from the variables of age greater than 40 years, 
unfavourable aetiology, INR greater than 3.5, serum bilirubin greater than 300µmol/L or interval 
of jaundice to development of encephalopathy of greater than 7 days. (78) The Clichy-Villejuif 
criteria also identify patients with ALF at risk of death without LT. The criteria state that LT 
should be considered if there is the presence of grade 3 encephalopathy and factor V 
concentrations of less than 20% in patients aged less than 30 years or the presence of grade 3 
encephalopathy and factor V concentrations of less than 30% in patients aged more than 30 
years. (79) 
In patients with pregnancy induced ALF, the King’s College criteria have never been 
validated, nor indeed were any patients with pregnancy associated ALF included in the original 
cohort when the criteria were established. (78) This raises the question as to whether 
“standard” King’s criteria are applicable for assessing poor prognosis and need for LT in this 
individual cohort of patients. Furthermore it suggests that patients with pregnancy induced ALF 
could be receiving unnecessary LT or perhaps more concerning we may be falsely reassured by 
those patients not meeting poor prognostic signs which have never been assessed or validated 








1.3.9 Liver transplantation for the pregnancy specific liver disorders 
Liver transplantation for pregnancy associated ALF is uncommon and information 
regarding the indications for and outcomes of transplantation is limited for both the patient and 
the graft. (53, 73, 80) 
Reported literature on transplantation for both HELLP syndrome and AFLP is sparse. The 
largest single experience for HELLP syndrome consists of 7 patients. (80) A review of the 
published literature in 2008 found 9 reported cases, (81-86) and an addition 8 cases were 
identified from review of the united network for organ sharing (UNOS) database. (73) Of the 17 
Kings College Criteria identify patients at risk of death without early liver 
transplantation in non-paracetamol-induced acute liver failure 
EITHER both of 
 Prothombin time (PT) >100s (INR > 6.5)  
 Presence of hepatic encephalopathy 
 
OR any encephalopathy plus any three of the following five criteria 
 Patient age 40 years 
 Serum bilirubin >300 µmol/L 
 Duration of jaundice before the onset of encephalopathy >7 days 
 PT >50s (INR > 3.5) 




patients, a 17% overall mortality was reported. The authors suggested that the indications for LT 
in HELLP syndrome were; persistent bleeding despite surgical intervention, extensive liver 
necrosis or liver failure, whereas contained haematoma should be managed conservatively with 
close haemodynamic monitoring and repeated imaging. (87)  
Reports of LT for AFLP are sporadic. (53, 54) Outcomes appear largely favourable. The 
European Liver Transplantation registry (ELTR) database has recorded the majority of all 
transplant activity since 1968. During this period there have been 6 LT’s performed for AFLP 

















1.4 Cirrhosis in Pregnancy 
1.4.1 Abnormalities in gonadal and sex hormones in cirrhosis 
End-stage liver disease alters the physiology of the hypothalamic-pituitary-gonadal axis. 
The majority of the work highlighting the endocrine disorders that occur in conjunction with 
chronic liver disease has been carried out in men. In males, cirrhosis has been shown to be 
associated with reduced circulating testosterone, (88-90) low levels of gonadotrophins, 
luteinising hormone (LH) and follicle stimulating hormone (FHS), resulting in a hypogonadal 
state. In addition, serum oestrogens and prolactins are elevated in cirrhotic men which may 
further impact sexual dysfunction. (89, 91, 92) The above disorders in sex hormones can occur 
in any patient with cirrhosis, however it has been suggested that alcohol consumption may have 
additional detrimental effects on the hypothalamic-pituitary-gonadal axis. (92) Functional 
studies and questionnaire based studies report that erectile dysfunction is common in males 
with cirrhosis. Studies also report impotence rates of between 60-90%, reduced libido/interest 
in sex and a decreased volume of ejaculatory fluid. (89, 93)  
In women with cirrhosis, fertility is reduced. This is due to a combination of metabolic 
endocrine, nutritional and sexual dysfunction. (94-98) The incidence of amenorrhoea / oligo 
amenorrhoea has been reported to be 60% in women of child bearing age awaiting liver 
transplantation. (99, 100) The cause for the amenorrhoea is complex. In women with cirrhosis 
like men, a reduction in the gonadotrophins (FSH and LH) has been demonstrated implying 
dysfunction of the hypothalamic-pituitary axis. (101) In cirrhotic patients, disruption of the 
hypothalamic-pituitary axis in conjunction with disturbed oestrogen metabolism occurs 
resulting in infertility. (97) Cundy et described 2 distinct hormonal profiles in women with 
cirrhosis and amenorrhoea. (97) The first suggests a hypothalamically driven process with low 
serum gonadotrophins, oestradiol and testosterone levels in association with a low body mass 
index. (97) This profile mimics those seen in patients with secondary amenorrhea due to 
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anorexia nervosa and suggests that chronic under-nutrition in patients with cirrhosis is likely to 
impact on fertility. The second is a cohort of patients with normal nutritional and gonadotrophin 
status. (97) This group has higher oestradiol and testosterone levels mimicking profiles seen in 
patients with amenorrhoea due to polycystic ovarian syndrome. Amenorrhoea and infertility 
driven by underlying cirrhosis is largely irreversible unless liver transplantation is performed. 
(96) 
 
1.4.2 Sexual functioning in patients with cirrhosis 
Chronic illness is acknowledged to be associated with sexual dysfunction. The cause for 
this is often multifactorial contributed to by the physical effects of illness such as malaise, 
fatigue and in males the presence of impotence. However a wider range of social and 
psychological factors including altered body image, lack of self-esteem, feelings of guilt and, for 
women, loss of their role as the primary care giver have all been reported as causes for 
decreased libido in association with chronic disease. (93) 
In women with cirrhosis, sexual functioning has been largely over-looked. A recent 
study comprising of interviews on sexual function in 71 women undergoing assessment for liver 
transplantation reported that 56% had no sexual activity and 13% reported a decrease in sexual 
activity, with the greatest decrease being in those women with more severe liver disease as 
assessed by the model for end stage liver disease (MELD). (93) 
Sexual interaction helps to foster and maintain long term secure relationships which 
help patients thrive after LT. Sexual health has been poorly studied in patients with chronic liver 
disease and also in those after LT, despite its importance to recipients and their partners. This is 
likely to reflect other demands on physician’s time regarding assessment for LT or maintaining 
good graft function. In addition, academically it is a difficult area to study with sexual practices 
varying widely amongst patients, and finally the subject matter still has a taboo around it. 
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1.4.3 Assisted Conception 
 In light of the above physiological changes, women with cirrhosis can often have 
difficulty conceiving and request advice regarding assisted conception. To-date, no published 
data, information or guidelines exist regarding the maternal safety and success rates of assisted 
conception (AC) in this unique cohort. Theoretically pregnancy is likely to carry an unacceptable 
high risk (hepatic decompensation and death) especially in those patients with cirrhosis of a 
severity to impair ovulation. Furthermore the intense hormonal ovulation induction regimens 
may potentially have an adverse effect in patients with non-cirrhotic autoimmune and 
cholestatic liver disease and those following liver transplantation 
 Assisted conception in patients with liver disease raises questions with regards to what 
cohorts of patients with liver disease can be safely offered assisted conception and which 
cohorts does it confer and unacceptable risk.  
 
1.4.4 Pathophysiology of pregnancy in women with cirrhosis 
Cirrhosis is typically an irreversible, progressive disease where sustained damage to the 
hepatocytes results in fibrosis and nodular regeneration. The fibrotic liver causes an increase in 
pressure in the portal venous system causing shunting of the blood and extrahepatic collateral 
circulation. This results in loss of hepatic filtration of toxins in the blood, the development of 
ascites and the potential risk of haemorrhage from tortuous collaterals through the gastro-
intestinal tract. 
When pregnant, many physiological and hormonal changes occur within the human 
body including a rise in maternal metabolism, heart rate and cardiac output. The resultant 
changes in hepatic blood flow through the structurally abnormal liver during pregnancy results 
in a further increase in portal pressure and the development or worsening of varices and ascites 
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along with deficiencies in metabolism and excretion of substances normally cleared by the liver. 
In women with underlying cirrhosis these physiological changes result in increased demands on 
the liver putting the patient at risk of hepatic decompensation with the development of 
encephalopathy and ascites. Furthermore the increased circulating volume along with the direct 
pressure of the gravid uterus in the inferior vena cava results in a significantly increased risk of 
variceal haemorrhage. 
 
1.4.5 Historical perspective of cirrhosis and pregnancy 
Pregnancy in cirrhotic women is rare. This relates to a combination of metabolic, 
endocrine, nutritional and sexual dysfunction as outlined above. (94-98) Historically, women 
with cirrhosis have therefore been considered infertile, although occasional successful 
pregnancies have been reported. (102) Additionally, due to the undefined risks, women with 
cirrhosis were routinely advised against pregnancy by their physicians.  
The first case in the published literature describing pregnancy in a women with 
underlying cirrhosis was reported in 1954. (103) Between this initial report and 1968 a total of 
64 pregnancies were reported in 47 women. (104) A significant deterioration of liver function or 
gastrointestinal bleeding occurred in 32 out of the 47 women (68%). 
In 1968, Whelton and Sherlock reported on the clinical course and outcome in 16 
pregnancies in 13 women all with biopsy proven cirrhosis either secondary to “chronic active 
hepatitis” or primary biliary cirrhosis. (102) Foetal outcomes included 5 abortions (4 
spontaneous), 3 still births, 1 neonatal death and 7 live births. Maternal outcomes included 1 
death from hepatic failure at 30 weeks gestation, 1 episode of severe variceal bleeding at 5 
months gestation requiring portocaval anastomosis and one episode of decompensation with 
the development of ascites. (102) 
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More than 25-years later, a further case series reporting on the outcomes of pregnancy 
in 11 women with cirrhosis between 1974 and 1992 was published. (105) In this series the foetal 
mortality was 8%, with 6 small for dates neonates and 3 premature births. Maternal 
complications were common with 6/11 (55%) experiencing a variceal bleed during pregnancy, 3 
(27%) developing ascites and 3 (27%) developing a significant infectious puerperal complication. 
(105) 
Although this historic information is useful, and undeniably tells us that pregnancy in 
women with cirrhosis carries a significant risk both for the mother and baby, its utility in the 
present day to provide preconception counselling to women with cirrhosis enquiring about 
pregnancy is limited. With current advances in neonatal intensive care and the routine 
administration of corticosteroids for foetal lung maturity in premature births, infant mortality 
rates are therefore likely to be lower than the above reported series. Moreover, maternal 
outcomes are likely to have improved with the advent of endoscopic techniques and a better 
understanding and treatment of the complications of cirrhosis. Unfortunately however, the 
optimal management of pregnancy in women with cirrhosis in the current day remains 
undefined. What still remains unclear is why some women with cirrhosis have an uneventful 
pregnancy whereas others are complicated by significant hepatic decompensation and death. 









1.4.6 Variceal Haemorrhage 
Variceal bleeding is the leading cause of maternal mortality in patients with underlying 
cirrhosis. Overall, any patient with pre-existent varices will have between a 25-75% risk of 
developing an episode of variceal haemorrhage during pregnancy. (48, 106) Mortality from 
variceal bleeding in pregnancy has been reported to be between 18% and 50%. (48) Prognosis is 
significantly better in those women who bleed secondary to non-cirrhotic portal hypertension 
with mortality rates of between 2 and 6%, likely due to the absence of underlying synthetic liver 
dysfunction. (107)  However these figures are from over 10-years ago and with the advent of 
new medications, improved endoscopic technique and radiologically placed shunts mortality is 
likely to have decreased considerably.  
The optimal management of portal hypertension during pregnancy remains challenging 
with the absolute need for variceal screening during the second trimester, primary prophylaxis 
against variceal haemorrhage and the management of a variceal haemorrhage during pregnancy 
largely undefined. Management is based on best guess experience extrapolated from the non-
pregnant literature. Pre-conception, in a patient with “at-risk” varices, prophylactic endoscopic 
band ligation of varices, although not proven, appears appropriate. (108) Case reports 
describing this strategy in pregnancy have been published, although no randomised trials have 
been carried out to prove efficacy. 
The American Association for the Study of Liver Disease (AASLD) recommends that once 
pregnant, women with cirrhosis should have a screening endoscopy in the second trimester. 
(109, 110) This represents the time when portal pressure increases, due to increased circulation 
blood volume and direct compressive effects of the gravid uterus on the inferior vena cava. 
Previous studies have reported the prevalence of clinically significant varices in the second 




Treatment of an acute variceal bleed in pregnancy is essentially the same as in the non-
pregnant patient. It includes resuscitation, stabilisation, correction of coagulopathy and close 
monitoring ideally in a critical care unit. Endoscopic intervention includes variceal banding or 
sclerotherapy to try and control bleeding. (112) The administration of vasopressin or synthetic 
analogues is not routinely advised because of their vasoconstrictive effects and associated 
uterine ischaemia. Upper gastrointestinal endoscopy appears safe during pregnancy, with the 
main reported risks being that of foetal hypoxia from sedative drugs or positioning. (113) 
Insertion of radiologically or surgically porto-systemic shunts have been used as salvage 
therapy when endoscopic procedures have failed to control acute bleeding in cirrhotic patients, 
however consideration must be given to foetal radiation exposure. (102, 114, 115)  
The mode of delivery in a woman with portal hypertension needs careful consideration. 
It is preferable to avoid excessive straining during labour in women with documented 
oesophageal varices, and a shortened second stage of labour is recommended, with forceps or 
ventouse-assisted delivery if needed. The need for Caesarean section remains controversial with 
one opinion being that it should only be performed according to obstetric indications, as 
women with cirrhosis are at increased risk of abdominal wall varices, bleeding during labour, 
poor wound healing and infection, (116) whereas other data suggests that variceal 
haemorrhage associated with labour remains a leading cause of morbidity and mortality in such 
women. (117) 
 
1.4.7 Decompensation of pre-existing cirrhosis related to pregnancy 
The changes in hepatic blood flow during pregnancy can result in an increase in portal 
pressure and ascites can develop. Due to the presence of portosystemic shunts and an increase 
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in baseline metabolism, products normally metabolised by the liver can increase, in particular 
ammonia, leading to encephalopathy. 
As in non-pregnant patients, precipitants for encephalopathy include infection, 
constipation, gastrointestinal bleeding, electrolyte disturbance, dehydration, and medications 
including opiates and sedatives. (118) Management includes identification and treatment of any 
precipitant, whilst admitting the patient to a place of safety until the condition resolves. (118) 
 
1.4.8 Prognostic models in cirrhosis and their wider utilisation 
Cirrhosis is the end result of repeated hepatocellular damage from any aetiology. It is 
defined histologically as a diffuse process evidenced by bridging fibrosis and nodular 
regeneration. Clinically, cirrhosis can be divided into either “compensated” or 
“decompensated”, Compensated cirrhosis generally describes a patient with preserved 
synthetic function, without ascites of encephalopathy. Decompensated cirrhosis is defined by 
the presence of either ascites, encephalopathy, jaundice or variceal haemorrhage. This crude 
clinical differentiation is important as the presence of decompensation denotes a significantly 
reduced survival. (119) 
A scoring classification system was developed in 1964 by Child and Turcotte to predict 
the survival of cirrhotic patients undergoing surgery for portal hypertension. (120) The score 
included bilirubin and albumin along with the presence of ascites, encephalopathy and 
nutritional status. A modified version was developed in 1973, where nutritional status was 
replaced by prothrombin time. (121) Since this time further studies have shown that the “Child 
Pugh” (CP) score can be used to predict prognosis in a variety of clinical settings including 
ascites, (122) variceal haemorrhage, (123) suitability for resection of hepatocellular carcinoma, 
(124) non-hepatic surgery (125) and assess need for liver transplantation. Although the CP score 
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is used extensively in clinical practice, it does have several limitations. Firstly the presence and 
severity of encephalopathy and ascites is subjective. Secondly each result is grouped with an 
empirical cut off and thirdly all variables are equally weighted. 
Various newer more sensitive and specific scoring systems now exist in clinical practice 
to assess the severity of cirrhosis. These include the model of end stage liver disease (MELD), 
Meld Sodium (MELD-Na) and the United Kingdom End Stage Liver Disease (UKELD). (126-130) 
 
Table 1.4.8: Prognostic models used to assess risk in cirrhotic liver disease 
 
The MELD score was initially developed to predict mortality following transjugular 
intrahepatic portosystemic shunt (TIPS) insertion. (126, 127) This scoring system is now widely 
used in clinical practice to predict prognosis in patients with cirrhosis and to help guide listing 
for, and in some institutions allocation of organs in liver transplantation. (128, 131) Recently, its 
utility has also been extended to predict outcome in other clinical scenarios including alcoholic 
MELD = {(0.957 x loge creat mg/dl) + 0.378 x (loge br mg/dl) + (1.120 x loge  
 
MELD Na = MELD − Na − [0.025 × MELD × (140 − Na)] + 140  
(where the Na concentration was bound between 125 and 140 mEq/L) 
 
UKELD  = 5 x {1.5 x log(INR) + 0.3 x log(creat) + 0.6 x log(br) - 13 x ln(Na)+70} 
(where INR = International normalized ratio, Creat = serum creatinine (umol/l), 




hepatitis, paracetamol induced liver injury, acute liver failure and survival following non liver 
related surgery in cirrhosis. (132-136) 
The United Kingdom End Stage Liver Disease score is a validated scoring system which 
incorporates INR, serum creatinine, bilirubin and sodium. (130) The UKELD has been compared 
to MELD and MELD-Na.in a cohort of 452 UK transplant waiting list patients and was shown to 
be a superior predictor transplant list mortality. These finding have never been confirmed in 
additional or non UK cohorts. (130, 137) 
 
1.4.9 Defining the risk of pregnancy in cirrhotic patients 
As outlined above, in women with cirrhosis who are contemplating pregnancy there is a 
significant increased risk of complications and death. At present preconception counselling is 
based on historic case reports and series. The reported series do not take into account the 
severity of the underlying liver disease which is likely to be a significant factor in the incidence 
of complications. Thus women are given generic, non-specific information with regards to their 
individual risk.  
The use of MELD or other scoring systems in predicting obstetric, foetal and maternal 
outcome in cirrhotic patients who become pregnant has not been assessed. In light of their 
widening use in other aspects of liver disease their use in predicting outcomes in cirrhotic 









1.5 Pregnancy in specific chronic liver disease states 
1.5.1 Autoimmune Hepatitis 
Autoimmune hepatitis (AIH) is a disorder that has been recognised for over 50 years. 
First described by Waldenstrom in the early 1950’s as a chronic form of hepatitis with a classical 
phenotype of liver disease in a younger aged women, often in conjunction with extra-hepatic 
manifestations including arthralgia, endocrine abnormalities and amenorrhoea. (138) Reports 
regarding pregnancy in patients with AIH exist from as early as the 1970’s but the reported 
outcomes were largely unfavourable, with a high incidence of obstetric complications noted 
including early foetal loss, prematurity, low birth weight and a high rate of caesarean sections. 
(102, 139) Moreover maternal complications included pre-eclampsia, flares in disease activity, 
hepatic decompensation and death. (102, 139) 
Subsequent to these initial reports, there have been several recent case series 
indicating more favourable outcomes. (14, 140-142) Combining the largest 4 series in the 
published literature on AIH and pregnancy gives data on 142 conceptions. (14, 140-142) The 
maternal outcomes reported are largely favourable; however pregnancy is not without risk to 
the mother with 3 reports of hepatic decompensation, 1 liver transplant and 3 maternal deaths 
(1 liver related) all related to pregnancy. (14, 140-142) Foetal outcomes are favourable with a 
heathy infant expected in the majority of patients and live birth rates reported to be between 
71% and 86%. (14, 140-142) These live birth rates are comparable to patients with other 




Despite our increase in knowledge surrounding the management of AIH during 
pregnancy, several concerns remain. Flares in disease activity have been reported to occur in 7- 
21% of patients within the gestational period and occur at a rate varying from 11-86% in the 
post-partum period. (14, 140-142) In the majority of patients a flare can be controlled by 
augmentation of the immunosuppression however, in rare cases, a flare can lead to hepatic 
decompensation with the potential need for liver transplantation (LT) or death of the patient 
and/or foetus. (140, 142) 
Distinguishing between which patients are likely to have an uneventful pregnancy and 
those at risk of the above complications is currently challenging. In addition, the optimal 
therapeutic regimen to prevent disease flares remains undefined, with some centres 
discontinuing azathioprine due to a theoretical risk of birth anomalies, (141) whilst others 
continue it throughout pregnancy to minimise the potential risk of a flare in AIH activity. (140, 
142)  Finally, in those patients with underlying cirrhosis who become pregnant, there are likely 
to be additional maternal and foetal risks including a higher incidence of maternal 
decompensation, significant variceal / post-partum bleeding and foetal prematurity. (48, 144) 
The safety of pregnancy in patients with AIH and underlying cirrhosis remains undefined and the 
published literature is sparse. 
 
1.5.2 Primary sclerosing cholangitis 
 Primary sclerosing cholangitis (PSC) is a chronic inflammatory condition of unknown 
cause, affecting all parts of the biliary tree. (145) The natural history is that of progressive 
obliteration of the bile ducts resulting in biliary cirrhosis, hepatic failure and potentially 
chalangiogcarcinoma. (145) The onset is usually between 25-45 years and although more 
common in men effected females are of childbearing age. (145) 
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 The aetiology and pathogenesis of PSC is incompletely understood. A variety of 
causative mechanisms have been postulated including exposure of the biliary epithelium to 
toxins, infectious processes and ischaemia. (145) In addition genetic and autoimmune factors 
may play a role. The evidence for an autoimmune/immune mediated aetiology is favoured by its 
strong association with inflammatory bowel disease, the increased frequency of serum auto-
antibodies, (146) elevated levels of circulating immune complexes (147, 148) and disordered 
cellular immune function. (149) Pregnancy has been shown to affect the course of autoimmune 
conditions including systemic lupus erythematosus, rheumatoid arthritis and AIH. (16, 140, 150) 
Information regarding the outcomes and risks of pregnancy for the mother and baby and the 
effect of pregnancy on the natural history of PSC is sparse. This renders the counselling and 
management of young patients wanting or reporting pregnancy difficult. 
 On reviewing the published literature, case reports give varied outcomes ranging from 
severe foetal complications including placental haemorrhage, spontaneous rupture of 
membranes and foetal bradycardia to healthy term infants. The effect of pregnancy on maternal 
disease varies from improvement in cholestasis to pruritus and evolvement of dominant 
strictures. (151-153) There have been two case series on pregnancy in patients with PSC 
published. The first by Janczewska et al described 13 pregnancies in 10 women (4 with 
cirrhosis). (154) The outcomes were favourable with no foetal losses reported and no significant 
deterioration in maternal liver function tests. Wellge et al describe 25 patients in 17 female PSC 
patients. (155) No serious maternal complications were reported although serum liver tests 
increased markedly (twice baseline) in 20% during the gestational period and 32% in the post-
partum period. The foetal loss rate was 16% and there were 2 preterm deliveries. (155) 
Interestingly, in the two reports, pruritus was the most common complaint affecting 11/27 
women and often worsened in the third trimester with difficulty distinguishing it from IHCP. 
(154, 155) Polymorphisms in the ABCB4 gene are common to both conditions and raise the 
question as to whether IHCP is more common in patients with PSC. (41, 156) 
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1.5.3 Primary Biliary Cirrhosis 
 Primary Biliary Cirrhosis (PBC) is an autoimmune liver disease that generally effects 
middle aged women. (157) It is characterised by a chronic inflammatory destruction of the 
interlobular and septal bile ducts that results in chronic cholestasis and biliary cirrhosis and 
portal hypertension. It is an autoimmune disorder characterised by highly specific 
autoantibodies, activated T cells in areas of bile duct destruction and association with 
autoimmune disorders. (157) The disease had predominance for women with a female to male 
ratio of 9:1 and a median range of onset of 50-years. 
 Information regarding pregnancy in women with PBC is rare, as PBC is a condition that 
typically has been described to effecting middle aged women and furthermore, historically 
women with pruritus were advised against pregnancy. Over the last decade several normal 
deliveries have been reported in women with PBC without an obvious effect on the underlying 
liver disease. (158-161) Poupon et al described 9 pregnancies in 6 patients with PBC, in which 
there were no foetal losses, a median gestation of 37 weeks and all infants healthy at 4 years 
follow-up. (160) Maternal outcomes were also favourable, with all mothers remaining 
asymptomatic throughout pregnancy. Interestingly, in contrast to case series reported in 
women with PSC, (155) in this small series cholestatic parameters and mitochondrial antibody 
titres fell in all women during the gestational period. (160) However in the first three months 
postpartum, cholestatic parameters deteriorated in all cases but subsequently returned to 
preconception values. (160) A recent publication has confirmed the above findings, reporting a 
favourable safety profile in pregnant women with PBC with a tendency to a post-partum flare in 
cholestatic parameters. (162) 
1.5.4 Overlap syndromes 
 Overlap syndromes encompass variant forms of the hepatic autoimmune diseases  
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including AIH, PBC, and PSC. Patients with these variant syndromes usually have a mixture of 
hepatic and cholestatic features on biochemical, radiological and histological investigations. 
Generally about 10% of patients with AIH will have co-existent features suggestive of PBC and 
8% features of PSC. (163) 
 Autoimmune sclerosing cholangitis (AISC) is an overlap syndrome between autoimmune 
hepatitis (AIH) and primary sclerosing cholangitis (PSC), predominantly occurring in children. 
(164) Fifty five percent of patients effected are female. (164) Patients present with serological 
and histological features of AIH, (165) but cholangiographic features of PSC, (145) usually to a 
less advanced degree than those observed in adult primary sclerosing cholangitis. (166) 
Immunosuppression (azathioprine and prednisolone) usually controls the inflammatory 
component but has little effect on the bile duct disease and for that reason ursodeoxycholic 
acid (20-30mg/kg) is usually used in conjunction. The medium term prognosis is good with 
survival into adulthood expected, (166) and with this many women have the desire to become 
pregnant. The effect of pregnancy in women with AIDC, and indeed other overlap syndromes is 
undefined both in relation to maternal, foetal and disease outcomes.    
 
1.5.5 Budd Chiari Syndrome 
 The Budd-Chiari syndrome (BCS) results from obstruction to hepatic venous outflow, 
usually secondary to hepatic vein thrombosis. Several associated underlying pro-thrombotic 
aetiological factors have been identified with the most common being an overt 
myeloproliferative disorder (MPD). Pregnancy itself is a hyper-coaguable condition and BCS can 
present de-novo in association with pregnancy. 
Historically, reports of BCS in association with pregnancy were associated with poor outcomes 
for the foetus and death of the mother from hepatic failure or portal hypertension being 
common. The standard treatment for BCS has been refined over several decades with survival 
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rates improving from 50% to 90% 5-year survival. These survival rates have been mirrored in the 
survival of pregnant women with BCS. A recent report of 7 cases of BCS in association with 
pregnancy reported survival in all mothers, but poor foetal outcomes remained with 3 
miscarriages and 1 intrauterine death. Interestingly 6/7 women had evidence of an underlying 
pro-coagulant factor in addition to pregnancy when tested. This data suggests that de-novo BCS 
in pregnancy is unlikely to occur without the presence of an additional underlying pro-
thrombotic tendency. 
   In light of the increasing survival of young women with BCS, the desire for pregnancy 
often occurs once their underlying condition has improved. Successful pregnancies have been 
reported following a diagnosis of BCS, however the pro-thrombotic risk pregnancy confers 
means there is a theoretical risk of BCS recurrence. In a recent series, 24 pregnancies were 
reported in 16 women previously diagnosed and treated for BCS. Maternal outcomes were 
good, with no reported mortality, 3 pregnancy related thrombotic episodes and an increased 
risk gynaecological bleeding. Foetal outcomes were less favourable were less with 7/24 foetal 














1.6 Pregnancy and Liver Transplantation 
1.6.1 Sexual function and fertility following LT 
Liver transplantation has evolved over several decades to become a universally 
accepted treatment for patients with ALF and chronic end-stage liver disease which is refractory 
to medical treatment. Survival following LT have steadily improved over the last 2 decades, with 
current five-year survival rates reported to be in excess of 70% with long term survival expected 
in the majority. (167, 168) As survival rates following LT continue to improve, the goal of 
transplantation in the current day is not only to ensure survival but to also to attain a quality of 
life (QOL) for patients similar to their pre-morbid state. (169) Tools used to assess the success of 
LT are now incorporating QOL parameters such as physical, psychological, social and sexual 
function along with medical parameters such as graft and patient survival. Several studies have 
demonstrated that general QOL improves dramatically after LT. (170-172) A recent meta-
analysis identified 44 longitudinal QOL studies, which incorporated 4381 patients, looking at pre 
and post LT outcomes. (173) General QOL (p<0.0001), social functioning (p<0.0001), physical 
health (p<0.0001) and psychological health (p=0.014) were all significantly improved by LT. 
Interestingly sexual function, which was assessed in 12 of the included studies was not found to 
be significantly different pre and post LT (p=0.58). (173) 
Three studies have been published specifically addressing sexual function in women 
following liver transplantation. The first included 28 female LT recipients, where 71% were 
sexually active with 75% having weekly intercourse following LT. (174) The second by Ho et al. is 
less favourable with data on 62 female LT patients where problems with libido (26%), 
dyspareunia (40%) and inability to reach orgasm (26%) were described. (175) Patients attributed 
their sexual problems to side effects of medications, liver disease, and depression. A third study 
by Sorrell and Brown, assessed the prevalence of sexual dysfunction in 71 women presenting for 
LT assessment and then followed 14 of the same women post LT. (93) In women pre LT, 56% 
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were not sexually active at the time of assessment and 42% described decreased interest in sex. 
Following LT, 8/14 women had a sexual partner of whom 50% were sexually active. (93) The 
data from the second two studies suggest that the expectation that sexual function will recover 
post LT may be misplaced in certain patients and is more complex process involving general 
health, age, psychological, emotional and social factors.   
Functionally in males, abnormalities in the hypothalamic-pituitary-gonadal axis are 
reversed post LT. (91, 176) In women similar studies have not been formally done, however, the 
majority of women of child-bearing age will recover regular menstrual bleeding within one year 
post-transplant, indicating that similar hormonal changes in females occur post LT. (96, 99, 177) 
 Transplant teams should endeavour to discuss sexual health, fertility and pregnancy as a 
sexual relationship and a family help promote feelings of self-worth, stability and confidence, all 
of which will help create a better QOL following LT.  
 
1.6.2 Pregnancy Post Liver Transplantation 
The first successful pregnancy following LT was reported 1978, with a healthy boy 
delivered at 40.5 weeks gestation, weighing 2,400g, with both the mother and baby in excellent 
health 1-year post-delivery. (178) Subsequent to this many case series have been reported, 
which have expanded our knowledge regarding the safety and outcomes pregnancy post LT. 
(179-182) Overall, the outcomes are largely favourable, with a healthy neonate and stable graft 
function expected in the majority. (179, 180) However, available data suggests that pregnancy 
in LT recipients can be associated with unpredictable graft deterioration, an increased risk of 
pre-eclampsia and diabetes in the mother. For the foetus prematurity, low birth weight with the 




1.6.3 Graft Function 
 Pregnancy is associated with an increased risk of an episode of acute cellular rejection 
(ACR). In the gestational period, case series have reported the incidence of graft rejection to be 
between 10 and 17%. (179-183) Post-partum, the incidence is lower with reports of between 3 
and 12%. (179-181) The majority appear to be easily controlled with baseline 
immunosuppression augmentation or intravenous methylprednisolone. Graft loss directly 
related to ACR in pregnancy is very rare, although reports of pregnancy termination as a 
consequence of deteriorating graft function exist. (179) 
The timing of pregnancy appears important in relation to episodes of ACR. Published 
data has suggested that delaying pregnancy for at least 12 months following LT is associated 
with a lower risk of ACR. (179) This strategy is supported by the National Transplant Pregnancy 
Register (NTPR) in the USA, which gives data regarding pregnancy outcomes in 189 patients 
following LT. (184) The rationale is thought that by delaying pregnancy for a year post-LT allows 
stability of graft function and immunosuppression levels along with a reduction in the incidence 
of opportunistic infections and surgical complications. 
The reason for increased rejection risk during the gestational period is unexplained. 
Pregnancy leads to a period of immunological tolerance, as previously discussed, in order for 
mother to tolerate the paternal antigens expressed by the foetus. Thus one may expect 







1.6.4 Maternal Risk during pregnancy following Liver Transplantation 
 The most common maternal complications encountered during pregnancy following 
liver transplantation are hypertension, pre-eclampsia and eclampsia. (90, 179) The incidence of 
pre-eclampsia and eclampsia combined has been reported to be between 14% and 23%. (179, 
181, 185) Similar levels of hypertensive related complications are seen in the renal transplant 
population. The reason for the increase in pregnancy related hypertension disorders is likely to 
be multi-factorial incorporating the direct nephrotoxic effects of calcineurin inhibitors, chronic 
corticosteroid usage and an increased incidence of underlying renal dysfunction. (184) 
 Other less common maternal risks include risk of bacterial and viral infections (27%) 
secondary to immunosuppression and a potential increased risk of gestational diabetes (5%) 
related to tacrolimus medication. (184-186) 
  
1.6.5 Foetal Risk during pregnancy following Liver Transplantation 
A live birth rate of 73%, a spontaneous abortion rate of 19% and therapeutic abortion 
rate of 6% has been reported by the NPTR. (187) The prevalence of prematurity and low birth 
weight is significantly higher than the general population. The NTPR reports a premature birth 
rate of 30% with low birth weight effecting 30% of neonates. (186) Although it is postulated that 








1.6.6 Mode of Delivery 
Caesarean section rates are much higher in LT recipients than the general population, 
with published series suggesting rates of between 35-63%. (179, 180, 186, 188) The reason for 
this remains unclear but may reflect the higher incidence of hypertensive related complications 
and thus the need for earlier delivery. Moreover, the range in caesarean section rates varies 
from different institutions and relate to obstetric experience or era effect in the obstetric 
management of post LT pregnancies. 
  
1.6.7 Immunosuppression Risk 
Data regarding the safety of medications commonly used in patients post LT during 
pregnancy is scarce. Most of our information is obtained from its use in patients with other 
disease entities such as inflammatory bowel disease or other solid organ transplant cohorts. The 
United States Food and Drug Administration (FDA) categorise the safety of drugs in pregnancy 










Table 1.6.7: The United States Food and Drug Administration categories of the safety 




A Adequate and well-controlled studies have failed to demonstrate a risk to the 
fetus in the first trimester of pregnancy (and there is no evidence of risk in later 
trimesters). 
B Animal reproduction studies have failed to demonstrate a risk to the fetus and 
there are no adequate and well-controlled studies in pregnant women. 
C Animal reproduction studies have shown an adverse effect on the fetus and 
there are no adequate and well-controlled studies in humans, but potential 
benefits may warrant use of the drug in pregnant women despite potential risks. 
D There is positive evidence of human fetal risk based on adverse reaction data 
from investigational or marketing experience or studies in humans, but potential 
benefits may warrant use of the drug in pregnant women despite potential risks. 
X Studies in animals or humans have demonstrated fetal abnormalities and/or 
there is positive evidence of human fetal risk based on adverse reaction data 
from investigational or marketing experience, and the risks involved in use of the 
drug in pregnant women clearly outweigh potential benefits. 
N FDA has not classified the drug. 
 
1.6.7.1 Corticosteroids 
Prednisolone can cross the placenta, thus potentially exposing the foetus to adverse 
effects of the drug. (189) The major foetal risks regarding steroids are cleft palate (particularly 
with high dose exposure in the first trimester), premature rupture of the membranes and 
intrauterine growth restriction. (IUGR) (190, 191) Reports of low birth weight and IUGR 
associated with steroid usage during pregnancy are confounded by the severity of underlying 
disease necessitating corticosteroid therapy. In addition, foetal adrenal hypoplasia and 
suppression of the foetal pituitary have also been described, although both are uncommon due 
to the rapid maternal metabolism and placental breakdown of corticosteroids. Prednisolone is 
considered a class B drug in terms of its risk for pregnancy by the FDA.  
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Overall, it is generally accepted amongst experts that maintenance of graft tolerance 
and prevention of rejection is crucial and that risks associated with steroids are outweighed by 




The teratogenic potential of cyclosporine appears low. A meta-analysis of 15 studies 
including 410 women on cyclosporine reported major malformations rate of 4.1%. This is not 
significantly different from that reported in the general population. (192) The meta-analysis 
concluded that cyclosporine does not appear to be teratogenic, however, increased rates of 
prematurity, low birth rate and neonatal hyperkalaemia were reported. Cyclosporine has been 
assigned to pregnancy category C by the FDA, Cyclosporine should be given during pregnancy 
only when benefit outweighs risk. 
 
1.6.7.3 Tacrolimus 
In the last decade, tacrolimus has been used routinely in the post-transplant setting and 
consequently data regarding its safety in pregnancy is emerging. The neonatal malformation 
rate in reported series is approximately 4%, which is similar to the risk associated with 
cyclosporine. (179, 188, 192) In LT recipients Jain et al. described 49 pregnancies on tacrolimus. 
(180) They reported a congenital abnormality rate of 2/49 (4%), consisting of a 
tracheoesophageal fistula and valvular heart disease in one baby and non-functioning kidney in 




1.6.7.4 Mycophenolate mofetil 
Mycophenolate mofetil (MMF), an inhibitor of purine biosynthesis, has been shown to 
cause abnormal development of ova in animal models and therefore is potentially teratogenic. 
(193) A recent review of data of 119 human pregnancies with maternal exposure to MMF found 
outcome data for 65 and demonstrated a live birth rate of only 34% with miscarriage occurring 
in 31% and elective abortion in 20%. (194) The rate of congenital abnormalities, at 15%, was 
higher than that seen in the general population. (194) The most frequent congenital 
abnormalities reported included external ear and other facial malformations such as cleft lip 
and palate. Thus when women of child bearing age are commenced on MMF they should be 
counselled regarding its safety in pregnancy. If they wish to become pregnant the drug must be 
discontinued with at least a 6 month wash out period before conception. MMF is considered by 
the FDA a class D drug in terms of the risks associated with its use in pregnancy. 
 
1.6.7.5 Azathioprine 
In animal models, azathioprine has been associated with skeletal abnormalities, cleft 
palate, hydrops fetalis and haemopoetic abnormalities of the foetus. (195, 196) In humans, 
lymphopenia, hypogammaglobulinaemia and thymic hypoplasia have all been reported in 
children born to mothers on azathioprine. However, these latter changes seem to all be 
reversible after birth with no long-term effects on the child. Furthermore, azathioprine has been 
linked to pre-term deliveries, (197) and in light of the above reports, physicians historically 
recommended patients with AIH to discontinue azathioprine if they were trying to conceive.  
Recently, experience with azathioprine in pregnancy has increased dramatically with 
information derived from other patient populations especially those with inflammatory bowel 
disease, rheumatoid arthritis and patients following solid organ transplantation. (140) In light of 
60 
 
the above studies, it is generally recommended that azathioprine therapy should be continued 
during pregnancy, at the same dose used to maintain stable graft function. At present no 
evidence exists to suggest that discontinuing the azathioprine for the gestational period is 
beneficial for the mother or foetal outcomes.  
Azathioprine is classified as a Food and Drug administration (FDA) category as class D, 
which states that positive evidence of risk to the foetus exists, but it is accepted that as in many 
medical conditions the potential benefits of its use throughout pregnancy may outweigh the 
risk.  
 
1.6.8 Breast Feeding 
Most physicians advise against breastfeeding due to concerns over the safety of 
neonatal exposure to immunosuppressants. Corticosteroids, azathioprine and tacrolimus are all 
known to be excreted in breast milk. Corticosteroids, however, are excreted in extremely low 
concentrations and are felt to be safe during breastfeeding. (198) Meanwhile, both azathioprine 
and tacrolimus levels are excreted in breast milk and in some cases levels are equivalent to, or 







Chapter 2: Aims of Thesis 
2.0 General 
 As highlighted in the introductory chapter of this thesis, the available literature to guide 
the management of patients in pregnancy is sparse and for the majority of women with liver 
disease information regarding pregnancy is limited to case reports and small case series only. 
This has resulted in generic advice being given regarding the risks / safety of pregnancy. In light 
of the fact that underlying “liver disease” represents a spectrum of severity generic advice 
regarding risk is clearly not appropriate for all women. Combining this with the fact that there 
are a wide variety of disease aetiologies that are likely to respond differently to pregnancy, 
further evaluation of these unique cohorts of women is needed. 
 Additionally, acute liver failure in pregnancy is rare, and again the published literature 
regarding poor prognostic outcomes and indications for consideration of liver transplantation is 
extremely limited. Further work delineating maternal risk is needed along with an assessment of 
whether current prognostic criteria is used to guide consideration of liver transplantation is 
applicable. 
 The overall aim of this thesis is to improve the understanding regarding the outcomes of 
pregnancy in patients with pre-existing liver disease and those who develop liver disease 
specifically related to the pregnant state. Specific attention is given to different underlying liver 
conditions and prediction of complications based on preconception parameters. It is postulated 
that this work will improve the preconception counselling that patients with liver disease 
receive, the management and monitoring during pregnancy and ultimately lead to an 
improvement in outcomes for the mother, foetus and the liver. In light of the above the overall 
aims of this thesis are to: 
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1) Develop a better understanding of the effect of pregnancy in women with liver disease 
with regard to maternal, foetal and hepatological risk 
2) Try to identify whether there are any objective preconception factors that may indicate 
increased risk to mother, baby and liver 
3) Assess if there are any disease specific risks associated with pregnancy with respect to 
the underlying hepatological pathway i.e. autoimmune disease, women with cirrhosis, 
women post liver transplantations and again whether these can be predicted prior to 
conception. 
4) Identify any poor prognostic factors associated with pregnancy induced acute liver 
failure and whether in this setting standard liver transplant listing criteria are applicable. 
 
To address this further, five areas have been evaluated and the specific aims are presented in 








Chapter 3: Patients and Methods  
3.1 General 
The Institute of Liver Studies at King’s College Hospital is a tertiary referral centre for 
patients with liver disease of any aetiology. A variety of comprehensive databases of patient 
information detailing those seen or admitted at the Institute of Liver Studies have been kept 
dating back to as far as 1979. 
 These databases briefly consist of HepBase, which is a prospectively collated database 
of all patients seen at the institute of liver studies dating from 1980 until 2009. HepBase 
includes patient’s clinical letters, bloods, histopathology reports and discharge summaries 
detailing any inpatient admissions. 
 MEDTRACK represents a physiological database, whereby data is entered daily on all 
patients who are admitted to the liver intensive care unit. This details information including 
organ status, and need for organ support. It also includes physiological parameters and 
aetiology. 
 An additional liver intensive care data-base detailing all patients admitted with acute or 
acute on chronic liver disease detailing the cause of liver disease / failure, admission parameters 
including bloods, lactate, encephalopathy and outcome data including survival and liver 
transplantation. 
 A dedicated autoimmune hepatitis database which includes information detailing 
patient’s presentation, management and medication, survival and complications. 
 Finally a database regarding all liver transplant activity within the institute of liver 




3.2 Selection of patients 
 The above databases were interrogated using search terms including “pregnancy”, 
“conception”, “Miscarriage”, ”abortion”, “termination”, “in vitro fertilisation”, “assisted 
conception”, “HELLP syndrome”, “AFLP” and “live birth”. A comprehensive master database of 
all women who were under the care of, or had been seen at the ILS whom had conceived or 
wanted to conceive was compiled. This method was thought to be the best way of identifying all 
patients which either chronic liver disease who had become / wanted to become pregnant and 
those who had developed acute liver injury as a result of pregnancy and transferred to the liver 
intensive care unit at King’s College Hospital. Whilst many patients were identified on repeated 
occasions from different databases, it was felt this was the most comprehensive method to 
ensure that minimal patients were missed.  
 The master database is therefore a collection of all patients with liver disease and 
pregnancy who have been seen at the ILS, King’s college Hospital over the last 2 decades. The 
retrospective collection of data was felt to be the most suitable to address the main aims of this 
thesis as pregnancy in liver disease is relatively rare, and a prospective study was thought not to 
allow sufficient patient numbers to allow the aims of this thesis to be addressed within the time 
frame available. Before data collection was commenced, a sample year of all patients seen at 
the ILS was reviewed and it confirmed that prospective collection of data would not allow a 
sufficient number of patients to be identified in order to achieve the main aims of this thesis.  
 From the master database of patients with liver disease and pregnancy, the patients 
were then subdivided into specific groups in order to gather more clinical information and 
answer the aims of the thesis as described in chapter 2. Patients were divided into those with 
pregnancy induced acute liver injury, cirrhosis, autoimmune hepatitis, post liver transplantation, 
cholestatic liver diseases and those undergoing assisted conception. The clinical records of all 
patients were reviewed and relevant data pertaining to the aims of this study were extracted. 
65 
 
3.3 Extraction of data 
 To address the aims specific to women with pregnancy associated acute liver failure, 
information was obtained detailing maternal age, previous pregnancy details, maternal 
comorbidities, presentation details, diagnosis as based on Swansea / Mississippi criteria for 
HELLP and AFLP, delivery details, foetal outcomes (gestation, survival, complications), admission 
haematological and biochemical results, lactate, presence of encephalopathy, ascites, organ 
support, bleeding, need for surgery, listed for transplantation, survival and length of stay. In 
those patients listed for transplantation the indications for listing were reviewed. The above 
information was recorded on a database with no patient identifiable information. 
 To assess pregnancy risk and outcome in mothers with established cirrhosis and to 
answer the aims laid out for this cohort of women, all women with either histopathological 
evidence of cirrhosis or evidence of cirrhosis based on a combination of radiological and 
biochemical tests were selected from the master database. The clinical and electronic notes 
were reviewed and data was extracted. In particular information regarding maternal age, 
previous pregnancies, cause of cirrhosis, diagnosis of cirrhosis (histological vs radiological and 
biochemical), maternal co-morbidity, previous maternal decompensation, presence of varices, 
bloods at clinic appointment prior to conception, assisted conception and whether the 
pregnancy was planned. Foetal outcomes were collected with regards to miscarriage and 
gestational week, termination of pregnancy, liver birth and gestational week, mode of delivery, 
birth weight, admission to special care baby unit and congenital abnormalities. Maternal 
outcomes were collated including variceal screening, decompensation (variceal bleeding, 
encephalopathy, ascites) need for intensive care support, need for liver transplantation and 
maternal death.  
 To assess pregnancy risk and outcome in mothers with autoimmune hepatitis and to try 
and address the aims laid for this cohort of women, all women with AIH was defined by the 
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revised International Autoimmune Hepatitis Group were selected from the master database. 
Baseline characteristics were obtained from the medical notes and from investigations 
performed at the clinic visit immediately prior to conception being reported. Particular 
information gathered included maternal age at conception, duration of AIH prior to conception, 
frequency and severity of flares in AIH activity prior to conception, baseline biochemical and 
haematological data, presence of cirrhosis, assisted conception, presence of portal 
hypertension, details of previous hepatic decompensation (variceal bleeding, encephalopathy, 
ascites) and medication details including termination of pregnancy, miscarriage, gestational 
week, mode of delivery, gestation for live births, foetal weight, need for admission to special 
care baby unit and presence of any congenital abnormalities or developmental delays. Maternal 
outcomes were collected and included information pertaining to flare in AIH activity and timing 
of flare in relation to pregnancy (gestational week / post-partum), peak abnormalities in 
biochemical parameters during a flare, medication augmentation and details, response to 
augmentation, evidence of hepatic decompensation (variceal bleeding, encephalopathy, 
ascites), intensive are admission, need for liver transplantation and death.  
 To assess pregnancy risk and outcome in mothers following liver transplantation and to 
answer the aims laid for this cohort of women all women who had undergone liver 
transplantation were selected from the master database. The clinical and electronic records 
were reviewed and data was extracted from the medical notes and from investigations 
performed at the clinical visit immediately prior to conception being reported. Specific data 
collected included maternal age at conception, data of liver transplant, and indication for 
transplantation, time interval between liver transplantation and conception and presence of 
any maternal comorbidities. Maternal therapy was recorded detailing immunosuppressive 
therapy, including specific drugs, doses and any changes made prior, during or after pregnancy. 
Data regarding foetal outcomes was gathered to include miscarriage and gestational week, 
termination of pregnancy and indication, live birth and gestational week, mode of delivery, 
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indication for caesarean section, birth weight, need for admission to a special care baby unit, 
and presence of any congenital abnormalities or developmental abnormalities. Maternal data 
detailing outcomes was collected to include maternal complications during pregnancy 
(hypertension, pre-eclampsia, eclampsia, renal failure, sepsis, gestational diabetes) and death. 
Information regarding graft rejection was gathered to include timing of rejection, diagnosis of 
rejection (biopsy proven vs. clinical), treatment of rejection and graft loss. 
 To assess the effect of pregnancy in rarer cohorts including those women with AISC or 
cholestatic liver dysfunction these women were first identified form the master database. 
Information pertaining to their pregnancy was collected in order to address the aims laid out. 
Specific information collected included diagnosis, age at conception, planned conception, 
assisted conception, medication at the time of conception and throughout pregnancy, 
biochemical parameters at conception, and the presence of cirrhosis. Outcome data was 
collected including miscarriage, termination of pregnancy, live birth, gestation, need for special 
care baby unit support and maternal complications including, changes in biochemical profile in 
the 3rd trimester and post-partum period, medication changes, decompensation, need for ITU 
support and death. 
 To address the aim described in chapter 2 regarding the outcomes of assisted 
conception in women with liver disease the master database was again interrogated to identify 
all women who had been referred for consideration of assisted conception. The medical and 
electronic notes were reviewed to obtain information regarding underlying diagnosis, presence 
of cirrhosis, sex hormones, baseline biochemical and haematological data and maternal age. In 
those women accepted for assisted conception, data regarding successful conception, 
miscarriage, live birth, gestation and mode of delivery were recorded. Information detailing why 
patients were declined for assisted conception was obtained. Finally maternal outcomes were 
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recorded including effect of hormonal therapy on hepatic biochemistry, complications, need for 
ITU support and death were obtained.  
 
3.4 Statistical analysis 
 Data is presented throughout the results section using median and range for numerical 
values. To determine whether significant differences existed between groups, the Students t 
test, or the Mann-Whitney-U non-parametric method as appropriate was applied. Differences in 
nominal data were compiled either by the Chi squared test or using a Fisher’s exact test when 
the number was less than 5 in any given cell of a 2x2 table. A p value of <0.05 was considered to 
be of statistical significance. 
 ROC curves were generated to analyse and compare maternal outcomes related to 
pregnancy. 
 All statistical analysis was performed using SPSS statistical software package version 14 







Chapter 4: Outcomes of severe pregnancy related 
liver disease; refining the use of prognostic markers 
and the role of liver transplantation 
4.1 Introduction 
Pregnancy associated liver failure is characterised by an acute onset, rapid progression 
and significant maternal mortality. (44, 74, 200, 201) Acute fatty liver of pregnancy, the 
hypertension related liver diseases including pre-eclampsia, the haemolysis, elevated liver 
enzymes, low platelets (HELLP) syndrome and liver rupture/infarction, are all disorders specific 
to the pregnant state. (144) Amongst these, there is a wide spectrum of severity ranging from 
minor biochemical abnormalities to acute liver failure. Outcomes at the more severe end of the 
spectrum are difficult to predict and prognostic information is limited to small series.(53, 74, 87) 
Liver transplantation (LT) for pregnancy associated liver failure is uncommon and information 
regarding the indications for and outcomes of transplantation is limited for both the patient and 
the graft.(53, 80, 87)  
The natural history of acute liver failure is variable and survival without liver 
transplantation (LT) ranges from 10–90% mostly dependent on the underlying aetiology and 
grade of encephalopathy and presence of multi-organ failure. (78) Survival has been 
transformed by the introduction of emergency LT, which now forms part of routine care for 
patients with ALF.  The original King’s College criteria for non-paracetamol acute liver failure 
(Table 1.3.8), identify patients with ALF early in their clinical course that are at high risk of death 
and thus may benefit from LT. (78)   
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In patients with pregnancy induced ALF, the King’s College Criteria have never been 
validated, nor indeed were any patients with pregnancy associated ALF included in the original 
cohort when the criteria were established. (78) This raises the question as to whether 
“standard” King’s criteria are applicable for assessing poor prognosis and need for LT in this 
individual cohort of patients.  
Without a clear understanding of poor prognostic factors in this individual cohort, 
identification of those patients at high risk of death from ALF may fail to be recognised and thus 
not have access to LT as a lifesaving treatment in a timely manner. Furthermore using criteria 
that have never been validated in this cohort to guide LT may lead to incorrectly subjecting a 
patient that would have recovered with medical management to a life of immunosuppression, 
its side effects and increased mortality. 
 Reported literature on transplantation for both HELLP syndrome and AFLP is sparse. The 
largest single centre experience for HELLP syndrome consists of 7 patients. (80) A review of the 
published literature in 2007 found 9 reported cases (81-86) and an additional 8 cases were 
identified from review of the united network for organ sharing (UNOS) database. (87) Of these 
17 patients, a 17% overall mortality was reported. The authors suggested that the indications 
for LT in HELLP syndrome were; persistent bleeding despite surgical intervention, extensive liver 
necrosis or liver failure, whereas, contained haematoma should be managed conservatively 
with close hemodynamic monitoring and repeated imaging. (87) 
Reports on LT for AFLP are sporadic. (53, 54) Outcomes appear largely favourable. The 
European Liver Transplantation Registry (ELTR) database has recorded the majority of all 
European LT activity since 1968. During this period there have been 6 LT performed for AFLP 





In light of the paucity of literature on the outcomes, complications and the role of 
transplantation in this unique cohort, we undertook a review of all patients with pregnancy 
associated liver disease severe enough to warrant intensive care admission between 1997 and 
2008. The aims were to  
 To identify the aetiology of pregnancy induced acute liver failure and its effect on 
clinical presentation and foetal outcome 
 To identify the common maternal complications encountered in women who develop 
pregnancy induced acute liver failure 
 To identify the frequency of death and need for liver transplantation in this cohort 
 To assess whether current prognostic criteria, such as the original King’s College 
Criteria, are applicable to this unique cohort in identifying those at risk of death. 
 To identify if there are any early admission parameters that are associated with death 
or need for liver transplantation which may improve identification of women who may 
benefit in the future from liver transplantation 
 To examine the effect of era on outcome, highlighting significant changes as 
appropriate, comparing the current cohort to 46 women admitted with severe 
pregnancy related liver disease between 1986 and 1996. (74)  
 
4.3 Patients and Methods: 
The liver intensive care unit (LITU) at King’s College Hospital is a tertiary referral centre 
for patients with acute liver failure (ALF). In a previous study from this unit, pregnancy related 
liver disease accounted for less than 5% of all admissions with ALF between 1986 to 1996. (74) 
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All patients admitted to the LITU with pregnancy associated liver disease between 1997 and 
2008 were reviewed and included in the current study.  
The diagnosis of HELLP syndrome was made using the following criteria; the presence of 
pre-eclampsia and a platelet count of less than 100x10³ cells/µl, a serum aspartate 
aminotransferase (AST) level of greater than 70 IU/L, a serum lactate dehydrogenase (LDH) level 
of greater than 600 IU/ml and/or a total bilirubin of greater than 1.2 mg/dl and the findings of a 
microangiopathic haemolytic anaemia with characteristic schistocytes on a blood film. (200) All 
patients met the Tennessee criteria for complete HELLP syndrome, with haemolysis on a 
peripheral blood film, a raised LDH >600IU/L, thrombocytopenia <100x109/L and elevated 
transaminases AST>70IU/L. (70) 
The diagnosis of AFLP was made on clinical and laboratory features including 
presentation in the 3rd trimester, features of ALF including jaundice, coagulopathy, 
encephalopathy or hypoglycaemia with or without the presence of pre-eclampsia. (48) All 
patients with AFLP met the Swansea criteria previously proposed by Ch’ng et al. for establishing 
the diagnosis of AFLP. (19) Patients with viral or drug related ALF in pregnancy were excluded. 
On admission, patients were treated with full supportive care. Inotropic support, 
continuous veno-venous haemofiltration (CVVHF) and ventilatory support were given when 
clinically indicated. All patients underwent an ultrasound examination of the liver and hepatic 
vasculature. When clinically indicated, computed tomography was performed. Patients who 
were bleeding, or at risk of bleeding, were given coagulation support to maintain international 
normalised ratio (INR) of less than 1.5 and platelet support to achieve a platelet count of greater 
than 50x10³ cells/µl. All patients had a full non-invasive liver screen to exclude other causes of 
liver disease, including autoantibodies, viral serology for hepatitis A, B, C and E viruses, 
cytomegalovirus and Epstein-Barr virus, ferritin, copper studies and serum immunoglobulins. 
Those who were deemed as having fulminant hepatic failure, were treated using a standardized 
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care pathway to optimize the likelihood of survival. Briefly, this consisted of sodium chloride 
infusions to maintain sodium levels between 145 and 150 mmol/l and ventilatory support 
where appropriate to keep PaCo2 levels between 4 – 4.5 Kpa. A reverse internal jugular line was 
inserted to provide data on cerebral perfusion, and when indicated, an intracerebral pressure 
monitoring device was inserted, in those patients who had deteriorated to grade 3/4 
encephalopathy. N-Acetyl-Cysteine was infused at 150mg/kg/day for a maximum of 5 days and 
CVVHF was utilized as appropriate. Prophylactic antifungal and antibacterial cover was utilized. 
These protocols have been previously validated and published as standards of care in the 
management of ALF at King’s College Hospital NHS Foundation Trust. (202, 203) 
 
4.4 Statistical Analysis  
Data is presented using median and range for numerical values. To determine whether 
significant differences existed between groups, we applied the Student’s t test, or the Mann-
Whitney-U non-parametric method as appropriate. Differences in nominal data were compared 
either by the Chi squared test or using Fishers exact test when the number was less than 5 in 










4.5 Results  
4.5.1 Presentation and delivery: 
There were 54 admissions to King’s College Hospital liver intensive care unit (LITU) 
between 1997 and 2008 with pregnancy associated liver disease. The median age at 
presentation was 30 years (range 21 – 40) with a median gestation of 35 weeks (range 27-40). 
Thirty two women (60%) were pregnant with their first child, 18 (33%) women were pregnant 
with their second child and 4 (8%) women were pregnant with their third child. Of those women 
who had previously been pregnant; 3 previous pregnancies were complicated by pre-eclampsia 
and 1 by HELLP syndrome. There were 6 twin pregnancies (11%).  
The presentation to hospital was varied. Overall 42 patients presented with a 
combination of malaise (n=38), nausea and vomiting (n=29) and abdominal pain (n=38). Of the 
remaining 12, 7 had pre-eclampsia without the above symptoms, 1 presented with jaundice and 
4 women had a normal labour with a post-partum presentation consisting of either collapse and 
hypoglycaemia or confusion in conjunction with deranged hepatic enzymes.  
Regarding delivery, thirty-nine (72%) deliveries were performed by emergency 
caesarean section, whereas 15 were vaginal in nature. In those women diagnosed with AFLPD or 
hypertension related disease prior to delivery, 90% (45/50) delivered within 24 hours of 
presentation, with the remaining 5 delivering between 24 and 48 hours of presentation. Fifty-







Figure 4.5.1 – Diagram demonstrating the commonest presenting complaints in women who 











 4.5.2 Aetiology of Disease and effect clinical features on arrival at King’s College 
Hospital 
Eighteen of the 54 patients admitted were diagnosed with AFLP all of which fulfilled the 
Swansea Criteria for diagnosis. Thirty-two patients had hypertension related disease; of these 
26 had HELLP (1 of whom had small vessel veno occlusive disease (VOD)), 2 had liver rupture, 2 
had subcapsular haematoma/tears and 2 with pre-eclamptic liver disease (1 associated with 
small vessel VOD)). The remaining 4 patients had intrahepatic cholestasis of pregnancy (n=1), 
ischemic hepatitis secondary to massive post-partum haemorrhage (n=1), AFLP in the context of 
highly active anti-retroviral therapy (HARRT) which had been prescribed throughout pregnancy 
(n=1), and, finally 1 patient had VOD in isolation. 
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All patients with HELLP syndrome had pre-eclampsia. Twenty three (82%) were 
nulliparous and there were 2 twin pregnancies. On arrival at King’s LITU 9/26 (35%) were either 
intubated or encephalopathic. All patients had thrombocytopenia with a median platelet count 
of 48x10³ cells/µl (range 15-99x10³cells/µl). The majority of these patients had received platelet 
support at their referring hospital, rendering values artificially high. Bilirubin levels were raised 
in 25/26 (96%) patients with a median value on admission of 48µmol/l (range 14 – 388µmol/l).  
In comparison, only 11% of patients with AFLP had pre-eclampsia and 9/18 (50%) were 
nulliparous. On arrival at King’s LITU 56% of patients with AFLP were intubated and ventilated. 
All AFLP patients had a raised bilirubin with a median level of 123µmol/l (range 37-194 µmol/l), 
and 8/16 (50%) had a platelet count of less than 100x10³ cells/µl (range 33-180 cells/µmol/l).  
Patients with AFLP had a statistically significant higher INR level (p=0.0015), bilirubin 
(p=0.0065), creatinine (p=0.04) and platelets (p<0.001) and lower AST levels (p<0.001) when 

















Table 4.5.2:  
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4.5.3 Foetal Outcomes. 
The overall foetal mortality rate was 7% (4/60). This comprised of 4 deaths; 2 deaths 
occurred in foetuses from patients with HELLP syndrome, whereas 2 occurred in patients with 
AFLP. Three of the four foetal deaths occurred in women with twin pregnancies. 
The first foetal death was in a 35 year old woman who was pregnant with twins, and 
presented at 30 weeks gestation with HELLP syndrome complicated by a sub-capsular 
haematoma. An emergency caesarean section was preformed but the second twin was still 
born. The subsequent two foetal deaths occurred in a 30 year old woman who presented with 
abdominal pain at 34 weeks gestation, was diagnosed with AFLP and went into spontaneous 
labour 36 hours after presentation. Unfortunately both her twins were still born. She 
subsequently developed grade IV encephalopathy, required intubation for airway protection, 
but recovered with supportive medical care. The final foetal death occurred in a 28 year old 
women who presented with nausea, vomiting and abdominal pain at 31 weeks gestation. She 
was diagnosed with HELLP syndrome, which was complicated by ischaemic hepatitis secondary 
to placental abruption. The baby was delivered vaginally, but was still born. The women 
developed ascites and renal failure but recovered with supportive medical care.  
Interestingly foetal death was not associated with the severity of the maternal liver 
disease, as guided by maternal platelet count, INR, bilirubin, AST, creatinine or the presence of 









Table 4.5.3: Severity of maternal liver disease at presentation and impact on foetal 
survival 
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* Statistical significant value for Foetal death vs. Foetal survival (p<0.05). 
 
Thirteen neonates required admission to the special care baby unit for supportive care 
and all were subsequently discharged, with no ongoing medical sequelae. Admission to the 




4.5.4 Maternal Outcomes 
The overall maternal survival rate was 87% (47/54). Four deaths occurred in patients 
with AFLP, 2 patients had severe necrotising pancreatitis and died of sepsis and multi-organ 
failure. The third patient died from a hypovolaemic cardiac arrest secondary to a bi-lobar liver 
rupture following an emergency cesarean section. The final patient with AFLP who died had 
been on long term anti-retroviral therapy and died from sepsis and MOF, with the sepsis 
severity precluding LT in that case. Three patients with hypertension/eclampsia related disease 
died. The first underwent LT for acute liver failure but had delayed graft function and was re-
listed for LT. Following re-transplantation she died of MOF and sepsis. The second death in this 
category was in a patient with pre-eclampsia, who had progressive encephalopathy and liver 
failure. She died from MOF whilst awaiting a liver graft. The final patient died secondary to 
hypovolaemia with bi-lobar liver rupture and failure to achieve haemostasis. (Table 4.5.4)  
Patients that died were more likely on admission to have encephalopathy (6/7(86%) 
versus 18/47(38%) p=0.04), have a higher lactate (5.0, (1.05-18) versus 1.62, (0.7-12) p=0.03) 
and to be commenced on CVVHF (7/7 versus 10/47 p=0.01). There was no statistical difference 
in platelet count, INR, bilirubin, AST, serum creatinine or the rate of bleeding complications. 
None of the patients that died met the non-acetaminophen King’s College criteria for poor 
prognosis in acute liver failure.  
Closer examination of the patients with ALFP who died revealed a 31 year old woman 
who presented with foetal distress, deranged LFT’s and acute pancreatitis. She developed 
pancreatic ascites, a laparotomy demonstrated necrotic pancreatitis and a cholestatic liver. 
Liver biopsy was compatible with ALFP. She died of sepsis and multi-organ failure (MOF) on day 
16 following admission. The second death occurred in a 33 year old patient who presented with 
jaundice, abdominal pain, hypoglycaemia and a raised INR. Following emergency caesarean 
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section, she was admitted to ITU with grade 2 encephalopathy. She also had CT evidence of 
severe necrotising pancreatitis. Laparotomy findings demonstrated turbid ascites and liver 
biopsy was consistent with AFLP. She died of sepsis and multi organ failure on day 10 following 
admission. In light of the severity of the pancreatitis neither of these patients were listed for LT. 
The third death in this category was in a 24 year old woman who had a caesarean section for 
foetal distress. She developed abdominal distension with deranged hepatic enzymes and 
laparotomy revealed bi-lobar liver rupture. Such was the degree of bleeding that she was 
rendered anhepatic. She died of a cardiac arrest on the operating table. Finally one patient died 
with AFLP who had been on long term to anti-retroviral therapy from sepsis and MOF, with the 
sepsis severity precluding LT in that case 
For patients with HELLP syndrome, the first death occurred in a 23 year old woman who 
presented with pre-eclampsia at 31 weeks gestation. Following caesarean section she was 
admitted to ITU with transaminitis and renal failure. CT scan showed necrotic infarction of the 
right lobe. She subsequently underwent LT but had delayed graft function and in conjunction 
with progressive clinical deterioration she was re-listed for LT. She underwent re-
transplantation, but later died of MOF and sepsis. The second death was in a 37 year old woman 
who presented with pre-eclampsia and underwent an emergency caesarean section. She had 
progressive encephalopathy, rising lactate levels and was listed for transplant. She died from 
MOF whilst awaiting an organ. The final patient died secondary to hypovolaemia with bi-lobar 
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4.5.5: Liver Transplantation and outcomes 
Six patients were listed for LT, 3 with HELLP, 1 with AFLP, 1 with ischaemic hepatitis 
secondary to severe post-partum haemorrhage and 1 with pre-eclamptic liver disease. Three 
patients were listed due to acute liver failure all with encephalopathy, coagulopathy and 
hyperbilirubinaemia and two patients were listed on the basis of having functional Budd-Chiari 
syndromes, secondary to haematoma causing compression on the hepatic veins. The final 
patient was listed because of failure to control hepatic blood loss in conjunction with worsening 
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hepatic function. None of the listed patients fulfilled the non-acetaminophen King’s College 
criteria. Two of the six listed patients died, 3 patients underwent successful LT and one patient 
recovered with medical management alone. 
Of the 3 patients that underwent successful LT, all are maintained on tacrolimus based 
immunosuppression, and graft function remains excellent over a median follow-up period of 8 
years.  
 
Table 4.5.5.1: Diagnosis, clinical features and outcomes of patients with pregnancy 
associated acute liver failure that were listed for liver transplantation. 
 
 




































































































Patients who were listed for liver transplantation had a higher AST (3040 IU/L, (3000-
3739 IU/L) versus 307 IU/L, (16-775 IU/L), p<0.01), a higher lactate after a period of 
resuscitation (6.0 mg/dl, (2.6-12.0 mg/dl) versus 2.0mg/dl, (0.7-18.0 mg/dl), p<0.01) and lower 
platelets (40 cells/µl, (21-54 cells/µl) versus 70 cells/µl, (15 – 225 cells/µl), p=0.01) on admission 
to out LITU. Additionally listed patients and were more likely to require CVVH (6/6 versus 22/48, 
p=0.02) and to have encephalopathy (6/6 (100%) versus 7/48 (15%) p<0.01), when compared to 
non-listed patients. There was no statistical difference in levels of bilirubin, creatinine and INR 























Table 4.5.5.2: Differences in clinical, biochemical and haematological parameters 





Patients listed for liver 
transplantation (n=6) 
Patients not listed for liver 
transplantation (n=48) 
p value 
AST (10-50 IU/L) 
 
Lactate (<2 mg/dl) 
 














Length of ITU stay (days) 
3040 (3000 - 3739) 
 
6.0 (2.6 – 12.0) 
 
40 (21 – 54) 
 
 




89 (66 – 208) 
 




31 (3 – 43) 
307 (16 - 775) 
 
2.0 (0.7 – 18.0) 
 
70 (15 – 225) 
 
 




63 (9 - 338) 
 






























4.5.6 Analysis of differences between medical survivors and those that died / received 
liver transplantation 
Analysis of differences in admission characteristics to intensive care between medical 
survivors and those patients that were either transplanted or died revealed that lactate (p=0.03) 
(following a period of resuscitation) and the presence of any grade of encephalopathy (p=0.04) 
were the only statistical significant parameters separating survival from both death and LT 
(Table 4.5.6.1).  
Table 4.5.6.1:  Differences in clinical, biochemical and haematological parameters on 
admission to intensive care between medical survivors and those who died or 
underwent transplantation. 
 



























1551 (16 – 7755) 
 
2.5 (0.8 – 6.6) 
 
81 (19 – 255) 
 
 
1.99 (0.58 – 4.47) 
 
5.26 (0.81 – 22.69) 
 




627 (48 – 3040) 
 
7.8 (3.5 – 18.0)* 
 
73 (25 - 153) 
 
 
1.94 (0.83 – 3.73) 
 
5.61 (0.52 – 12.16) 
 




3345 (3000 – 3739)* 
 
7.3 (2.6 – 12.0)* 
 
34 (21 – 54)* 
 
 
2.04 (1.61 – 2.5) 
 
4.85 (3.85 – 5.49) 
 




1714 (48 – 3739) 
 
7.6 (2.6 – 18)* 
 
57 (21 – 153) 
 
 
1.98 (0.83 – 3.73) 
 
4.23 (0.5 – 12.2) 
 
2.1 (1.1 – 4.3) 
 
90* 
*p<0.05 when compared to medical survivors 
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Figure 4.5.6.1: Box and Whisker plot comparing admission lactate levels in patients 
who survived, died and were transplanted. 
 


















The differences in lactate levels between the three groups are demonstrated above. The 
receiver operator characteristic (ROC) curve for lactate (figure 4.3.6.2) demonstrates an area 
under the curve (AUC) of 0.84 at a 95% confidence interval (0.64 - 0.98). Furthermore an 
admission lactate greater than 2.8mg/dl, following a period of volume resuscitation had a 73% 
sensitivity and a 75% specificity for predicting which patients with ALF in pregnancy are likely to 
die or require transplantation. The AUC was not predictive of death or transplantation in other 






Figure 4.5.6.2: ROC curves for lactate (and other admission parameters) as a 

















































Table 4.5.6.2: Table showing the area under the curve for admission haematological 





Test Result Variable(s) 
 
 
Area under curve 
 
 
Asymptotic 95% Confidence Interval 
Upper Bound Lower Bound 
Lactate .836 .646 .979 
Platelet .359 .174 .545 
INR .693 .512 .875 
Bilirubin .516 .300 .733 
Creatinine .510 .325 .695 
AST .532 .325 .740 
 
 
A lactate level of greater than 2.8mg/dl, after appropriate volume resuscitation, has 
been shown above to have a 73% sensitivity and a 75% specificity for predicting which patients 
are likely to die or require LT. The only other parameter we identified as being statistically 
significant in predicting death or need for LT is the presence of any grade of encephalopathy. 
Combining a serum lactate of greater than 2.8mg/dl with the presence of encephalopathy 
correctly identified 9/10 patients that either died or were transplanted (sensitivity 90%). The 
one patient who died without meeting the above criteria had AFLP in conjunction with acute 
pancreatitis and subsequent MOF. Of the 44 patients who survived 6 (14%) had a combination 
of a lactate greater than 2.8mg/dl and encephalopathy (specificity 86%). The negative predictive 





4.5.7: Maternal complications 
The main complications, other than death and need for LT discussed above were renal 
failure, haemorrhage, sepsis, encephalopathy and cerebral oedema.  
Haemorrhage, defined as the presence of frank blood either in abdominal drains or 
suspected on radiological imaging in conjunction with haemodynamic instability and the need 
for red blood cell transfusion occurred in 59% (32/54).  Twenty one out of thirty two (66%) cases 
were gynaecological, 15/32 (47%) were hepatobiliary and 4/32 (13%) patients bled from both 
sites. Surgical intervention to manage the bleeding was needed in 23/32 (72%) patients. There 
was no association between the mode of delivery (vaginal versus caesarean) and the incidence 
of bleeding complications from a gynaecological source (p=0.22) or a hepato-biliary source 
(p=0.51). Length of stay was significantly longer in patients that bled (10 days, (1-43) versus 4 
days, (1-14) p=0.004). 
Sepsis was more common in those with bleeding complications (21/32 (66%) versus 
8/22 (36%) p=0.02). The overall prevalence of culture positive sepsis was 29/55 (52%) and was 
associated with a significantly prolonged LITU stay (10 days, (2-43) versus 3 days, (1-23) 
p=0.005).  
The prevalence of renal failure was 63%, as classified using the ‘RIFLE’ criteria (Risk of 
renal dysfunction, Injury to the kidney, Failure of kidney function, Loss of kidney function and 
End stage kidney disease).(204) The median creatinine level on admission was 1.72 mg/dl (range 
0.59-4.5mg/dl). CVVH was required in 27/54 (50%) patients, however none required ongoing 
renal replacement therapy after discharge from hospital.     
 Liver specific complications included encephalopathy of any grade in 56% (26/54), 
ascites in 26% (14/54) and cerebral oedema as defined by arterial ammonia greater than 150, 
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encephalopathy and or raised pressure on an intra-cerebral pressure monitoring device in 15% 
(8/54).  
4.3.8: Effect of era on outcome. 
 Finally to assess the effect of era on outcome of women transferred and admitted to 
King’s College Hospital Liver Intensive Care Unit the current data set was compared to a 
previous collected cohort of patients. In this cohort, patients were collected over a 10-year 
period from 1986 – 1996. In total 46 patients with severe hepatic dysfunction in late pregnancy 
were transferred indicating that the number of admissions with pregnancy associated liver 
disease has remained constant over the two era’s.  
Between the two eras 1986-1996, and 1997–2008, there appears to be a change in the 
aetiology of liver disease presenting. During the first era, 32/46 (70%) of the patients were 
admitted with AFLP whereas 7/46 (15%) were admitted with HELLP. This compares to a 
prevalence of 18/53 (33%) with AFLP and 26/54 (48%) with HELLP syndrome in the subsequent 
11 years. Yet, despite this apparent change in case-mix, baseline haematological and 
biochemical parameters on admission have remained similar over the two time periods. 
Similarly, mortality rates have not changed significantly between the two eras (9% versus 13%). 
Between 1986 and 1996, 2 patients were listed for LT, one with AFLP and liver rupture who died 
before a liver became available, and the second patient 1 with pre-eclamptic liver rupture who 
underwent successful LT and continues to survive.  Although the number of patients listed for 
liver transplantation has increased over the 2 time periods this did not reach statistical 
significance (p=0.2), and perhaps this increase represents institutional experience in 





Table 4.5.8.1: Aetiology of liver disease and effect of era on clinical parameters and 
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4.6 Discussion  
In this chapter we have demonstrated that there are key clinical and biochemical 
parameters on admission to intensive care that allow early detection of patients at significant 
risk of death and/or in need of LT in severe pregnancy associated liver disease. Patients that 
died or were transplanted were more likely on admission, to have a higher lactate level, and 
have encephalopathy. In addition, we have identified that current prognostic models of poor 
survival in ALF, including the original King’s College Criteria may not correctly identify patients at 
risk of death without LT in this clinical setting.  
The Original King’s college criteria for non-acetaminophen aetiology, identify patients 
with ALF early on their admission that are at high risk of death and thus may benefit from LT. 
(78) None of the patients in this cohort that were listed for transplantation fulfilled these 
criteria. Although all patients were encephalopathic, none met the requirement of either an INR 
greater then 6.5, or any three parameters from the variables of age greater than 40 years, 
unfavourable aetiology, INR greater than 3.5, serum bilirubin greater than 300µmol/L or interval 
of jaundice to development of encephalopathy of greater than 7 days. This is likely in-part, 
related to the high incidence of bleeding complications in pregnancy associated ALF (59% in this 
study) and the consequence of correction of coagulopathy through the use of blood products 
resulting in artificially low INR values. In addition to this virtually all our patients (96%) were 
under the age of 40, a key parameter in the original criteria. Finally, in our series, only 2 patients 
had a bilirubin of greater than 300µmol/L and all had progression from development of jaundice 
to development of encephalopathy duration of less than 7 days. Consequently, a patient with 
pregnancy induced ALF, could be denied the benefit of listing if strict adherence to these criteria 
is enforced.  
In patients with pregnancy induced ALF, the King’s criteria have never been validated, 
nor indeed were any patients with pregnancy associated ALF included in the original cohort 
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when the criteria were established. (78) This raises the question as to whether “standard” King’s 
criteria should be used in this individual cohort of patients. In 2002, Bernal et al. increased the 
sensitivity of the acetaminophen Kings College criteria by adding the parameter of serum 
lactate, following a period of resuscitation. (205) Serum lactate is often elevated in patients with 
ALF due to increased systemic production secondary to a combination of tissue hypoperfusion 
with subsequent tissue hypoxia and decreased hepatic clearance secondary to injured 
hepatocytes. In addition to this, patients with AFLP have an abnormality in mitochondrial beta 
oxidation of fatty acids associated with 3-hydroxyacyl-CoA dehydrogenase deficiency which 
results in excess fatty acids within the liver causing direct hepatoxicity, elevating the lactate 
further. Patients at the severe end of the HELLP spectrum have extensive hepatocyte injury as 
reflected by the elevated AST due to complications of infarction, haemorrhage and rupture 
further compounding hyperlactatemia in this group. In light of the pathophysiology in 
pregnancy induced liver failure it is unsurprising that lactate has been identified in this cohort as 
a discriminating factor when considering LT or predicting poor outcomes. 
Additional prognostic scoring systems have been published and validated, albeit never 
in pregnancy associated liver failure. These include the Clichy criteria and the BiLE score 
(bilrubin, lactate and aetiology score). (79, 206, 207) The Clichy criteria define that the presence 
of grade 3 or 4 encephalopathy with suppressed factor V levels (defined according to age) 
identifies patients who would benefit from transplantation in acute liver failure. (79, 207) In 
pregnancy associated liver failure, this prognostic system is likely to be unhelpful due to the 
correction of clotting disturbance. The BiLE score in contrast, which incorporates serum 
bilirubin, lactate and aetiology may be of greater use in pregnancy induced liver failure since it 




Reported literature on transplantation for both HELLP syndrome and AFLP is sparse. The 
largest single centre experience for HELLP syndrome consists of 7 patients. (80) A review of the 
published literature in 2007 found 9 reported cases (81-86) and an additional 8 cases were 
identified from review of the United network for organ sharing (UNOS) database.(87) Of these 
17 patients, a 17% overall mortality was reported. The authors suggested that the indications 
for LT in HELLP syndrome were; persistent bleeding despite surgical intervention, extensive liver 
necrosis or liver failure, whereas, contained hematoma should be managed conservatively with 
close haemodynamic monitoring and repeated imaging. (87) Our experience supports this 
paradigm of management. In this series, 2 patients with HELLP syndrome died, one awaiting 
liver transplant and second from MOF and sepsis, following re-transplantation. One further 
patient underwent successful transplantation with the indication being extensive haemorrhagic 
liver necrosis in association with poor hepatic function.  
 Reports on LT for AFLP are sporadic. (53, 54) Outcomes appear largely favourable. In 
this study, only one patient with AFLP was listed for LT but recovered with medical management 
and was subsequently taken off the waiting list. The European Liver Transplantation Registry 
(ELTR) database has recorded the majority of all European LT activity since 1968. During this 
period there have been 6 LT performed for AFLP confirming that LT is only performed or 
undertaken in exceptional cases. 
Pancreatitis is a recognized complication of AFLP which is associated with poor maternal 
outcomes. (208) The largest reported series in the literature described 12 patients with AFLP 
and co-existing pancreatitis. (208) Of these, 2 patients died, 3 patients developed pancreatic 
pseudocysts and 1 developed haemorrhagic pancreatitis. In all cases, the radiological and 
biochemical findings of pancreatitis occurred after the onset of hepatic abnormalities. In our 
current series 2/18 (11%) patients with AFLP had associated pancreatitis. Interestingly, both 
patients died, confirming that the development of associated pancreatitis is a poor prognostic 
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sign. Consequently, it is our belief that since associated pancreatitis is associated with more 
adverse outcomes, that all patients with AFLP should also undergo screening for pancreatitis.  
This study does have several limitations. Firstly, there is unquestionable selection bias 
given the referral patterns to our institution. Admission criteria to the institution are difficult to 
define and the decision to transfer a patient was based on review of the case and discussion 
with the referring centre. Thus, the bias in our series is towards more severe hepatic 
dysfunction and patients with bleeding complications who might need surgical intervention in 
the course of management. Other limitations include the retrospective nature of the cohort, 
although, it is apparent that no single centre could generate a prospective study with adequate 
recruitment numbers and comparable data does not generally exist, even in multi-centre series.  
In summary, severe pregnancy associated liver disease is a condition with a high 
morbidity and mortality. We have reported the complications encountered in clinical practice, 
identified predictors of poor outcome and shown that standard listing criteria for 
transplantation may be inappropriate in this unique cohort. We have identified that the serum 
lactate on admission is a predictor of both death and listing for transplantation, but his needs to 
be validated in further prospective analysis. This study may therefore aid management of 
patients in the intensive care and allow accurate discussions about outcomes to occur with 





Chapter 5: Utilisation of prognostic scoring systems 
to predict outcomes in pregnant women with 
cirrhosis 
5.1 Introduction 
Pregnancy in cirrhotic women is rare relating to a combination of metabolic, endocrine, 
nutritional and sexual dysfunction as discussed in chapter 1. (94-98) Disruption of the 
hypothalamic-pituitary axis in conjunction with disturbed oestrogen metabolism leads to 
anovulation, amenorrhoea and infertility.(96, 97) Historically, women with cirrhosis have 
therefore been considered infertile although, occasional successful pregnancies have been 
reported in women with well compensated cirrhosis. (102) The current literature regarding 
maternal and foetal outcomes is limited to case reports and small historic series which have 
limited value in advising women today regarding the safety of pregnancy. (102, 105) 
It is recognized that women with cirrhosis who become pregnant are at risk of 
worsening liver synthetic function and hepatic decompensation including the development of 
ascites, variceal haemorrhage and encephalopathy.(48, 95) Overall, maternal mortality for 
pregnant women with cirrhosis has been reported to be as high as 10.5% in the early 1980’s, 
however, (98) with advances in the management of liver disease and variceal haemorrhage, 
mortality is likely to have improved.  
In chapter one it is detailed how various scoring systems exist in clinical practice to 
assess the severity of cirrhosis and guide management of such patients. These include the 
model for end stage liver disease (MELD), MELD Sodium (MELD-Na), the United Kingdom end 
stage liver disease (UKELD) and Child-Pugh (CP) scores. (120, 126-130) Although the MELD score 
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was initially developed to predict mortality following trans-jugular intrahepatic portosystemic 
shunt (TIPS) insertion, (126, 127) this scoring system is now widely used in clinical practice to 
predict prognosis in patients with cirrhosis and to help guide listing for, and allocation of organs 
in liver transplantation.  (128, 131) 
Recently its utility has been extended to predict outcome in other clinical scenarios 
including alcoholic hepatitis, paracetamol induced liver injury, acute liver failure and survival 
following non liver related surgery in cirrhosis. (132-136) The use of MELD score or other scoring 
systems in predicting outcome and complications in cirrhotic patients who become pregnant 
has not been assessed. In light of their widening use in other aspects of liver disease, our 
hypothesis is that these scoring systems may have utility in risk stratifying cirrhotic patients 















In light of the paucity of literature on the outcomes, complications and the role of 
prognostic scoring systems in predicting outcomes of pregnancy in cirrhotic women a review of 
all patients at our centre between 1984 and 2009 with cirrhosis and pregnancy was undertaken. 
The aims were: 
 To identify the foetal outcomes in women with cirrhosis with regard to miscarriage, still 
birth, gestation, need for special care support, congenital and developmental 
abnormalities. 
 To identify maternal complications in women with cirrhosis including mortality and 
liver and non-liver related morbidity. Particular attention was given to hepatic 
decompensation (ascites, encephalopathy, variceal bleeding).  
 To assess the use of prognostic scoring systems (calculated pre conception) at 
predicting maternal or foetal adverse outcomes. 
 To assess whether prognostic scoring systems or other markers of portal hypertension 
(platelet count, known varices, imaging) pre-conception might predict presence of 
varices on screening endoscopy in the second trimester. 
 To establish evidence based guidance that quantifies risk for women with cirrhosis 
wishing to conceive. 
 
5.3 Patients and Methods 
All cirrhotic patients who reported pregnancy at our institution between 1984 and 2009 
were reviewed. The clinical records were reviewed in all patients and data extracted in a 
standard fashion. The diagnosis of cirrhosis was made on histological grounds on the basis of 
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liver biopsy or using a combination of radiological and laboratory investigations in cases where a 
biopsy wasn’t deemed necessary on clinical grounds.  
MELD, MELD Na, UKELD and CP scores were calculated where appropriate information 
was available, according to published formulae. (120, 127, 130) Scores were calculated from 
information gathered at the clinic visit immediately prior to pregnancy being reported. Maternal 
complications during pregnancy were recorded including hypertension, pre-eclampsia, 
gestational diabetes and renal failure along with specific hepatological complications including 
encephalopathy, ascites, development of jaundice and variceal haemorrhage. Data on 
abortions, including spontaneous and elective terminations of pregnancy were obtained in 
addition to the gestational duration, live birth rate and foetal outcomes. Upper gastrointestinal 
endoscopy results were reviewed to assess the prevalence of varices, and the impact of 
screening on delivery and bleeding rates. MELD, MELD Na, UKELD and CP scores at the time of 
conception were correlated with outcomes to assess if complications can be predicted more 
accurately in this group.  
 
5.4 Statistical analysis 
Data is presented using median and range for numerical values. To determine whether 
significant differences existed between groups, we applied the Student’s t test, or the Mann-
Whitney-U non-parametric method as appropriate. Differences in nominal data were compared 
either by the Chi squared test or using Fisher’s exact test when the number was less than 5 in 
any given cell of a 2x2 table. A p value of <0.05 was considered to be of statistical significance. 
ROC curves were generated to analyse and compare the accuracy of the MELD and UKELD 
scores in predicting adverse maternal outcomes related to pregnancy. All statistical analysis was 




There were 62 pregnancies in 29 cirrhotic women. Cirrhosis was diagnosed on liver 
biopsy in 41/62 (66%) and by radiological and laboratory parameters in 21/62 (34%). For the 
pregnancies, the underlying aetiology of cirrhosis was autoimmune (n=27), alcohol related 
(n=10), viral (n=6), biliary atresia (n=6), genetic (n=4), vascular (n=2) and other (n=7). The 
median age at conception was 29 years (range 16-40 years). Three patients conceived using in-
vitro fertilization and 21/62 (34%) of pregnancies were unplanned. There were 2 twin 
pregnancies, these occurred in women who had not undergone IVF.  
Median MELD score at conception was 7 (range 6-17), median Meld-Na was 9 (6-17), 
median UKELD at conception was 44 (range 36-53) and median CP score was 5(5-8). Thirty 
seven pregnancies occurred in patients who were Child’s class A and 16 were Childs class B.  
Scores could not be calculated in 7 patients due to absence of occasional pieces of laboratory 
data at the time of conception. Eleven pregnancies occurred in 8 women who had a previous 
episode of decompensation, (3 encephalopathy, 5 ascites). Three women had a previous 
variceal bleed prior to becoming pregnant.  
 
5.5.1 Foetal Outcomes 
The live birth rate was 58% (36/62). There were 9/62 (15%) elective terminations of 
pregnancy and 13/62 (21%) spontaneous miscarriages (spontaneous loss of pregnancy prior to 
20 weeks gestation). Four of the 62 (6%) pregnancies were still births (spontaneous loss of 
pregnancy after 20 weeks gestation). Three pregnancies were conceived using IVF, 2 of which 
resulted in spontaneous miscarriage and 1 neonate was born at 27 weeks with cerebral palsy. 
Regarding terminations, 5 were medically advised due to concerns regarding maternal safety 
with respect to the severity of the underlying cirrhosis or portal hypertension. The median 
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MELD score in the medically advised terminations was 8 (range 6-15) and median UKELD was 45 
(range 37 – 51); the remaining were related to patient preference. Neither MELD score (p=0.64), 
MELD-Na (p=0.45), UKELD score (p=0.46) nor CP score (p=0.24) at conception were predictive of 
a termination of pregnancy, when compared with scores in mothers who had a live birth. This is 
likely due to the impact of patient wishes regarding termination as well as medical advice based 
on the severity of the underlying liver disease. Spontaneous foetal loss occurred in 27% of 
pregnancies, including miscarriage and still birth. Interestingly, this was not associated with 
higher MELD (p=0.88), MELD-Na (p=0.28), UKELD (p=0.45) or CP (p=0.29) scores at conception 
when compared to mothers who had a live birth. 
 The median gestational week was 36 weeks (range, 24-38 weeks). Prematurity, defined 
as a birth prior to 37 weeks gestation, occurred in 64% of the live births and 18% delivered prior 
to 30 weeks gestation. A higher MELD score (8(6-15) v 6(6-15), p=0.01), MELD-Na score (11(6-
15) v 9 (6-13), p=0.01), UKELD score (47 (41-50) v 42(39-47), p=0.01), and CP score (5(5-7) v 7(5-
8), p=0.03) at conception was associated with a birth prior to 37 weeks gestation. Aetiology of 
the underlying liver disease had no impact on the gestational week. Eighteen deliveries were by 
caesarean section and 18 were vaginal. Neither MELD score (p=0.31), MELD Na (p=0.91), UKELD 
score (p=0.29) nor CP score (p=0.32) at conception defined the mode of delivery. Neonatal 
intensive care was required for 17% (6/36). The need for admission of a neonate to intensive 
care was associated with higher maternal MELD score (11(7-15) v 6(6-15), (p=0.04), UKELD score 
(48(42-49) v 42(41-48), p=0.04) but not CP score (7(5-8) v 6(5-7), p= 0.35) or MELD Na (7(6-14) v 
9(6-15), p=0.28) at conception.   
Eleven pregnancies occurred in 8 women who had previously had an episode of 
decompensation. These resulted in 4 live births, 3 miscarriages, 2 still births and 2 terminations 
of pregnancy. An episode of maternal hepatic decompensation prior to pregnancy was not 
associated with spontaneous pregnancy loss (p=0.31).  
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There were no infant peri-natal deaths. Two children however have cerebral palsy and 
one child had learning difficulties but in other regards reached developmental milestones 
normally.  
 




















36 Live Births 
9 Terminations 






4 Still Births 23 born before 
37 weeks 




Table 5.5.1: Utility of the prognostic scoring systems in predicting foetal outcome. 
 
 MELD MELD-Na UKELD CP 
Live birth v 
miscarriage or 
still birth 
7(6-15) v 7(6-16) 
P=0.88 
8(6-15) v 9(8-17) 
p=0.45 
43(36-50) v 44(40-51)  
P=0.45 
5(5-8) v 6(5-8) 
p=0.29 
Live birth v 
termination 
 
 7(6-15) v 8(6-15) 
p=0.64 
9(6-14) v 9(7-17) 
p=0.28 
43(36-50) v 45(37-51) 
p=0.46 
6(5-8) v 6(5-8) 
p=0.24 
Gestational 
week <37 v > 37  





47 (41-50) v 42(39-47) 
 P=0.01 





7(6-15) v 6(6-15) 
p=0.31 
9(7-15) v 8(6-13) 
p=0.91 
43 (36-50) v 42 (20-
48) 
P=0.29 
6(5-8) v 6(5-7) 
p=0.86 
Neonatal ICU v 
ward 
 





48(42-50) v 42(36-48) 
P=0.02 












5.5.2 Maternal Complications 
Maternal mortality directly associated with pregnancy occurred in 1/62 (1.6%) 
pregnancies, although this represents 1/29 mothers in total (3.4%). A significant maternal 
complication, occurred in 6/62 (10%) of the pregnancies (6/29 (21%) of mothers) and included 
variceal bleeding (n=3), decompensation with development of significant ascites (n=2) and 
hepatic encephalopathy (n=1).  
Review of these cases in more detail demonstrated that the first variceal bleed occurred 
at 31 weeks gestation following an emergency caesarean section for foetal distress. The patient 
became haemodynamically unstable, underwent emergency laparotomy which revealed 
ruptured splenic varices. A splenectomy was undertaken but haemostasis could not be achieved 
and she died following a hypovolemic arrest. The second patient had a variceal bleed in the 
second trimester which was controlled using endoscopic band ligation. A healthy baby was 
delivered by caesarean section at 34 weeks gestation, but she died 6 months later following a 
further variceal bleed. The third case of variceal bleeding again occurred again in the second 
trimester and was controlled using endoscopic therapy. A healthy baby was delivered at 34 
weeks gestation by caesarean section. The mother remains clinically stable at 3-years post-
delivery.  
Two patients developed new onset ascites associated with pregnancy. The first had 
spontaneous rupture of membranes and cord prolapse at 25-weeks. She underwent emergency 
caesarean section at 27 weeks, required admission to critical care and was hospitalised for a 
total of 6-weeks following delivery. She remains clinically well at 5-years follow-up. The baby 
also required intensive care, was ventilated for 48 hours and has mild cerebral palsy. The 
second patient who developed ascites underwent an emergency caesarean section at 34 weeks 
gestation for foetal distress. Although the baby required intensive care support the mother 
remains well at 3-years follow-up. The final patient has autoimmune hepatitis and developed 
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significant deterioration of her liver function tests post-partum. She developed encephalopathy, 
and underwent transplantation. She died 14 months later from graft failure secondary to 
recurrent rejection on a background of poor adherence.  
In addition to the aforementioned cases, there was one further maternal death 28 
months following the delivery of her second child. Despite priority listing for liver 
transplantation she died awaiting a graft. Two further patients required transplantation, with 
one patient transplanted for chronic liver disease 4-months following a termination of 
pregnancy and the second transplanted 24 months post-delivery.  
 
Table 5.5.2:  Maternal Deaths in women with cirrhosis who became pregnant 
Age at 
conception 







birth to death 
(months) 
Transplanted 
16 7 43 Yes Yes 16 Yes – 2 
months post-
partum 
34 15 47 Yes No 28 No 
33 14 47 Yes Yes 6 No 








5.5.3 Use of prognostic scores to predict maternal outcomes 
A higher median MELD score (10, (7-14) v 7, (6-17), p=0.01) and UKELD score (48, (43-
48) v 43, (36-51), p=0.02) at conception was associated with an increased risk of the mother 
developing a significant liver related adverse event. Interestingly, neither MELD-Na (p=0.16) nor 
Child Pugh (p=0.2) score at conception were associated with an increased risk of the mother 
developing a significant liver related adverse event. 
Evaluation of the receiver operator characteristic (ROC) curves for MELD and UKELD 
scores at conception and the development of a significant liver related complication for the 
mother both demonstrated an area under the ROC curve (AUC) of 0.80 at a 95% confidence 
interval (figure 5.5.2). Furthermore, a MELD score of greater than 10 points demonstrated 83% 
sensitivity and 83% specificity for predicting which patients with cirrhosis were likely to 
experience a significant liver related complication during pregnancy. Regarding UKELD, a score 
of greater than 47 demonstrated an 83% sensitivity and a 79% specificity for predicting which 
patients with cirrhosis are likely to experience a significant liver related complication. 
Interestingly no patient who had a MELD score of 6 or a UKELD score of less than 42 developed 










Figure 5.5.2: Receiver Operator Curve for MELD and UKELD as a predictor for maternal 






















Over a mean maternal follow-up period of 7 years, in addition to the aforementioned 
cases, there was one further maternal death 28 months following the delivery of a second child. 
Despite priority listing for liver transplantation she died awaiting a graft. Two further patients 
required transplantation, with one patient transplanted for chronic liver disease 4-months 






MELD = 0.798 
               (95% CI 0.661 – 0.935) 
UKELD = 0.801  
(95% CI 0.950 – 0.953) 
109 
 
5.5.4 Variceal Screening and Bleeding 
Forty-one women carried pregnancies into the second trimester. Of these, 93% (38/41) 
underwent endoscopic screening for varices. One patient went into spontaneous labour 
following endoscopic screening at 24 weeks gestation. Her MELD and UKELD scores at 
conception were 8 and 45 respectively. The baby required neonatal intensive care and has 
learning difficulties on follow-up. No other complications related to endoscopy were noted.  
Oesophageal varices were present in 50% (19/38) of those screened. No gastric varices 
were reported. The MELD, MELD-Na, UKELD and CP scores at conception were not associated 
with the presence of varices on screening endoscopy in the second trimester. The platelet count 
however at conception was predictive of the presence on varices on screening endoscopy (84 
(28-225) vs. 184 (62-308), p<0.001). ROC curve analysis of platelet count at conception (as a 
predictor for varices on screening endoscopy in the second trimester) demonstrated an AUC of 
0.856 (Fig 5.5.4). Furthermore a platelet cut off of 110 x10^9cells/l gives a 78% sensitivity and 












Figure 5.5.4: Receiver operator curve for platelet count as a predictor of oesophageal 
varices on screening endoscopy in the second trimester of pregnancy 
 
Three patients had a variceal bleed associated with pregnancy, as discussed above.  All 
three women were known to have varices prior to conception, one of whom had had a prior 
episode of variceal bleeding. MELD (p=0.06) and UKELD (p=0.08) scores at conception were 
associated with a trend towards variceal bleeding but this did not reach statistical significance.  
Women who had varices detected on screening endoscopy were more likely to deliver 
by caesarean when compared with women without (13/18 vs. 4/15, p=0.02). Neither MELD 
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(p=0.31) nor MELD-Na score (p=0.91), UKELD score (p=0.29) nor CP score (p=0.32) at conception 
were associated with the mode of delivery. No patient with confirmed varices had significant 
bleeding following caesarean section from the presence of abdominal wall varices.  
 
5.6 Discussion 
 In this chapter we have identified that pregnancy in patients with cirrhosis carries a high 
incidence of maternal morbidity, occurring in 10% of pregnancies. A live birth rate of 58% is 
reported with 75% of neonates born prematurely and 17% of live births requiring neonatal 
intensive care support. We have also demonstrated that the prognostic scoring systems of 
MELD, MELD-Na, UKELD and CP score at the time of conception can be used to predict certain 
outcomes and complications that may be encountered during pregnancy. Moreover we have 
found that a MELD score of 10 or above prior to conception has an 83% sensitivity and 
specificity for predicting a serious liver related complication during pregnancy or after delivery. 
This information therefore allows tailored advice to be given to the individual regarding their 
specific risks associated with pregnancy in relation to the severity of their underlying cirrhosis.  
Discussions regarding pregnancy and its associated risks are rarely undertaken in 
women with cirrhosis due to the high incidence of infertility. Failure to discuss contraception in 
cirrhotic women of child bearing age can therefore lead to a number of unplanned and/or 
unwanted pregnancies (38% in this cohort). Furthermore the safety of undergoing planed 
termination of pregnancy in patients with cirrhosis is unknown, with publications limited to 
isolated case reports. In our cohort of 9 patients who underwent medical termination, one 
patient had a deterioration of hepatic function and needed transplantation. We suggest 
therefore, that all women of child bearing age with cirrhosis should be advised regarding the 
importance of contraception to avoid unwanted and unplanned pregnancies along with the 
potential risks associated with a termination.  
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Spontaneous pregnancy loss in this study was 27%, when both miscarriage and still 
births were combined. By comparison a relatively recent prospective population study in 2003 
stated a self-reported clinical abortion rate of 7.9% in the general population. (209) 
Interestingly, this study has shown that although the foetal loss rate is increased significantly in 
women with cirrhosis, this specific occurrence does not appear to correlate with the severity of 
the underlying cirrhosis. This may be related to several factors, the first being that cirrhotic 
women have irregular menstruation as cirrhosis advances and that consequently, an early 
pregnancy loss in patients with more advanced cirrhosis could be missed. Secondly, due to the 
limitations of the retrospective nature this study, many early losses may not have been reported 
to us. Indeed, previous published reports have estimated the spontaneous abortion rate to be 
higher, reported between 30% and 40% of pregnancies in women with cirrhosis.  (210) 
Previous case series of foetal outcomes in cirrhotic patients reported a foetal mortality 
rate of 8%, (105). This is considerably greater than in our report where no peri-partum foetal 
deaths occurred. This original study however was published in 1994 and included patients from 
an era dating to back to 1970’s. It can be postulated therefore that mortality rates have fallen as 
a consequence of improved standards of medical care over the last two decades. (211) Although 
our cohort does include patients from as early as 1984, the majority of patients 57/62 (92%) 
date from 1990, making advances in medical care likely to be a significant contributing factor in 
foetal survival. Additionally, although the earlier study offered minimal information regarding 
the severity of the mothers underlying liver disease, 6/11 were reported as having developed an 
episode of decompensation prior to conception and 6/11 had a variceal bleed during pregnancy. 
This suggests that the underlying maternal liver disease was more severe in the earlier 




The optimal management of portal hypertension during pregnancy remains challenging 
with the absolute need for variceal screening during the second trimester, primary prophylaxis 
against variceal haemorrhage and the management of a variceal haemorrhage during pregnancy 
largely undefined. Management is based on best guess experience extrapolated from the non-
pregnant literature. In a patient with ‘at-risk’ for bleeding oesophageal varices, endoscopic band 
ligation of varices, although not proven, is appropriate. Case reports describing this strategy in 
pregnancy have been published,(108) although no randomized trials have been carried out to 
prove efficacy. Currently, the American Association for the Study of Liver Disease (AASLD) 
recommends that once pregnant, women with cirrhosis should have a screening endoscopy in 
the second trimester,(110) since this represents the time when portal pressure increases, due to 
increased circulating blood volume and direct compressive effects of the gravid uterus on the 
inferior vena cava. Previous studies have reported the prevalence of varices in the second 
trimester to be in excess of 50%. (212) This current study reports a similar prevalence with 
varices reported in 50% of those screened. In this study, variceal haemorrhage occurred in 3 
cases, which is much lower than previous reports where the incidence of bleeding has been 
reported to be as high as 50%. (105, 111) The lower incidence of haemorrhage, in this study is 
likely in-part to reflect screening in the second trimester and subsequent delivery by caesarean 
section if large or ‘at risk’ varices were present. Additionally, the use of non-selective beta 
blockers in patients who were deemed ‘at-risk’ or who had undergone a previous variceal bleed 
may have modified this outcome. We have demonstrated that a cut-off platelet count of 
110x10^9cells/L has an 78% sensitivity and 89% specificity for predicting the presence of varices 
at screening endoscopy in the second trimester. Based on this finding, it may be possible if 
confirmed in other cohorts to use this cut-off platelet count as an arbiter for categorizing 
patients into those that require screening for varices in pregnancy. However, it must be 
acknowledged that current AASLD guidelines recommend screening everyone with cirrhosis for 
varices regardless of the platelet count.(110) 
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Caesarean section, although not proven, is thought to avoid the theoretical increased 
bleeding risk associated with an increase in portal pressure in the context of the Valsalva 
manoeuvre during labour. It must be appreciated that these women may also have abdominal 
wall varices and a caesarean section should not be regarded as entirely safe, although no 
significant bleeding was reported in this cohort. The optimal timing of when to book patients in 
for a caesarean section remains challenging and the risks between electively delivering a 
premature baby and the avoidance of a spontaneous labour must be balanced. 
Liver related maternal complications including variceal bleeding, development of ascites 
and encephalopathy occurred in 10% of pregnancies. One patient died directly as a result of the 
complication and a further 2 patients that had a significant complication during pregnancy died 
at 6 and 16 months following delivery. This raises the question as to whether patients that 
decompensate during pregnancy should be considered for transplantation post-delivery even if 
their synthetic function recovers. Similarly, it suggests that although the prognostic scores such 
as MELD or UKELD are significantly lower than those at which transplantation would ordinarily 
be considered, patients that decompensate during pregnancy are a group that lack functional 
hepatic reserve and therefore may benefit from earlier transplantation.  
This study has also demonstrated that a MELD score of greater than 10 points has an 
83% sensitivity and specificity for identifying which patients during pregnancy are likely to have 
a significant liver related complication. This highlights the fact that physicians cannot be 
reassured by “low” MELD scores in pregnant patients with cirrhosis and suggests women with a 
MELD score of 10 or above should be advised against pregnancy. This is interesting since data 
from non-pregnant cohorts with cirrhosis has shown that in patients with a MELD score of less 
than 14 prior to transplant, transplantation is associated with a higher mortality than in patients 
with similar MELD score who are not transplanted. (213) 
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In conclusion we have demonstrated that the MELD and UKELD scores at conception 
can be used to predict likely outcomes of pregnancy in cirrhotic patients. Higher scores are 
associated with foetal prematurity and neonatal intensive care admission. Additionally a MELD 
score of greater than 10 or a UKELD of greater than 47, have a greater than 80% sensitivity and 
specificity for predicting which patients with cirrhosis are likely to experience a significant liver 
related complication and it may be safest to advise these patients against becoming pregnant. 
Conversely, patients with a MELD score of 6 or less can reassured that the risk of encountering a 
significant complication is minimal.  












CHAPTER 6: Predicting outcomes of pregnancy in 
women with Autoimmune Hepatitis 
6.1 Introduction: 
 
Autoimmune hepatitis (AIH) is a disorder that has been recognised for over 50 years. 
First described by Waldenström in the early 1950’s as a chronic form of hepatitis with a classical 
phenotype of liver disease in a younger aged women, often in conjunction with extra-hepatic 
manifestations including arthralgia, endocrine abnormalities and amenorrhoea.(138) Reports 
regarding pregnancy in patients with AIH exist from as early as the 1970’s but the reported 
outcomes were largely unfavourable, with a high incidence of obstetric complications noted 
including early foetal loss, prematurity, low birth weight and a high rate of caesarean 
sections.(102, 139) Moreover maternal complications included pre-eclampsia, flares in disease 
activity, hepatic decompensation and death.(102, 139) 
Subsequent to these initial reports there have been several recent case series indicating 
more favourable outcomes.(14, 140-142) Combining the 4 largest series in the published 
literature on AIH and pregnancy gives data on 142 conceptions. (14, 140-142) The maternal 
outcomes reported are largely favourable; however pregnancy is not without risk to the mother 
with 3 reports of hepatic decompensation, 1 liver transplant and 3 maternal deaths (1 liver 
related) all related to pregnancy.(14, 140-142) Foetal outcomes are favourable with a healthy 
infant expected in the majority of patients and live birth rates reported to be between 71% and 
86%. (14, 140-142) These live birth rates are comparable to patients with other autoimmune 
conditions, but remain lower than the reported live birth rates for the general population. (143)  
Despite our increase in knowledge surrounding the management of AIH during 
pregnancy, several concerns remain. Flares in disease activity have been reported to occur in 7- 
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21% of patients within the gestational period and occur at a rate varying from 11-86% in the 
post-partum period. (14, 140-142) In the majority of patients a flare can be controlled by 
augmentation of the immunosuppression however, in rare cases, a flare can lead to hepatic 
decompensation with the potential need for liver transplantation (LT) or death of the patient 
and/or foetus. (140, 142)  
Distinguishing which patients are likely to have an uneventful pregnancy and those at 
risk of the above complications is currently challenging. In addition the optimal therapeutic 
regimen to prevent disease flares remains undefined, with some centres discontinuing 
azathioprine due to a theoretical risk of birth anomalies, (141) whilst others continue it 
throughout pregnancy to minimise the potential risk of a flare in AIH activity.(140) Finally, in 
those patients with underlying cirrhosis who become pregnant, there are likely to be additional 
maternal and foetal risks including a higher incidence of maternal decompensation, significant 
variceal / post-partum bleeding and foetal prematurity. (48) The safety of pregnancy in patients 













The data discussed above and in the introductory chapter indicate that pregnancy in 
this cohort of women is not without risk with reports of disease flares, hepatic decompensation, 
need for liver transplantation and death. Despite the above detailing potential complications in 
this cohort of women, identifying those women which women are likely to have an uneventful 
pregnancy and those at risk of the above complications is yet to be defined.  
The aims of this chapter were therefore: 
 To assess the incidence and severity of maternal complications in women with 
autoimmune hepatitis who become pregnant 
 To assess the incidence and severity of foetal complications in women with 
autoimmune hepatitis who become pregnant 
 To identify if there are any pre conception parameters that would enable physicians to 
predict / identify those women with AIH who are at greatest risk of developing 
complications in association with pregnancy. 
 To assess the safety and usage of immunosuppressive regimes with regards to foetal 
and maternal safety. 
 To allow individualised rather than generic advice to be given to individual patients 








The master database, as described in the methods chapter was interrogated to identify 
all women with AIH who had reported pregnancy or whom were trying to conceive (1982-2009). 
In total, 81 pregnancies had been self-reported by 53 women. All women included fulfilled the 
criteria for definite AIH as defined by the revised International Autoimmune Hepatitis Group 
criteria. (214) Baseline characteristics were obtained from the medical notes and from 
investigations performed at the clinic visit immediately prior to conception being reported.  
Information was gathered on disease duration, activity of disease, number and 
frequency of disease flares and medication regimen prior to pregnancy. In addition, the 
presence of cirrhosis was recorded if there was histological evidence on biopsy or it was 
deemed likely based on a combination of radiological and laboratory parameters. Maternal 
complications during pregnancy and in the post-partum period were recorded including flares in 
AIH activity, hepatic decompensation and any other adverse events. Data on abortions, 
including spontaneous and elective terminations of pregnancy were obtained in addition to the 
gestational duration, live birth rate and foetal outcomes.  
 For the purpose of this study, a flare of AIH was defined as a two-fold increase in serum 
aspartate aminotransferase (AST) activity above the upper limit of normal or a lesser increase in 
AST in conjunction with increased serum globulin concentration and the re-emergence of 
symptoms. Disease remission was defined as the disappearance of symptoms, improvement of 
serum AST levels to less than twice normal, normal gamma globulin levels and if biopsy done 






6.4 Statistical Analysis 
 Data is presented using median and range for numerical values. To determine whether 
significant differences existed between groups, we applied the Student’s t test, or the Mann-
Whitney-U non-parametric method as appropriate. Differences in nominal data were compared 
either by the Chi squared test or using Fishers exact test when the number was less than 5 in 
any given cell of a 2x2 table. A p value of <0.05 was considered to be of statistical significance. 
All statistical analysis was performed using the SPSS statistical software package version 14 

















A total of 81 pregnancies in 53 women with AIH were reported between 1982 and 2009 
at the Institute of Liver Studies, King’s College Hospital. The median age at diagnosis of AIH was 
20 years (range 5-42 years) and the median age at conception was 26 years (range 16-42 years). 
The median duration of disease prior to conception was 7 years (range 0-25 years). Sixty three 
percent (51/81) of patients were in biochemical remission for over a year prior to conception. 
Thirty three conceptions occurred in 21 women who had underlying cirrhosis. Six pregnancies 
were conceived with the help of in vitro fertilisation (IVF). 
 
6.5.1 Assisted conception 
There were 7 conceptions with IVF occurring in 5 women. Overall these resulted in 4 live 
births (one chid had cerebral palsy), 1 still birth and 2 miscarriages. The median age at 
conception was 35-years (range 29-42 years).  
There were three conceptions in 2 women with cirrhosis (Childs Pugh A). The first 
women had 2 miscarriages at 8 and 10-weeks with no adverse maternal effects noted. The 
second women with cirrhosis delivered a healthy baby at 36-weeks following an uneventful 
pregnancy, however she had a significant deterioration in hepatic function 12-months post-
partum and died whilst undergoing a liver transplant assessment. 
There were 4 conceptions with IVF in 3 non-cirrhotic women. Two women delivered 
healthy babies at 38-weeks’ gestation. The first had a mild post-partum flare in AIH activity 
which settled spontaneously; the second developed de-novo AIH 3 month’s post-partum which 
was successfully treated with a combination of prednisolone and azathioprine. The final non 
cirrhotic patient had 2 conceptions with IVF. In the first pregnancy she developed severe AIH 
activity at 24-weeks, with the development of ascites. A caesarean section was performed at 28 
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weeks and the child has cerebral palsy.  Her second pregnancy was complicated by a 
spontaneous rupture of membranes at 20 weeks resulting in foetal loss. There was no change in 
the AIH activity.   
 
Table 6.5.1: Outcomes of 7 conceptions with IVF in 5 women with AIH 






















No adverse maternal effect 
 






YES Live Birth 36-
weeks 
No effect Significant deterioration 12 months 
post-partum, and mother died 
awaiting transplant assessment 
3 
 
40 NO Live Birth 38-
weeks 
Post-partum 
flare – settled 
spontaneously 
Overlap with PBC 
4 
 
40 NO Live Birth 38-
weeks 
De Novo AOH at 
3 months post-
partum 
























Recovered post-delivery with 
prednisolone and azathioprine 
 









6.5.2 Therapeutic Regimens 
At conception, 61 patients (75%) were receiving therapy for control of their AIH. Of 
these, 27 patients were on prednisolone monotherapy (mean dose 10mg/day, range 2.5mg - 
40mg), 7 were on azathioprine monotherapy (range, 1mg/kg/day-2mg/kg/day) and 25 patients 
were on combination therapy of azathioprine (1mg/kg/day - 2mg/kg/day) and prednisolone 
(mean dose 5mg (range 2.5-20mg)). In addition, one patient was taking tacrolimus (2mg/day) in 
conjunction with prednisolone. Amongst those patients on medication, 46 (74%) had been 
stable on their medication regimen for over 1-year prior to conception. 
Twenty patients were on no treatment prior to conception, 2 were de novo 
presentations of AIH in association with pregnancy, 5 were cirrhotic with burnt out disease, 6 
were in biochemical and histological remission and had subsequently had treatment 
discontinued at a median time of 32-months prior to conception. The remaining 7 had their 
medication stopped either due to personal wishes or on medical advice with regards to their 
wish to become pregnant.   
In total, 32 conceptions occurred in women on azathioprine. Of these, there were 21 
live births, 6 elective terminations, 4 spontaneous abortions and 1 maternal (and subsequent 
foetal) death. Of the live births, there were no reported foetal anomalies. In the 20 conceptions 
that occurred in women on no treatment, there were 17 live births, 2 elective terminations and 
one still birth at 21 weeks gestation. Of the live births abnormalities have occurred in 2 children. 
The first has cerebral palsy as described above and the second developed Perthes’ disease of 
the hip. 
A comparison between those pregnancies that occurred on therapy (prednisolone, 
azathioprine or tacrolimus) with pregnancies that occurred in women not on 
immunosuppression revealed no significant differences in the live birth rate (42/61 vs. 17/20, 
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p=0.24), termination rates (10/61 vs. 2/20, p=0.72), miscarriage rates (8/61 vs. 0/20, p=0.19) or 
gestational period (39 (28-40) vs. 39 (27-30), p=0.8).  
However, the incidence of a flare occurring in AIH activity at any time in the gestational 
period or and time in the post-partum period was significantly higher in those women that were 
not on therapy when compared to those on therapy (10/20 vs. 16/61, p=0.048). Data pertaining 
to pregnancy outcome and disease flares in relation to therapy is summarised in table 6.5.2. 
Table 6.5.2: Effect of therapy on maternal and foetal pregnancy outcomes 












































































6.5.3 Foetal Outcomes 
The live birth rate was 73% (59/81). Of the remaining 22 conceptions, there were 8 
spontaneous miscarriages (10%), 12 terminations of pregnancy (5 of which were medically 
advised), 1 still birth and 1 foetal death related to unexpected maternal death as a result of 
severe pulmonary hypertension due to pulmonary emboli. The median gestation was 38-weeks 
(range 27-40 weeks) and the median birth weight was 2750 grams. Prematurity, defined by a 
live birth prior to 37-weeks’ gestation occurred in 12/59 (20%) of pregnancies. 
Six neonates (11%) required admission to a SCBU immediately after birth. All survived to 
hospital discharge however one neonate born at 28 weeks gestation by caesarean section has 
cerebral palsy (as discussed above). One neonate died 10 weeks following delivery (mortality 
rate 1/59, (0.2%)) due to overwhelming sepsis. In that instance the mother was not taking 
azathioprine. 
Importantly, the live birth rate was lower in individuals who were cirrhotic at the time 
of conception (14/33 vs. 4/48, p=0.02). In addition, a neonate was statistically more likely to 
need admission to the special care baby unit (SCBU) if the mother had pre-existing cirrhosis 
(4/19 vs. 2/40, p=0.07) or had a flare in disease activity during pregnancy (2/4 vs. 4/55, 
p=0.047). Prematurity, as defined by a birth prior to 37 weeks gestation was not statistically 
associated with the absence of maternal therapy (p=0.07), nor associated with a flare in AIH 
activity during the gestational period (p=0.18).   
All children have been followed up for a median of 7-years. Two significant 
abnormalities have been identified (both in mothers not on azathioprine). The first is the child 





Table 6.5.3: Foetal outcomes in women with AIH 
 Live Birth rate Prematurity 
<37 weeks 
SCBU 
Cirrhosis vs. no Cirrhosis 
(n=33)                 (n=48) 
19/33 vs. 40/48 
p=0.02 
5/19 vs. 7/40  
p=0.43 
 
4/19 vs. 2/40 
p=0.07 
 
Maternal disease remission 
> 1year (n=52) vs. no 
remission (n=29) 
38/52 vs. 21/29 
p=0.95 
8/38 vs. 4/21  
p=0.99 
 
3/38 vs. 3/21 
p=0.65 
Therapy (n=61) vs. no 
therapy (n=20) 
 
42/61 vs. 17/20 
p=0.25 
6/42 vs. 6/17  
p=0.07 
 
5/42 vs. 1/17 
p=0.66 
AIH gestational flare (n=5) 
vs. no gestational flare 
(n=76)  




2/4 vs. 10/55  
p=0.18 




6.5.4 Maternal Outcomes  
The overall maternal complication rate was 31/81 (38%) conceptions. These consisted 
of 1 maternal death (whilst pregnant), 3 maternal deaths within 12 months of delivery. Two 
patients required liver transplantation (LT) within 12 months of delivery and 1 patient 
decompensated during pregnancy but subsequently re-compensated post-delivery. In addition 
to the above a flare in disease activity occurred in association with 26 pregnancies (32%) and 2 
women had a severe post-partum haemorrhage requiring blood transfusion.  
A flare in disease activity was the most common complication occurring in 26/81 (33%) 
pregnancies (median AST 200, range 80-1025 IU/L). Twenty occurred post-partum (within the 
first 3 months following delivery), and 6 during the gestational period. Medication 
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augmentation was required in 20 cases and consisted of increased doing of prednisolone 
(20/26), azathioprine (4/26) and tacrolimus (2/26).  In 5 cases, a flare in disease activity 
precipitated an episode of hepatic decompensation. A flare in AIH was more likely in patients 
who had not achieved disease remission for greater than 1-year prior to conception (14/29 vs. 
12/52, p=0.03) or were older at conception (26 vs. 29 years, p=0.047). Additionally, patients 
who had a flare in association with pregnancy were more likely to decompensate from a liver 
standpoint (5/26 vs. 1/55, p=0.01).  
A serious maternal adverse event (death or LT during or within 12 months of delivery or 
hepatic decompensation during or within 3 months of delivery) occurred in association with 9 
pregnancies (11%). The maternal death which occurred in pregnancy underwent post-mortem 
examination and the cause of death was a result of severe pulmonary hypertension due to 
pulmonary thrombi (discussed above). Six conceptions were associated with hepatic 
decompensation. The first women who decompensated was cirrhotic at conception, and she 
developed a significant deterioration of her liver function tests peri-partum. Post-partum she 
developed encephalopathy, and subsequently underwent liver transplantation (LT). She died 14-
months later from graft failure secondary to recurrent rejection on a background of poor 
adherence. The second woman was also cirrhotic at conception. At 10 weeks gestation she 
developed ascites which was resistant to diuretics. She underwent a termination of pregnancy 
at 12-weeks’ gestation and re-compensated. The same women had a second pregnancy 1-year 
later she developed a gestational flare at 26-weeks she delivered at 28-weeks but 
decompensated with ascites post-partum. She underwent LT 12-months later and remains well 
over the subsequent 10-year follow-up period. The third women had a variceal bleed at 31-
weeks’ gestation. The bleeding was controlled endoscopically and she delivered a healthy baby 
at 34-weeks by caesarean section. She died 7-months later from a further variceal bleed. The 
fourth women who decompensated (discussed above) developed severe AIH activity at 24 
weeks and her baby delivered at 27-weeks has cerebral palsy. Her disease remains stable on 
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immunosuppression 11-years post-delivery. The final woman who decompensated, had a post-
partum flare and developed significant jaundice and small volume ascites. She was transplanted 
3-yers post-partum.  In addition to the above cases, 2 further women died within 1 year of 
delivery; the first developed severe worsening of her liver function 12-months post-partum and 
died whilst undergoing a LT assessment. The second was poorly compliant with AIH treatment, 




















Table 6.5.4: Summary of 9 conceptions with severe adverse maternal outcomes in 
association with pregnancy 
 





1 No Died 28 weeks gestation 24 Died Death: sudden death at 25 weeks for 
pulmonary hypertension secondary to 
thromboembolism 
2 Yes Post-partum flare with 
encephalopathy – transplanted 
217 Alive / healthy Death: 14-months post-partum, from 
poor compliance on chronic rejection 
3 Yes Post-partum flare – very difficult 
to control. Significant jaundice 
mild ascites. 









Post-partum flare with 
decompensation (ascites) 
 
Ascites at 10 weeks, unable to 






Born 28 weeks 










Severe flare at 24 weeks, 
decompensated with ascites  
 
200 Baby delivered 
at 28 weeks – 
cerebral palsy 
Alive 
Remains stable on immunosuppression 
6 Yes Variceal bleed at 31 weeks, 
controlled endoscopically 
30 Alive healthy, 
34 weeks 
Death: 7 months post-partum secondary 
to uncontrollable variceal bleed. 
7 Yes Severe PPH  Born 32 weeks 
needed SCBU 
Death: Variceal bleed 1 year post-
partum, refused blood transfusion 
8 Yes Uneventful pregnancy 28 Healthy Deterioration 12 months post-partum, 
died whilst having LT assessment 
 
6.5.5 Impact of cirrhosis 
Thirty three conceptions occurred in 21 women with cirrhosis. The presence of maternal 
cirrhosis impacted on foetal outcome with the live birth rate being lower in mothers who were 
cirrhotic at the time of conception (14/33 vs. 4/48, p=0.02). Furthermore maternal cirrhosis was 
also associated with prematurity and the need for a neonatal admission to a special care baby 
(4/19 vs. 2/40, p=0.07) post-delivery, although this did not reach statistical significance.  
Maternal outcomes were also affected by the presence of cirrhosis. Conception in a 
women with AIH and underlying cirrhosis was more likely to be complicated by the mother 
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developing a serious maternal adverse event (defined above) when compared to conceptions in 
women with AIH without cirrhosis (7/33 vs. 2/48, p=0.028). This remained significant when an 
individual women’s outcomes were analysed rather than individual conceptions (p=0.041). 
The model for end stage liver disease (MELD) score was calculated in all cirrhotic 
patients where data available (n=19) from the clinic visit immediately prior to conception. Both 
a birth prior to 37 weeks (p=0.07) and the need for admission to a special care baby unit 
(p=0.06) were non-significantly associated with a higher MELD score at conception. Moreover a 
higher MELD score at conception was non-significantly associated with the development of a 
















In this chapter we have identified that pregnancy in AIH can be associated with a high 
incidence of disease flares (33%) and serious maternal adverse events (11%). We have shown 
that disease flares are associated with poor disease control in the year preceding pregnancy 
(p=0.03) and the absence of therapy whilst pregnant (p=0.047). Disease flares are clinically 
important as they were associated with a significantly increased risk of hepatic decompensation 
(p=0.01) and an increased need for neonatal admission to special care baby units (p=0.047). 
Furthermore we have shown that continuing immunosuppression throughout pregnancy in 
women with AIH is relatively safe with no apparent increased risk of adverse effects on either 
live birth rate or congenital anomalies. Finally we have demonstrated that in women with 
underlying cirrhosis the live birth rate is reduced and mothers with cirrhosis are more likely to 
develop a significant adverse event.  
Pregnancy is widely accepted to impact on AIH activity. In this study a flare in AIH 
activity occurred in 33%, with the majority (78%) occurring in the post-partum period. Previous 
studies on AIH during pregnancy report similar findings, with a stable course of AIH activity in 
the gestational period with the majority of flares occurring in the post-partum period. (14) The 
mechanism for this phenomenon is incompletely understood. However, evidence published 
regarding the aetiopathogenisis of AIH has demonstrated that an impairment in regulatory T-
cell number and function is key to the loss of immune tolerance and thus the emergence of an 
uncontrolled effector autoimmune response. (17, 18) Pregnancy induces the temporary 
development of immunological tolerance in order to allow the mother to tolerate the paternally 
derived antigens expressed by the foetus. Regulatory T-cells are therefore required for the 
maternal immune system to tolerate the foetal allograft, and there is an increase in their 
circulating number during pregnancy. (12, 13) Taking into account the above factors, it becomes 
clearer why patients with AIH, and indeed other autoimmune conditions frequently undergo 
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remission during pregnancy and then flare in the post-partum period, such that when 
pregnancy ends, tolerance breaks down and flares in disease activity occur.  
The delivery of a healthy baby is a prime consideration of any woman who wishes to 
become pregnant. Concerns regarding continuing immunosuppression whilst pregnant, and in 
particular azathioprine remain. In animal models, azathioprine has been associated with skeletal 
abnormalities, cleft palate, hydrops foetalis and haemopoetic abnormalities of the foetus. (195, 
196) In humans, lymphopenia, hypogammaglobulinaemia and thymic hypoplasia have all been 
reported in children born to mothers on azathioprine. (216) Furthermore, azathioprine has been 
linked to pre-term deliveries. (197) Experience with azathioprine in pregnancy has increased 
dramatically in recent times with accumulated data derived from other patient populations 
especially those with inflammatory bowel disease, rheumatoid arthritis or patients following 
solid organ transplantation. (179, 217, 218) The conclusions from these studies corroborate our 
findings, that azathioprine is safe and should ideally be continued during pregnancy to maintain 
maternal disease remission.  
In this current study, little has been found to suggest that azathioprine or its 
metabolites are toxic in pregnancy with its use having no adverse impact on the live birth rate, 
gestational age or rate of congenital abnormalities. Moreover, immunosuppressive therapy was 
associated with a significantly reduced maternal AIH flare rate (p=0.047) when compared to 
women with AIH not on therapy and foetal prematurity was more common in mothers not 
immunosuppressive on therapy, however this did not reach statistical significance (p=0.07). This 
study therefore adds growing support to the theory that the greatest chance of a healthy baby 
in patients with AIH is attained by continuing therapy with the aim of achieving a healthy 
mother throughout pregnancy via good disease control.  
The incidence of a serious maternal adverse event occurred in 9 conceptions (11%). This 
is significantly higher than that of the general population. (219) The increased incidence of a 
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serious maternal adverse event in association with pregnancy in women with AIH has been 
reported in other series; Schramm et al. and Terrabuio et al. both describe a serious maternal 
complication rate of 9% and 7.8% respectively. (141, 142) To-date, identifying which women 
with AIH are likely to have a risk free pregnancy and who are at an increased risk of developing 
serious complications has been challenging. This study has identified that sub-optimal disease 
control in the year prior to conception (p=0.03), the absence of therapy (p=0.047), cirrhosis 
(p=0.02) and increasing maternal age (p=0.047) are all pre-conception parameters that confer 
increased pregnancy risk. This study therefore will hopefully help to optimise pre-conception 
counselling allowing potential mothers to make informed decisions regarding pregnancy. 
We have demonstrated in the previous chapter that prognostic scoring systems such as 
MELD score can help identify pre conception which cirrhotic women are likely to develop liver 
related decompensation during pregnancy. (220) In this study we have identified that women 
with cirrhosis are more at risk of developing a serious maternal adverse event (p=0.028) and are 
more likely to have premature babies (0.07) with an increased need for admission to a special 
care baby unit (0.07) when compared to those mothers without cirrhosis. Moreover we have 
shown that in those women with cirrhosis a higher MELD score at conception is associated with 
a further increased chance of the above adverse outcomes.  Whilst we appreciate that not all of 
the above findings reach statistical significance and therefore must be interpreted with caution, 
we feel the findings have clinical significance and have thus been included in the manuscript.  
This study has several limitations. Firstly the retrospective nature means that all women 
were not monitored in the same way throughout their pregnancy. Pregnancy was self-reported 
and thus early miscarriage may not have been noted and thus the reported incidence may be 
falsely low.  Secondly as experience and treatment of AIH has evolved the treatment at out 
centre of AIH and pregnancy has changed. This means that all women were not treated with the 
same protocol during pregnancy, in that in the earlier pregnancies azathioprine was 
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discontinued due to concerns regarding its safety whereas our current practice is to maintain 
immunosuppression throughout pregnancy. Finally although we have identified several 
preconception parameters which are associated with adverse outcome, these have been 
evaluated by univariate analysis due to the relatively small numbers and may not be individually 
associated on multivariate analysis.  
In conclusion, we have shown for the first time that poor AIH control in the year prior to 
pregnancy and the absence of therapy are associated with an increased risk of a flare in AIH 
activity whilst pregnant. This is important as we found that AIH flares were significantly more 
likely to lead to hepatic decompensation, and an increased risk neonatal admission to SCBU. 
Furthermore we report no adverse effects of azathioprine and have demonstrated better foetal 
and maternal outcomes in patients on therapy.  We hope that this study will help optimise pre-













Chapter 7: Pregnancy following Liver 
Transplantation – predicting outcomes 
7.1 Introduction:  
Liver transplantation (LT) has evolved to be a universally accepted treatment for 
patients with acute liver failure and end-stage chronic liver disease. Survival rates following LT 
have improved steadily over the last 2 decades, with current five-year survival rates reported to 
be in excess of 70% and long-term survival is now expected in the majority of recipients.(167, 
168) As survival rates following LT improve, focus of medical care has broadened to incorporate 
factors that impact on quality of life. (173) For female transplant recipients of child bearing age, 
the desire for a family often arises and carries with it with questions regarding fertility and the 
safety of pregnancy for the mother, graft and foetus.  
The first successful pregnancy following LT was reported 1978, with a healthy boy 
delivered at 40.5 weeks gestation, weighing 2,400g, with both the mother and baby in excellent 
health 1-year post delivery. (178) Subsequent to this, many case series have been reported, 
(179-182) which have expanded our knowledge regarding the safety and outcomes pregnancy 
following LT. Overall, the outcomes are largely favourable. (179, 180) However, data suggests 
that pregnancy in LT recipients can be associated with unpredictable graft deterioration, an 
increased risk of pre-eclampsia, infections and diabetes in the mother. For the foetus, 
prematurity, low birth weight with the potential for long term disability exists. 
Acute cellular rejection (ACR) has been reported to complicate between 10 and 17% of 
patients in the gestational period, (179-183) and 3-12% of patients in the post-partum 
period.(179-181) Graft loss directly related to ACR in pregnancy appears rare with the majority 
of episodes controlled with immunosuppression augmentation or intravenous steroids. 
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Although ACR during pregnancy is unpredictable, there is evidence that delaying pregnancy for 
at least 12 months following LT is associated with a lower risk. (179, 184) Regarding non graft 
related maternal complications the incidence of pre-eclampsia and eclampsia are increased with 
rates of between 14 and 23%. (179, 181, 184) Other maternal risks include bacterial and viral 
infections (27%) and gestational diabetes (5%). (184) Foetal outcomes are largely acceptable 
with a live birth rate of 73% reported by the national transplant pregnancy register (NTPR) but 
with 30% of neonates born prematurely and 30% with low birth weight. (184)  
Distinguishing the minority of LT recipients who are at risk of the above serious adverse 
outcomes during pregnancy and those who are likely to have an uneventful pregnancy remains 
challenging. This makes tailoring pre-conception counselling to the individual difficult and 
results in each patient being given generic outcome data from a largely heterogeneous cohort 
of women. Combining this with the fact that much uncertainty remains regarding the effect of 
immunosuppression on foetal outcomes and the optimal timing of pregnancy following LT, 













The data discussed above and in chapter 1 indicates that pregnancy following liver 
transplantation is a realistic prospect for the majority of healthy female LT recipients with good 
outcomes for the mother, graft and foetus. Despite this, there remains a subset of patients in 
which pregnancy can precipitate rejection and can result in adverse outcomes. Detailing the 
potential complications in this cohort of women and trying to identify those who are at risk of 
adverse outcomes pre-conception is the focus of this chapter. The work detailed in this chapter 
aims: 
 To assess the effect of pregnancy on graft function post liver transplant 
 To assess the effect of liver transplantation on maternal complications during 
pregnancy 
 To assess the incidence and severity of foetal complications in women post LT who 
become pregnant 
 To identify if there are any pre conception parameters that would enable physicians to 
predict / identify those women post LT who are at greatest risk of developing 
complications in association with pregnancy. 
 To assess the safety and usage of immunosuppressive regimes with regards to foetal 
and maternal safety. 
 To allow individualised rather than generic advice to be given to post LT patients who 






7.3 Patients and Methods 
We reviewed and audited all LT patients who reported pregnancy at our institution 
between 1988 and 2011. Patients were identified from a prospectively collated liver database 
using the search terms pregnancy, LT, miscarriage, termination and live birth. The clinical 
records were reviewed in all patients and data extracted in a standard fashion. Details regarding 
maternal age, indication for LT, interval between LT and conception, and baseline 
immunosuppression were recorded. Maternal complications during pregnancy including 
hypertension, pre-eclampsia, gestational diabetes, sepsis and renal failure along with specific 
hepatological complications including acute cellular rejection and graft loss were recorded. Data 
on pregnancy losses, including spontaneous and elective terminations of pregnancy were 
obtained in addition to the gestational duration, birth weight, live birth rate and congenital 
abnormalities. Longer term outcomes were assessed regarding child development and graft and 
maternal survival.  
 
7.4 Statistical analysis 
Data is presented using median and range for numerical values. To determine whether 
significant differences existed between groups, we applied the Student’s t test, or the Mann-
Whitney-U non-parametric method as appropriate. Differences in nominal data were compared 
either by the Chi squared test or using Fisher’s exact test when the number was less than 5 in 
any given cell of a 2x2 table. A p value of <0.05 was considered to be of statistical significance. 
All statistical analysis was performed using the SPSS statistical software package version 14 





7.5 Results:  
A total of 117 conceptions occurred in 79 LT recipients between 1988 and 2011. The 
indications for LT are summarised in table 7.4.1. The majority of conceptions occurred in 
patients maintained on either cyclosporine (n=34) or tacrolimus (n=81) as their primary 
immunosuppression. In addition 1 patient was taking sirolimus and 1 was maintained on 
azathioprine and prednisolone.  The median age at conception was 29-years (range 19-47 years) 
and the median interval between LT and conception was 48-months (range 1 – 240 months). 
Overall 49 women had one conception, 19 women had 2 conceptions, 7 women had 3 
conceptions, 1 woman had 4 conceptions and 1 woman had 5 conceptions.  
Table 7.5.1: Indications for Liver Transplantation among 79 patients who reported 
pregnancy at King’s College hospital 
 
Aetiology N (%) 
Drug Toxicity 15 (19%) 
Seronegative hepatitis 12 (15%) 
Autoimmune hepatitis 10 (13%) 
Budd Chiari Syndrome 6 (8%) 
Wilsons Disease 6 (8%) 
Primary Sclerosing Cholangitis 5 (6%)  
Primary Biliary Cirrhosis 5 (6%) 
Secondary Biliary Cirrhosis 5 (6%) 
Viral 3 (4%) 
Miscellaneous * 12 (15%) 
 
* Alpha 1 antitrypsin deficiency, familial ductopenia, intrahepatic cholestasis, glycogen storage 
disease, Fibrolamellar liver tumour, Epitheloid haemangioendothelioma, congenital hepatic 
fibrosis, Crigler Najjar 
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7.5.1 Maternal Outcomes 
No patient died as a direct result of pregnancy. Four women (5%) had a complication 
associated with pregnancy that necessitated admission to the liver intensive care unit (LITU). 
The first patient developed a hepatic artery thrombosis (HAT) following a spontaneous 
miscarriage at 12 weeks, she required re-transplantation. The second patent underwent a 
termination of pregnancy (TOP) due to patient choice, following which she developed 
septicaemia secondary to a liver abscess in her auxiliary graft. The auxiliary graft was removed 
as her native graft function had recovered. The third patient developed infected ascites and 
streptococcal sepsis at 20-weeks’ gestation on a background of chronic ductopaenic rejection. 
She delivered at 28-weeks following spontaneous rupture of membranes and the neonate 
required a prolonged stay in the special care baby unit (SCBU). The final patient admitted to the 
LITU developed gram negative sepsis following intravenous methylprednisolone for treatment 
of acute cellular rejection (ACR) following a caesarean section at 36 weeks gestation. No 
common features existed in these women prior to conception that would have identified the 4 
women at increased risk of requiring admission to LITU.  
Additional maternal complications encountered during pregnancy included 
hypertension (n=22), pre-eclampsia (n=16), eclampsia (n=3) and gestational diabetes (n=8). 
Hypertension, pre-eclampsia or eclampsia were no more common with cyclosporine based 
immunosuppression when compared to those pregnancies in women on tacrolimus. 
Furthermore, the incidence of gestational diabetes was not higher in those women taking 






Table 7.5.2: Maternal complications related to pregnancy in relation to primary 
immunosuppression (2 patients excluded from analysis (patient on sirolimus / patient 
on prednisolone and azathioprine) 
 
 









22 (19%) 4 (12%) 18 (22%) 0.29 
Preeclampsia 16 (14%) 5 (15%) 11 (13%) 0.35 
Eclampsia 3 (3%) 1 (3%) 2 (2%) 0.99 
Gestational diabetes 8 (7%) 1 (3%) 7 (7%) 0.43 
Bacterial sepsis 6 (5%) 1 (3%) 5 (6%) 0.67 
Viral infections 5 (4%) 2 (6%) 3 (4%) 0.63 




7.5.2 Acute cellular rejection 
Eighteen cases of acute cellular rejection (ACR) were identified on clinical and 
biochemical parameters during pregnancy or in the immediate post-partum period (within 8 
weeks of delivery). Sixteen were confirmed histologically. In all cases the liver biopsy was done 
under ultrasound guidance and no complications were noted. No episode of rejection resulted 
in graft loss. Five cases were deemed to be of a severity to require intravenous methyl-
prednisolone, followed by a reducing course of prednisolone. The remaining 13 were controlled 
with augmentation of baseline immunosuppression and oral prednisolone.  
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Rejection was significantly more common in those women who conceived within 12 
months of LT (p=0.001) and was associated, non-significantly with cyclosporine based 
immunosuppression (p=0.08). An episode on rejection during the pregnancy did not impact on 
the gestation at delivery (p=0.67), the need for a neonate to be admitted to SCBU (p=0.26) or 
the live birth weight (p=0.13). Women that had an episode of rejection were more likely to be 
delivered by caesarean section (p=0.07) although this did not reach statistical significance.  
  
7.5.3 Long term maternal outcomes 
Over a median follow-up period of 52-months post-delivery, there were 3 maternal 
deaths. The first death was related to post-transplant lymphoproliferative disease, 18 months 
post-delivery of a healthy neonate. The second died of graft failure following a redo LT for 
chronic rejection, 7 years following a molar pregnancy. The final patient that died had 
autoimmune hepatitis and had been transplanted 4 times for chronic rejection. Her pregnancy 
miscarried at 10 weeks. No death was considered to be pregnancy related.  
Eight patients underwent re-transplantation at a median time of 60 months post LT 
(range 18 – 120 months). Indications for re-transplantation included chronic rejection (n=4), 
recurrent disease (n=3) and late hepatic artery thrombosis (n=1). In all cases, graft loss was 
thought to be unrelated to pregnancy. Interestingly, women that had an episode of ACR during 
pregnancy were more likely undergo re-transplantation over long term follow-up than those 







Eighty one patients were maintained on tacrolimus based immunosuppression and 34 
on cyclosporine throughout pregnancy. In addition 1 patient was taking sirolimus and 1 was 
maintained on azathioprine and prednisolone. Two conceptions occurred in women on 
mycophenolate moefetil and tacrolimus; 1 of these women had an elective termination, the 
second delivered at 28 weeks following hepatic decompensation on a background of chronic 
rejection. The neonate required admission to the SCBU for 7 weeks but has no congenital 
abnormalities and normal developmental milestones on follow-up. Patients who were on 
cyclosporine as their primary immunosuppressive agent were more likely to be on dual therapy 
with prednisolone (84% vs 31%, p=0.0002) and/or azathioprine (57% vs. 1%, p=0.0001) and had 
a trend towards an increased rate of pregnancy associated graft rejection (p=0.08). The choice 













Table 7.5.3: Foetal outcomes in relation to pregnancy and maternal 
immunosuppression (2 patients excluded from analysis (patient on sirolimus / patient 
on prednisolone and azathioprine) 
 
 









Miscarriage  20 (17%) 5 (15%) 15 (19%) 0.62 
Termination of pregnancy 12 (10%) 1 (3%) 11 (14%) 0.10 
Live Birth rate 83 (72%) 27 (79%) 54 (67%) 0.17 









Caesarean section 34 (41%) 10 (35%)  24 (44%) 0.45 
Normal birth weight 59 (71%) 18 (65%) 41 (75%) 0.30 
Low / very low birth weight  24 (29%) 10 (35%) 14 (25%) 0.30 
Gestation <37 weeks 26 (31%) 10 (35%) 16 (29%) 0.50 
SCBU admission 7 (8%) 3 (11%) 4 (7%) 0.68 
 
7.5.5 Foetal outcomes 
The live birth rate was 73% (85/117) including 2 twin births. Of the remaining 
conceptions, 20 (17%) miscarried (spontaneous loss of pregnancy prior to 24 weeks), 12 (10%) 
underwent an elective termination of pregnancy (TOP), there was 1 molar pregnancy and 1 still 
birth (spontaneous loss of pregnancy after 24 weeks gestation). The indications for patients 
having a TOP were medical advice secondary to deterioration in graft function / persistent 
severe chronic rejection (n=3), warfarin therapy in the 1st trimester (n=2), uncontrolled 
psychiatric illness (n=1) and patient choice (n=4). In 4 of the above cases, a TOP was associated 
with a significant maternal complication including precipitation of an episode of ACR in one 
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patient. Two patients had severe vaginal bleeding necessitating blood transfusion post TOP and 
finally one patient developed septicaemia secondary to development of a liver abscess in her 
auxiliary graft. Of the 20 patients that had a spontaneous miscarriage the median gestational 
week of pregnancy loss was 12 (range 6-18 weeks). There was no significant difference in pre-
conception IS regime, time from transplant, or maternal age that would have allowed an 
increased risk of miscarriage to be predicted.  
Overall, median gestation for the 85 live births was 38 weeks, with 26/85 (31%) of 
neonates born before 37 weeks gestation and 5/85 (6%) born at less than 30 weeks gestation. 
Of the 26 neonates born before 37 weeks gestation 9 were secondary to medically induced 
prematurity for maternal pre-eclampsia/eclampsia (n=6), maternal hepatic decompensation 
(n=1) and intra uterine growth retardation (n=2).  The median birth weight was 2745 grams 
(range 554 – 4256 grams), 71% of new-borns were of normal birth weight (>2500 grams), 19% 
were of low birth weight (1500-2500grams) and 10% were of very low birth weight 
(<1500grams). Seven neonates needed admission to the special care baby unit (SCBU) and all 
survived to hospital discharge. The need for admission to SCBU was associated with an earlier 
gestational week (p<0.0001) and a lower birth weight (p=0.0003). Both prematurity (p=0.001) 
and a low or very low birth weight (p=0.001) were associated with the development of maternal 
pre-eclampsia. No other adverse maternal events including ACR (p=0.67), diabetes (p=0.76), or 
sepsis (p=0.58) were significantly associated with prematurity.  
Thirty four (40%) women delivered by caesarean section and 51 (60%) had a vaginal 
delivery. There were no congenital abnormalities and only one child who was born at 24 weeks 
gestation has delayed developmental milestones. Maternal baseline immunosuppression had 





7.5.6 Timing of pregnancy: 
 Out of the 117 conceptions, 13 (11%) occurred within 12 months of LT and 105 occurred 
beyond 12 months of LT. Delaying conception for at least 1 year post liver transplantation had 
no differences in foetal outcomes with respect to the live birth rate (p=75), the need for a 
caesarean section (p=0.58), the incidence of prematurity (p=0.2) or the need for neonatal 
admission to the SCBU (p=0.99). The incidence of rejection was significantly higher in those 



















Table 7.5.4: Comparison of the rates of maternal complications and foetal outcomes 
classified according to conception within 12 months of transplant or conception 
beyond 12 months from transplant.  
 
 
 All Pregnancies 
N=117 
LT → conception 
<12 months 
LT → conception 




117 13 104  
Live Birth Rate 
 
85/117 (73%) 10/13 (77%) 75/104 (72) 0.75 
Rejection 
 
17/117 (15%) 6/13 (46%) 11/104 (11%) 0.001 
Pre-eclampsia / 
eclampsia 
19/117 (16%) 3/13 (23%) 16/104 (15%) 0.39 
Caesarean section 
 
36/85 (44%) 5/10 (50%) 31/75 (41%) 0.58 
Prematurity 
 
28/85 (32%) 5/10 (50%) 23/75 (31%) 0.20 
Admission to SCBU 
 










7.6 Discussion:  
In this large single centre outcome study of pregnancy post LT, we have demonstrated 
that a successful and safe pregnancy can be achieved for the majority of women. However, 5% 
needed admission to intensive care, 3% of women developed graft loss in association with 
pregnancy and 15% of conceptions were complicated by an episode of ACR, indicating that 
pregnancy following liver transplantation still caries significant maternal risk. A live birth rate of 
73% is reported with no congenital abnormalities. Prematurity is common occurring in 31% and 
7% of neonates needed SCBU support immediately post-delivery. 
Women of reproductive age who have undergone LT require extensive counselling 
regarding contraception and pregnancy. Ideally this should form part of pre-transplantation 
work-up.  Women with chronic liver disease are often infertile secondary to a combination of 
metabolic, endocrine, nutritional and sexual dysfunction.(94-97, 221) Disruption of the 
hypothalamic-pituitary axis in conjunction with disturbed oestrogen metabolism leads to 
anovulation, amenorrhea and infertility.(96, 97) LT often reverses infertility associated with 
chronic liver disease and up to 80% of women will have a normal menstrual cycle and return of 
fertility within 8 months of LT. (96, 222-224) If these women are not educated about this change 
in fertility, then, unwanted or unplanned pregnancies may occur. This is important since in this 
series a TOP was associated with an adverse event in 25% of instances including severe 
haemorrhage, precipitation of ACR and sepsis necessitating auxiliary graft removal. Therefore, 
TOP should not be considered as a “routine” procedure in this cohort and preventing an 
unwanted or unsafe pregnancy with appropriate contraception should be the aim. 
Another important factor in patient education is the ideal timing of a post LT pregnancy. 
Whilst successful pregnancies can occur in the first year post transplant, (179, 181) this study 
and earlier studies, have shown that the risk of developing an episode of ACR is significantly 
increased in those pregnancies occurring within 12 months of transplantation (p=0.001). The 
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reason for this is likely to reflect that in the early post LT period, rejection episodes are more 
frequent, irrespective of pregnancy, due to unstable immunosuppression levels and increased 
infection risk. This increased risk of rejection has resulted in the NTPR advising that pregnancy 
should be delayed for at least 12 months following LT. (184)  
The effect of ACR on the foetus and the longer term graft function remains to be 
defined. A previous series by Armenti at al. demonstrated that biopsy proven ACR during 
pregnancy was associated with worse new-born outcomes and an increased risk of recurrent 
rejection post-partum.(225) In this study we found no association between an episode of ACR 
during pregnancy and adverse foetal outcomes including delivery gestation (p=0.67), SCBU 
admission (p=0.26), the live birth weight (p=0.13) or congenital abnormalities. There was 
however a trend toward need for caesarean section (p=0.07) in women who had developed 
ACR, suggesting obstetric concern.  
In women who developed ACR, follow-up over a median period of 60-months indicated 
that they were more likely to require re-transplantation in future years (p=0.001) when 
compared to those women who did not develop ACR in pregnancy. This is interesting as in the 
renal transplantation literature, pregnancy has been shown to have no long term effect on graft 
function when compared to case control groups. (226) The findings of this study coupled with 
data from the NPTR raises the question as to whether an episode of graft rejection in pregnancy 
could be associated with an increased risk of graft loss in the longer term. It is likely that the 
pregnancy itself does not cause or predispose a patient to rejection or graft loss, but perhaps 
identifies those women who are already at an increased risk of graft loss due to poor graft 
tolerance and may therefore benefit from augmented baseline immunosuppression. A large 
case controlled study would be needed to answer the question whether pregnancy has an 




In this study the incidence of pre-eclampsia was 14% compared to an incidence of 
between 2-6% reported for the general population. Furthermore the development of pre-
eclampsia and was found to be significantly associated with prematurity (p=0.001) and low birth 
weight (p=0.001), likely in part due to iatrogenic premature delivery in order to maintain 
maternal safety. The increased incidence of pre-eclampsia in the LT cohort is yet to be fully 
explained but is likely due the vasoconstrictive effects of calcineurin inhibitors, chronic 
corticosteroid usage and possibly an increased incidence of underlying renal dysfunction.  
The foetal outcomes reported are favourable with a live birth rate of 73%, no congenital 
abnormalities and only 1 child born at 24 weeks with delayed developmental milestones.  
However the prevalence of low (19%) and very low birth weight (10%) is considerably higher 
than that of the general population where in England and Wales it is reported to be 7.2% and 
1.2% respectively. (227) This finding is likely linked to the high incidence of prematurity (31%) in 
this cohort. The cause for the high incidence of prematurity and low birth weight in babies born 
to LT recipients remains unclear and is likely to be multi-factorial, contributed to by 
immunosuppression, the high incidence of pre-eclampsia / eclampsia and iatrogenic delivery, 
ACR and maternal co-morbidity.  
Finally the concept of an “ideal” pregnancy without medication or increased risk of 
complications is perhaps not obtainable in this unique cohort due to the complex medical 
problems which occur in these patients and the need for continuous immunosuppressive 
therapy. Therefore, comparing data with the healthy population will show increased maternal 
risk and poorer foetal outcomes. What this study and the current literature tell us is that 
pregnancies in women post-LT can occur with successful outcomes but must be considered high 
risk and monitored regularly by transplant clinicians and specialist obstetricians. With transplant 
registries and repeated case series, pregnancy in LT recipients will define its own outcome 
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standards and it is already clear from this study and others that successful and safe pregnancies 















CHAPTER 8: Outcomes of Pregnancy in cholestatic 
liver conditions  
8.1 Introduction 
Pregnancy in women with cholestatic liver diseases is rare and there is a scarcity of data 
detailing the effect of pregnancy on both the mother and the foetus. This means that 
counselling and managing women with cholestatic liver diseases who are pregnant or wanting 
to become pregnant is difficult. Outcomes in the reported literature (as discussed on chapter 1) 
are varied depending on the aetiology of the underlying cholestatic liver disease. In women with 
PSC reports of pregnancy on maternal disease vary from improving biochemical parameters to 
severe pruritus and development of biliary strictures. (154, 155) In those women with PBC, the 
literature suggests that pregnancy is largely uneventful. (158-161) Finally rarer cholestatic liver 
diseases such as AISC exist with either no case reports of pregnancy or isolated case reports. 
8.2 Aims 
In light of the above, the aim of the work detailed in chapter 8 is: 
 To describe the outcomes / complications of pregnancy in women with cholestatic liver 
diseases 
 To describe the effect if any of pregnancy on hepatic biochemistry 
 To facilitate pre-conceptual counselling in the future for women with cholestatic liver 
disease 
 To assess foetal outcomes 
 To assess maternal safety 
 To separately assess outcomes in AISC  
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8.3 Patients and Methods 
All patients with a diagnosis of either PBC, PSC or rarer cholestatic liver diseases who 
reported pregnancy at our institution between 1984 and 2009 were identified. The clinical 
records were reviewed in all patients and data extracted in a standard fashion. The diagnosis of 
PBC was made if two of three objective criteria are present: serum AMA at titers ≥ 1:40, 
unexplained elevated ALP ≥ 1.5 times the upper normal value for over 24 weeks and compatible 
liver histology. (228) Patients were confirmed as having PSC if they had cholestatic liver 
enzymes and compatible radiology and / or histology. (145) A diagnosis of autoimmune 
sclerosing cholangitis (AISC) was based on histological evidence of AIH on liver biopsy and 
alterations of the bile ducts characteristic of sclerosing cholangitis on cholangiography in 
conjunction with seropositivity for ANA and/or SMA. (164) 
  Data was extracted in a standardised fashion, as described previously. Patient details 
including liver function tests at conception, throughout pregnancy and the post-partum period 
was collected. Fetal and maternal complications were collected. 
 
8.4 Results:  
We identified 27 conceptions in 20 women with cholestatic liver disease. The underlying 
hepatological diagnosis was primary biliary cirrhosis (n=6), primary sclerosing cholangitis (n=3), 
autoimmune sclerosing cholangitis (n=5) and genetic congenital syndromes (n=6, (alagilles n=4, 
PFIC n=2)). The median age at conception was 28-years. There were 4 conceptions in two 
women with cirrhosis. At conception the median alkaline phosphatase was 200 IU/L (55-709 





8.4.1 Foetal Outcomes 
The live birth rate was 81% (22/27), there were 4 miscarriages (2 in women with 
cirrhosis) and one termination of pregnancy. All neonates survived to hospital discharge and no 
congenital abnormalities were noted. The median gestation was 37-weeks (33-39-weeks). Four 
neonates required elective early delivery as a result of maternal cholestasis and pruritus, and 
clinical difficulties differentiating it from ICP. 
 
8.4.2 Maternal Outcomes 
The most common maternal complication was pruritus in the third trimester occurring 
in 13 (48%) pregnancies. The underlying diagnosis was not helpful in identifying which patients 
were likely to develop pruritus.  Four out of the thirteen women (31%) who developed pruritus 
in the 3rd trimester required premature delivery due to severe maternal cholestasis and pruritus 
and concerns for foetal wellbeing.  
Those women that reported pruritus had a significantly higher preconception GGT 
(p=0.002) and ALP (0.07) when compared to those women who did not develop pruritus. 
Similarly third trimester GGT (p=0.01) and ALP (p=0.04) levels were higher in those women who 
developed pruritus. Furthermore, the increment (∆) in GGT (p=0.045) and ALP (p=0.05) between 
preconception and the 3rd trimester was higher in those patients reporting pruritus. Underling 






Table 8.4.2 Biochemical characteristics in patients with cholestatic liver diseases with 
and without the development of pruritus 







138 (43 – 237)  289 (167- 439) 0.002 
Pre conception ALP 
(IU/L) 
154 (55-321)  368 (193-709) 0.07 
3rd Trimester GGT 
(IU/L) 
156 (48 – 293) 387 (243 – 590) 0.01 
3rd Trimester ALP 
(IU/L) 
189 (69 – 401) 473 (250-796) 0.04 
∆ GGT (IU/L) 40 (5-63) 102 (56-151) 0.05 
∆ ALP (IU/L) 53 (14-80) 122 (57-139)  0.05 
 
 
Twenty-three conceptions (85%) occurred on ursodeoxycholic acid (UDCA), of which 15 
women continued it throughout their pregnancy. The mean dose was 1000mg/day (range 500-
1500mg/day). Treatment with UDCA was not found to be protective against the development of 
pruritus. Women taking UDCA throughout pregnancy had a trend towards a lower increment in 
∆GGT (p=0.09) and ∆ALP (p=0.1) in the third trimester when compared to those women who 
discontinued it. No congenital anomalies were reported. 
Eight women had worsening of their liver function tests post-partum; 3 had AISC and 
developed elevated aminotransferases which was subsequently controlled with steroids, 5 
women developed worsening of their cholestatic parameters which settled with either re-
introduction or augmentation of their UDCA. At one-year post-partum there was no significant 
change from pre-conception GGT and ALP levels. 
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There were no maternal deaths. However one women (with cirrhosis) required 
admission to intensive care for 24 hours post-partum with an unexplained metabolic acidosis 
and a second had a significant post-partum haemorrhage. 
 
8.4.3 Pregnancy in Autoimmune sclerosing cholangitis 
There were 8 conceptions reported in 5 women. All women had been diagnosed with 
AISC in childhood, at a median age of 12-years (range 5-15 years). Three of five women were 
cirrhotic at the time of conception. Pregnancy was planned and discussed with the physician in 
all cases. All women conceived naturally. Regarding medication, all women were taking 
prednisolone prior to conception and no patient discontinued this medication whilst pregnant. 
Seven women were taking UDCA prior to conception, one woman discontinued it prior to 
pregnancy (patient choice). Two women were taking azathioprine for disease control and one 
discontinued it for pregnancy (patient choice). Below the specific details of each conception are 
outlined. Table 8.4.3 shows the outcomes of the 8 conceptions for both mother and baby. 
Figures 8.4.3.1 and 8.4.3.2 show the changes in AST and GGT activity respectively in relation to 









Table 8.4.3: Foetal and maternal outcomes of 8 conceptions in 5 women with AISC 
 
Woman Age at 
conception 
Cirrhotic Foetal Outcome Maternal outcome 
1  28 
 
No Live Birth Post-partum flare, settled  
with steroids and 
azathioprine 







Live Birth – Died at 12 
weeks from sepsis 
Live Birth 
Post-partum flare, settled 
with steroids and UDCA 
Post-partum flare, settled 
with steroids and UDCA 
3  25 
 
Yes Live birth at 31-weeks, 
needed SCBU 
Died 48 hours post-delivery – 
ruptured splenic varices 










No significant effect 
 
No significant effect 












Ventilated for 24 hours post-
partum, no change in LFT’s 
 
Woman 1: This 28-year old patient had non cirrhotic AISC and was maintained on UDCA 
(600mg/day) and prednisolone (5mg/day). Preceding pregnancy her liver function tests had 
been stable for more than 1 year and prior to conception her GGT was 135, ALP was 215 and 
AST was 60. Her pregnancy was uneventful, she remained on her baseline immunosuppression 
and no changes in her liver functions tests were noted. In the week prior to delivery she 
complained of mild pruritus and delivered a healthy baby at 38-weeks’ gestation. Immediately 
post-partum she had a significant flare in her liver disease with a peak AST of 257 IU/L and GGT 
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of 337 and ALP of 367. She required treatment augmentation with prednisolone (30mg/day) 
and azathioprine (125mg/day), which resulted in normalisation of her hepatic biochemistry. 
There was no hepatic decompensation as a result of the disease flare. Both the patient and child 
remain well 7-years from delivery. 
Woman 2: This patient had 2 pregnancies at ages 36 and 37-years. She was non cirrhotic and 
personally chose to discontinue both her UDCA (1250mg/day) and azathioprine (100mg/day) for 
both pregnancies but remained on 5mg of prednisolone. Both gestational periods were 
uneventful with no change in her AISC activity. She delivered both her babies vaginally at 38-
weeks gestation. The babies were both healthy and required no immediate medical input. Her 
1st baby died suddenly at 12 weeks from severe sepsis thought to be unrelated to maternal 
disease or medication. Following both pregnancies she developed a flare in her inflammatory 
activity with her AST peaking at 160 and 140 respectively (previously normal), her GGT peaking 
at 603 and 417 and her ALP peaking at 307 and 348. In both cases she needed augmentation of 
her prednisolone to 20mg/day and her UDCA was restarted. The patient remains well on long 
term follow-up. 
Woman 3: This 25 year old patient with AISC was cirrhotic based on radiological and blood 
parameters with a MELD score prior to conception of 10. She was known to have portal 
hypertension and was advised against pregnancy due to a high risk of hepatic decompensation. 
Her medications pre-conception and throughout pregnancy were UDCA (1250mg/day), 
azathioprine (100mg/day) and prednisolone (5mg/day). She underwent a screening endoscopy 
in her second trimester and oesophageal varices were confirmed and a caesarean section at 35-
weeks was planned. At 31-weeks she was admitted as an emergency for foetal distress and 
underwent an emergency caesarean section. Forty-eight hours post-surgery she developed 
hypovolaemic shock. A laparotomy revealed severe haemorrhage from splenic varices. A 
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splenectomy was undertaken but she died shortly after from a hypovolemic cardiac arrest. The 
child survived after a short stay in the special care baby unit. 
Woman 4: This patient had histologically proven cirrhosis with a MELD score prior to conception 
of 6. She had 2 pregnancies at aged 24 and 26.  Her baseline immunosuppression consisted of 
prednisolone (5mg/day) and UDCA (500mg/day) and this was maintained throughout both 
pregnancies. Pregnancy had no impact on her hepatic biochemistry in the gestational or post-
partum period. She delivered 2 healthy babies at 37 and 38 weeks gestation. Both the patient 
and children remain well at 5 years follow-up. 
Woman 5: This patient had biopsy proven cirrhosis with a MELD score prior to conception of 6. 
She was maintained on UDCA (1250mg/day) and prednisolone (2.5mg/day) prior to and during 
both pregnancies. Her 1st pregnancy miscarried at 10 weeks. There was no change in her hepatic 
biochemistry related to the miscarriage. The second pregnancy was uneventful with a healthy 
baby delivered vaginally at 37 weeks gestation. The patient developed no change in her baseline 
hepatic biochemistry during the pregnancy or in the post-partum period. Immediately post-
partum she required admission to intensive care and was ventilated for 24 hours due to 





























































8.5 Discussion: Pregnancy in Cholestatic liver diseases 
 Foetal outcomes in women with cholestatic liver diseases appears acceptable with a 
favourable live birth rate of 81% and no obvious neonatal concerns or congenital anomalies. 
These findings are in keeping with other case series published in PBC and PSC. (155, 160, 229) 
Pruritus development in the third trimester was the commonest maternal symptom occurring in 
48% of women. Pruritus was more common in those women with a higher pre-conception and 
third trimester GGT and ALP. In addition women taking UDCA throughout pregnancy had a trend 
towards a lower increment in ∆GGT (p=0.09) and ∆ALP (p=0.1), suggesting response to UDCA, 
either pre or during pregnancy, may be of interest in the development of pruritus. Reassuringly 
in all cases, pruritus and biochemical abnormalities returned to baseline at 1-year post-partum, 
perhaps suggesting pregnancy has no or little impact on the long term natural history of the 
cholestatic liver disorders. This hypothesis remains to be proven via long-term follow-up 
studies.  
 In this report there were no late foetal losses. Premature delivery of the foetus is a 
concern, with 31% of those women who develop pruritus and cholestasis requiring early 
delivery. In this case series, the premature delivery, was due to an inability to confidently 
distinguish the development of ICP and its associated increased foetal morbidity from 
worsening of baseline cholestatic parameters. The challenge in women with cholestatic liver 
diseases arises in distinguishing worsening of the underlying cholestatic liver disease (which 
from the published literature does not appear to have a negative impact on foetal wellbeing) 
and the development and intrahepatic cholestasis of pregnancy which is associated with an 
increased foetal mortality and morbidity. (31, 155, 160) Polymorphisms in the ABCB4 gene are 
common to both conditions and raise the question as to whether IHCP is more common in 
patients with PSC, however this currently remains speculation. 
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In women with AISC and pregnancy, the maternal outcomes in this report appear 
favourable. The commonest complication was a flare in inflammatory activity in the post-
partum period, which occurred in 3/8 pregnancies. In all cases the flare was controlled using 
prednisolone and/or azathioprine and/or UDCA. The biochemical abnormalities returned to pre-
conception levels in all cases within 3 months. This incidence of flares in disease activity was not 
an unexpected finding as in previous reports of pregnancy in patients with AIH, flares in disease 
activity were reported to occur in 7- 21% of patients in the gestational period and between 11-
86% of patients in the post-partum period. (14, 140-142) Moreover, a recent study by Wellge et 
al. described 25 pregnancies in patients with PSC. They reported an increase in liver enzymes, 
particularly serum aminotransferases (AST) in 20% and a post-partum increase in liver enzymes 
in 31%. (155) Caution is needed however, as although in this current case series all flares were 
easily controlled with medication augmentation, in larger series of women with AIH, reports of 
hepatic decompensation, liver transplantation and death have all been reported as a 
consequence of hepatic flares and pregnancy in AIH. (140-142) 
 In women with AISC and cirrhosis, there were five conceptions in 3 women with 
underlying cirrhosis. In this group there was one maternal death secondary to a hypovolaemic 
cardiac arrest subsequent to ruptured oesophageal varices. The second serious adverse event 
was admission of a woman to intensive care for 24 hours post-partum. Pregnancy in women 
with underlying cirrhosis is known to carry increased risks irrespective of underlying pathology, 
(230, 231) and need to be counselled pre-conception appropriately. 
 In this series 7/8 pregnancies resulted in a live birth, with 1 miscarriage at 8-weeks. One 
child died 3-months post-partum from overwhelming sepsis thought to be unrelated to 
maternal disease or medication. One neonate was born at 31-weeks and required admission to 
the special care baby unit. This neonate was born to the mother with a MELD score of 10. The 
above child and the remaining 5 births all remain well on long term follow-up with no 
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abnormalities reported. It is worthy of note that women with underlying cirrhosis are at an 
increased risk of having a premature birth and in the above case it is likely that the prematurity 
was as a result of the mothers underlying cirrhosis rather than AISC. 
 In conclusion, this case series in women with cholestatic liver diseases has 
demonstrated that the majority of women have an uneventful pregnancy. Worsening of 
pruritus and liver function tests can occur but these resolve post-partum, with the main risk 
being premature delivery due to the difficulties in separating distinguishing worsening of the 
underlying cholestatic liver disease and the development and intrahepatic cholestasis of 
pregnancy. In women with cirrhosis the risks encountered are due to the severity of the 
underlying cirrhosis as opposed to the specific disease and these have been discussed 
extensively in chapter 5. Specifically in women with AISC there is a risk that pregnancy may 
precipitate a flare in disease activity, similar to that reported in the AIH literature but overall 











CHAPTER 9: Assisted Conception in women with 
liver disease 
9.1 Introduction: 
Women with chronic liver disease and cirrhosis have reduced fertility and may request 
advice regarding the safety and success rates of assisted conception. To-date, no published 
data, information or guidelines exist regarding the maternal safety and success rates of assisted 
conception in women with underlying liver disease. Theoretically pregnancy could carry an 
unacceptably high risk (hepatic decompensation and death) in those patients with cirrhosis of 
sufficient severity to impair ovulation, with failure of ovulation perhaps a naturally protective 
mechanism for the mother given the severity of her underlying liver disease. Furthermore, one 
must consider that the intensive hormonal ovulation induction regimens could potentially have 
an adverse effect in patients with non-cirrhotic autoimmune and cholestatic liver conditions or 












In light of the above, the aim of the work detailed in chapter 9 is: 
 To assess the success rates of IVF in women with cirrhotic and non-cirrhotic liver disease 
 To assess the success rates of IVF in the post liver transplant cohort 
 To assess foetal outcomes 
 To assess maternal safety  
 
9.3 Patients and Methods 
All patient records of patients who had enquired or had been seen with regards to 
infertility, assisted conception or in vitro fertilisation at our institution between 1984 and 2009 
were reviewed. Clinical data was extracted in a standardised fashion with information on liver 
disease, severity, assisted conception, outcomes and complications. Specifically, data on 
maternal complications including worsening of parenchymal liver disease, hepatic 
decompensation, flares in disease activity, thrombotic complications were recorded. Regarding 
foetal outcomes, data on miscarriage, gestational duration, live birth rate and foetal outcomes 











 Eighteen women with liver disease were identified as being assessed for assisted 
conception. The median age at referral was 38 years (range 26-45 years) and seven of the 
women had underlying cirrhosis based on histology or a combination of laboratory and 
radiological parameters. The cause of their underlying liver condition was AIH (n=6), PBC (n=2), 
hepatitis B (n=1), Budd Chiari syndrome (n=1), non-cirrhotic portal hypertension (n=1) and post 
liver transplant (n=7).   
 Two women, with underlying cirrhosis were declined assisted conception due to 
concerns about the effect of hormonal therapy and pregnancy on maternal health. Neither of 
these two women had decompensated and their MELD, UKELD and CP scores were not 
significantly different from those women with cirrhosis who underwent assisted conception. 
Both women had a MELD score of 6 and UKELD of 47. 
 In total 16 women underwent in vitro fertilisation (IVF). Three women failed to conceive 
after 3 cycles of IVF. Of these women 2 had no ill effects from IVF however, one women (post 
LT) developed graft dysfunction after her 3rd cycle of treatment with a liver biopsy confirmed 
acute cellular rejection. She was treated with augmented steroid therapy.  
 There were 16 conceptions in the remaining 13 women; no multiple pregnancies 
occurred. The median gestation was 36 weeks (range 28-38 weeks). In women with underlying 
cirrhosis the live birth rate was 50%. There was one major adverse event with one woman 
developing hepatic decompensation (ascites and encephalopathy). She was delivered at 28 
weeks gestation. The baby had cerebral palsy, needed admission to the special care baby unit, 
but survived. Assisted conception in the 6 women who had been transplanted resulted in a live 
birth rate of 50%. Adverse events occurring in this cohort included a case of HELLP syndrome 
and in a separate woman, the development of obstetric cholestasis of pregnancy, both of which 
resulted in a pre-term delivery. A third woman had a still birth at 36 weeks (cause unknown). 
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Finally in the non-cirrhotic, non-transplanted cohort the live birth rate was 67%. This included 2 
women with autoimmune hepatitis who developed a flare in their disease activity in the post-
partum period which was controlled with immunosuppression augmentation.  
 











 In this series of women with liver disease undergoing assisted conception, we report a 
conception rate of 81% in a heterogeneous cohort of women with underlying liver disease and a 
live birth rate of between 50-67%. 
 Following liver transplantation in women of child bearing age, it is normal for fertility to 
recover and women often enquire about having children. (90) Previous published series and the 
work detailed in chapter 7 show that a live birth can be expected in the majority of women. 
There will inevitably be some women post-transplant who are unable to conceive for a variety 
of reasons and may enquire about the safety and success rates of assisted conception. There are 
no published case series of women conceiving with assisted conception following liver 
transplant and therefore the safety of IVF for the mother, baby and graft is unknown. In the 
renal transplant population, a recent series describes 7 singleton and 1 twin pregnancy after IVF 
and compared them to matched renal transplant patients who conceived naturally. (232) 
Interestingly, they describe that the rates of pre-eclampsia, prematurity, low birth weight and 
neonatal morbidity and mortality were all significantly higher in IVF conceptions compared to 
those women who conceived naturally. (232) From our own data, we have shown that IVF 
following transplantation can result in a heathy live birth, but potentially carries a significant 
risk, with the real possibility of hormonal manipulation acting as a trigger for ACR, prematurity 
and still birth. Further larger case series are needed to explore the safety of IVF following liver 
transplantation further. 
 In women with cirrhosis, conception and a successful pregnancy can occur. Data 
discussed in chapter 5 has shown that pregnancy in patients with cirrhosis carries a high 
incidence of maternal morbidity (10%), a live birth rate of 58%, with 75% of neonates born 
prematurely and 17% of live births requiring neonatal intensive care support.  The decision on 
whether to assist conception in women with underlying cirrhosis is more challenging than in 
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post LT patients. These women may not ovulate due to the effects of cirrhosis and this may 
represent a protective measure due to the body not being able to cope with the demands of 
pregnancy in the context of underlying cirrhosis. We describe IVF resulting in a successful 
implantation in 4 women with well compensated underlying cirrhosis. The live birth rate was 
50% and although 1 woman had hepatic decompensation resulting in a pre-term delivery at 28 
weeks. Further larger case series are required before conclusions are made about the safety of 
assisted conception in women with cirrhosis. Currently, until further information is awaited 
women need to be counselled regarding the risk of decompensation and avoid assisted 
conception if MELD is 10 or above. 


















CHAPTER 10: Discussion 
 
10.1 General discussion 
This thesis has documented in detail the risks related to pregnancy for mother and baby 
in the context of varied liver pathologies and disease severity. Moreover, it has identified pre-
conception parameters that are associated with adverse pregnancy outcomes. This body of 
work will therefore enable physicians to give individualised disease specific advice regarding the 
associated risks and outcomes of pregnancy. The following discussion highlights the major 
findings of this thesis and places them in the context of the literature. However, it must be 
emphasised that to-date, the aims outlined in this thesis have heretofore never been explored. 
Finally the limitations of the thesis are discussed along with potential areas for future work and 
development. 
 
10.1.1 Outcomes of severe pregnancy related liver disease; refining the use of prognostic 
markers and the role of liver transplantation 
A better understanding of parameters which indicate that a patient with pregnancy 
associated acute liver failure is at an increased risk of death and as a consequence might benefit 
from LT is an unmet need in the pregnancy specific liver diseases. In chapter 4 we demonstrate 
an unacceptably high maternal mortality rate of 13% with an additional 6% requiring liver 
transplantation. These poor outcomes occurred despite 90% of babies being delivered within 24 
hours of presentation and the remainder within 48 hours of presentation to hospital. Moreover 
we highlight that mortality rates in women with severe pregnancy associated liver disease has 
not changed in over 2 decades. Whilst it is also well accepted that prompt delivery of the foetus 
is a key intervention that  halts disease progression in the pregnancy associated liver diseases; 
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(42) this body of work highlights that at the severe end of the spectrum despite this 
intervention mortality or need for liver transplantation can be as high as 1 in 5 cases. 
We also highlight for the first time that in women with severe pregnancy associated 
liver dysfunction of such severity as to require admission to high dependency or intensive care 
unit, that the well published and validated King’s College Criteria for poor prognosis in acute 
liver failure are not predictive of risk of death and/or need for liver transplantation. (78, 233) In 
our cohort, no patient that died or underwent liver transplantation fulfilled the King’s College 
Hospital poor prognostic criteria for non-acetaminophen acute liver failure. (77, 78) Although, 
all patients had encephalopathy, none fulfilled the requirement of either an INR greater then 
6.5, or any three parameters from the variables of age greater than 40 years, unfavourable 
aetiology, INR greater than 3.5, serum bilirubin greater than 300µmol/L or interval of jaundice 
to development of encephalopathy of greater than 7 days. (78) Encephalopathy although 
sensitive in predicting need for transplant in our cohort was not specific occurring in 43% of 
medical survivors. The lack of defined criteria to identify which patients are at high risk of death 
without LT, or indeed identification of those patients who are likely to survive with medical 
therapy alone is of critical importance. Inaccurate selection criteria will result in subjecting a 
patient that would have recovered with medical management to the risk of liver transplant 
surgery, a life of immunosuppression, its side effects and increased mortality. Furthermore, 
failing to identify a patient with ALF who would survive only with LT, is meaning their death is 
inevitable. 
In this chapter we proceeded to identify that an admission a lactate of greater than 
2.8g/dl combined with the presence of any grade of encephalopathy has a 90% sensitivity and 
86% specificity for identifying those patients that died or underwent liver transplantation in our 
cohort. The negative predictive value was 97%. The one patient which was not identified by 
these criteria died from associated pancreatitis and although had liver dysfunction and 
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coagulation abnormalities did not clinically have any other features of liver failure and hence in 
“real life” the clinician would not be proposing LT as a treatment modality. With this patient 
excluded from analysis the criteria we propose are 100% specific for identifying those patients 
at risk of death from acute liver failure / need for liver transplantation.  
The criteria suggested by this thesis to identify patients at increased risk of death / LT 
with pregnancy associated acute liver failure need to be prospectively validated in a cohort of 
women outside of King’s Liver intensive care unit to confirm there sensitivity and specificity 
before they are incorporated into clinical care and used to make decisions regarding listing for 
LT. Once accurate criteria are established, it appears reasonable that pregnancy induced acute 
liver failure should have its own listing criteria for LT as in this specific group, for the reasons 
explored in chapter 4 and demonstrated in this thesis the current criteria are inadequate. 
Of interest, this body of work has highlighted the high incidence of significant bleeding 
complications (59%) encountered in women with severe pregnancy associated liver dysfunction. 
Bleeding sites were gynaecological (66%) or hepatobiliary (47%) or combined (13%) with 
surgical intervention required in 72%. No predictors of bleeding complications were identified 
and the incidence was no different in those women who delivered vaginally compared to 
caesarean section. When bleeding complication occurred the incidence of infection and length 
of ITU stay was significantly longer than those women without bleeding complications. This 
highlights the need for a high index of suspicion for bleeding in such women, potentially early 






10.1.2 Utilisation of prognostic scoring systems to predict outcomes in pregnant women with 
cirrhosis 
Women with cirrhosis who are of childbearing age often enquire about the safety of 
pregnancy. Obstetricians and hepatolgists have very limited information to give these women as 
available data is limited to case reports and small historic series as discussed in the introductory 
chapter. (102, 105) Furthermore it is well recognised that cirrhosis represents a spectrum of 
disease and hence it is reasonable to speculate that the risk pregnancy would confer is likely 
related to the severity of cirrhosis. 
In chapter 5 we have demonstrated that pregnancy in patients with established 
cirrhosis is associated with a high incidence of hepatic decompensation (10%) and a maternal 
mortality rate of 1.6%. Oesophageal varices were reported in 50%. The live birth rate was 
significantly reduced (58%) and of those 75% are born prematurely and 17% require neonatal 
intensive care support.  
We demonstrate in this thesis for the first time, that these adverse outcomes (maternal 
and foetal) in the context of cirrhosis, can be predicted pre-conception by using established 
prognostic scoring systems. (120, 126, 137) 
Regarding foetal outcomes, higher MELD score (p=0.01), MELD-Na score (p=0.01), 
UKELD score (p=0.01), and CP score (p=0.03) at conception are associated with a birth prior to 
37 weeks gestation.  The need for admission of a neonate to intensive care was associated with 
higher maternal MELD score (p=0.04) and UKELD score (p=0.04) but not CP score (p=0.35) or 
MELD Na (p=0.28) at conception. Although we demonstrated a significant foetal loss rate we 
were unable to find an association with the severity of the underlying cirrhosis as measured by 
MELD, UKELD and CP score pre-conception. This may be related to several factors, the first 
being that cirrhotic women have irregular menstruation as cirrhosis advances and that 
consequently, an early pregnancy loss in patients with more advanced cirrhosis could be missed. 
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Secondly, due to the limitations of the retrospective nature this study, many early losses may 
not have been reported to us. Indeed, previous published reports have estimated the 
spontaneous abortion rate to be higher, reported between 30% and 40% of pregnancies in 
women with cirrhosis. (210)  
Hepatic decompensation (variceal bleeding, ascites, hepatic encephalopathy) occurred 
in 6 women which equated to 10% of all conceptions. A higher median MELD score (p=0.01) and 
UKELD score (p=0.02) at conception was significantly associated with an increased risk of the 
mother developing a decompensating event. Evaluation of the receiver operator characteristic 
(ROC) curves for MELD and UKELD scores at conception and the development of a significant 
liver related complication for the mother both demonstrated an area under the ROC curve 
(AUC) 0f 0.8. Furthermore, a MELD score of greater than 10 points demonstrated 83% sensitivity 
and 83% specificity for predicting which patients with cirrhosis were likely to experience a 
significant liver related complication during pregnancy. Regarding UKELD, a score of greater 
than 47 demonstrated an 83% sensitivity and a 79% specificity for predicting which patients 
with cirrhosis are likely to experience a significant liver related complication. Interestingly no 
patient who had a MELD score of 6 or a UKELD score of less than 47 developed any significant 
hepatological complications related to their pregnancy.  
The novel data generated form this thesis is of critical importance as it allows accurate 
identification of those women who can be reassured pregnancy is likely to have a good outcome 
(MELD 6 or UKELD <47) and perhaps more importantly identifies a group of women that should 
be advised against pregnancy due to the high risk of associated hepatic decompensation 
(MELD>10 and UKELD>47).  
Regarding screening for the presence of varices, 93% of women underwent a 
gastroscopy in their second trimester and half were found to have oesophageal varices, 
reporting a similar incidence to other published series.(212) Prognostic scores at conception 
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could not predict the presence or absence of varies. The pre-conception platelet count was 
strongly associated with the presence of oesophageal varices (p<0.001), and ROC analysis 
concluded that using a platelet count cut off of 110 cells/mm3 gives an 89% specificity in 
predicting the presence of oesophageal varices. The use platelet count as a non-invasive marker 
of portal hypertension to predict the presence of varices, has been shown to be of use in 
patients with cirrhosis outside of pregnancy. However to-date non-invasive markers of portal 
hypertension are insufficient to confidently diagnose / exclude the presence of varices in clinical 
practice. 
  In this study, variceal haemorrhage occurred in 3 cases, which is much lower than 
previous reports where the incidence of bleeding has been reported to be as high as 50%.(105, 
111) The lower incidence of haemorrhage, in this study is unclear, but may reflect the use of 
beta blockers, less severe portal hypertension or even the fact that enrolment in a screening 
program for varices might have resulted in a higher beta blocker prescription rate. An episode 
of variceal haemorrhage could not be predicted by prognostic scores or preconception platelet 
count.  
Finally we noted in women who had an episode of hepatic decompensation in 
pregnancy, long term prognosis was reduced. One patient died directly as a result of the 
complication, and a further 2 patients that had a significant complication during pregnancy died 
at 6 and 16 months following delivery. This raises the question as to whether patients that 
decompensate during pregnancy reflect a group that lack functional hepatic reserve and should 
be monitored even more closely or even considered for transplantation post-delivery even if 
their synthetic function recovers. This however would be controversial, since their prognostic 
scores are significantly lower than those at which transplantation would ordinarily be 
considered. The numbers in this piece of work are too small to make any meaningful 
conclusions, but this does suggest an area for potential further research in the future. 
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10.1.3: Predicting outcomes of pregnancy in women with autoimmune hepatitis 
We have also reported in this thesis on 81 pregnancies in 53 women with AIH. We have 
confirmed in our series that pregnancy in AIH can be associated with a high incidence of disease 
flares (33%) and serious maternal adverse events (11%). We have demonstrated for the first 
time that disease flares are associated with poor disease control in the year preceding 
pregnancy (p=0.03), the absence of therapy whilst pregnant (p=0.047) and older age at 
conception (p=0.048). Moreover we demonstrated that a flare in autoimmune activity 
associated with pregnancy is a clinically important event as they are associated with a 
significantly increased risk of hepatic decompensation (p=0.01) and an increased need for 
neonatal admission to special care baby units (p=0.047). This work has demonstrated that 
continuing immunosuppression throughout pregnancy in women with AIH is relatively safe with 
no apparent increased risk of adverse effects on either live birth rate or congenital anomalies. In 
this work immunosuppressive therapy was associated with a significantly reduced maternal AIH 
flare rate (p=0.047) when compared to women with AIH not on therapy and foetal prematurity 
was more common in mothers not immunosuppressive on therapy, however this did not reach 
statistical significance (p=0.07). This study therefore adds growing support to the theory that 
the greatest chance of a healthy baby in patients with AIH is attained by continuing therapy with 
the aim of achieving a healthy mother throughout pregnancy via good disease control.  
The incidence of a serious maternal adverse event (death or decompensation) occurred 
in 9 conceptions (11%). This is significantly higher than that of the general population.(219) The 
increased incidence of a serious maternal adverse event in association with pregnancy in 
women with AIH has been reported in other series; Schramm et al. and Terrabuio et al. both 
describe a serious maternal complication rate of 9% and 7.8% respectively. (141, 142) To-date, 
identifying which women with AIH are likely to have a risk free pregnancy and who are at an 
increased risk of developing serious complications has been challenging. Whilst this study failed 
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to identify specific preconception parameters that predicted a serious maternal complication 
rate, we have identified that sub-optimal disease control in the year prior to conception 
(p=0.03), the absence of therapy during pregnancy (p=0.047) and increasing maternal age 
(p=0.047) predispose to a disease flare, which if it occurs confers a significantly increased risk of 
hepatic decompensation (p=0.01).   
Of concern in out cohort of 53 women, was 1 maternal death in association with 
pregnancy, 3 maternal deaths within 12 months of delivery and 2 women undergoing liver 
transplantation within 12 months of delivery. This equates to 11% of women and the only 
preconception parameter that conferred an increased risk of the above events was the 
presence of underlying cirrhosis. Therefore, as discussed previously, it behoves us as clinicians 
to evaluate closely patients in the year following delivery, particularly, those patients with 
underlying cirrhosis, portal hypertension and a history of poor disease control. 
 
10.1.4 Pregnancy following liver transplantation: predicting outcomes 
In this section, we described the outcomes of 117 conceptions in women post LT. We 
demonstrated that a successful and safe pregnancy could be achieved for the majority of 
women.  
The live birth rate was 73% without congenital abnormalities being reported. The rate 
of spontaneous miscarriage was 17% with no identifiable predictors pre-conception, 10% of 
women had elective terminations of pregnancy and there was one still birth. Thirty one percent 
of neonates were premature (gestation ≤37 weeks) which was associated with a reduced birth 
weight, need for admission to a special care baby unit and maternal development of pre-
eclampsia (likely iatrogenic to maintain maternal safety). No pre-conception parameters were 
associated with prematurity. The prevalence of low (19%) and very low birth weight (10%) is 
considerably higher than that of the general population where in England and Wales it is 
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reported to be 7.2% and 1.2% respectively. (227) The cause for the high incidence of 
prematurity and low birth weight in babies born to LT recipients remains unclear and is likely to 
be multi-factorial, contributed to by immunosuppression, the high incidence of pre-eclampsia / 
eclampsia and iatrogenic delivery, ACR and maternal co-morbidities.  
In the post-transplant phase, the education of women in relation to pregnancy and the 
likely outcomes is important. Often, pre-transplantation, women are infertile and amenorrhoeic 
due to the combined impact of cirrhosis on metabolic, nutritional, and hormonal function. 
Following transplantation, fertility can be restored as early as 1 month following LT and 
pregnancy can occur. Our data has highlighted that a termination of pregnancy post LT is 
associated with an adverse event in 25% of cases with complications including severe 
haemorrhage, precipitation of ACR and sepsis necessitating auxiliary graft removal. Therefore a 
TOP should not be considered as a “routine” procedure in this cohort and prevention of an 
unwanted or unsafe pregnancy with appropriate pre-pregnancy counselling and contraception 
should be the norm and the paradigm of best clinical practice. 
The rate of acute cellular rejection in association with pregnancy was 15% (n=18) and 
was associated with conception occurring within a year of LT, but not with any specific 
immunosuppression regimen (p=0.08). An episode of acute cellular rejection did not have any 
effect on foetal outcomes (gestational week, birth weight need for admission to a special care 
baby unit). This finding mirrors other studies. The reason for which this is likely to reflect that in 
the early post LT period, rejection episodes are more frequent, irrespective of pregnancy, due to 
unstable immunosuppression levels and increased infection risk.  
Additional maternal complications encountered during pregnancy included 
hypertension (n=22), pre-eclampsia (n=16), eclampsia (n=3) and gestational diabetes (n=8), 
there were no pre-conception parameters that allowed identification of these complication. The 
incidence of pre-eclampsia was 14% compared to an incidence of between 2-6% reported for 
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the general population. The increased incidence of pre-eclampsia in the LT cohort is yet to be 
fully explained but is likely due the vasoconstrictive effects of calcineurin inhibitors, chronic 
corticosteroid usage and possibly an increased incidence of underlying renal dysfunction.  
Interestingly we found that in women who developed ACR, follow-up over a median 
period of 60-months indicated that they were more likely to require re-transplantation in future 
years (p=0.001) when compared to those women who did not develop ACR in pregnancy. In the 
renal transplantation literature, pregnancy has been shown to have no long term effect on graft 
function when compared to case control groups. (226) It is likely that the pregnancy itself does 
not cause or predispose a patient to rejection or graft loss, but perhaps identifies those women 
who are already at an increased risk of graft loss due to poor graft tolerance and may therefore 
benefit from augmented baseline immunosuppression.  
 
10.1.5 Pregnancy in cholestatic liver conditions and assisted conception 
We have reported in chapters 8 and 9 that women with cholestatic liver disease have 
favourable outcomes regarding pregnancy. The live birth rate was 81% with no late foetal losses 
or congenital abnormalities. Pruritus was the commonest maternal complication occurring in 
65% of women and was associated with higher pre-conception GTT and ALP levels in 
conjunction with a higher increment in GGT and ALP between pre-conception and the levels 
measured in the third trimester. Pruritus was relieved by delivery and at 1 year post-partum, 
there was no significant change in GGT and ALP levels form preconception parameters. 
Urosdeoxycholic acid was tolerated well, and in this small cohort did not have any adverse 
effect on the pregnancy or foetal outcomes. Iatrogenic prematurity due to difficulty 
distinguishing between worsening cholestatic liver disease or ICP is a risk for such patients. 
Neither published data, nor guidelines exist regarding the maternal safety and success 
rates of assisted conception in women with liver disease. Theoretically, pregnancy is likely to 
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carry an unacceptable high risk (hepatic decompensation and death) especially in those patients 
with cirrhosis of a severity to impair ovulation. Furthermore the intense hormonal ovulation 
induction regimens may potentially have an adverse effect in patients with non-cirrhotic 
autoimmune and cholestatic liver disease or in those patients after liver transplantation.  
In this thesis, despite a retrospective look-back over 20-years, only 18 women with 
established liver disease were assessed for assisted conception. The cohort of women are 
heterogeneous with a variety of underlying liver pathologies including post LT patients. This 
makes  it difficult to draw definitive conclusions. What is apparent however, is that obstetricians 
and hepatologists have significant reservations about AC in such women due to the potential 
risks discussed in previous chapters. Moreover, what we can also conclude that the risk of 
assisted conception is certainly higher than women with infertility and the absence of liver 
disease. There is also the potential to precipitate ACR in LT patients and hepatic 













10.2 Limitations of thesis 
Although, this body of work has largely achieved its goal of defining the natural history 
of pregnancy in patients with underlying liver disease in addition to identifying poor prognostic 
factors in women with liver disease wanting to become pregnant or in those who develop 
severe pregnancy associated liver dysfunction, there are however several limitations to the 
work that warrant discussion.  
In evaluating and interpreting the results of these studies and their translation into 
current practice, it is pertinent to note the retrospective nature of the data collected and the 
limitation that the results in this thesis are dependent on the completeness of the databases 
and their interrogation.  Databases dating back to as early as 1979 were interrogated and all 
patients identified were included for data collection. Ninety two percent of patients included in 
this thesis reported pregnancy after 1990, and this in itself is likely to represent an era effect of 
physicians starting to accept that pregnancy could be a safe and viable option for women of 
child bearing age with liver disease. The historic nature of the data is important as there have 
been several key developments in hepatological, obstetric and neonatal care over this time 
period, including corticosteroids for foetal lung maturity, endoscopic techniques for ablation 
and treatment of varices and recognition of immunosuppression safety and importance in 
relation to pregnancy. (90, 211) These developments should result in an overall increased 
survival rate over time for such patients and therefore analysing the data as a whole may 
provide more negative results regarding outcomes than what would be expected in the current 
day. The era-effect in women admitted to intensive care with pregnancy associated liver 
dysfunction was assessed and of great concern is that mortality rates for such women has not 
changed significantly over a 20 year period. 
 Another recognition of the retrospective review of outcomes in women with liver 
disease and pregnancy is that there has been no standard monitoring or treatment of women 
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throughout the study period. Furthermore, choices regarding continuing/discontinuing 
medication and altering doses has not been standardised or randomised and therefore, any 
conclusions drawn could be subject to bias, An example in point is that although we found a lack 
of immunosuppression in AIH and pregnancy to be statistically associated with the development 
of a disease flare, when the reasons for absence of therapy are reviewed the group is widely 
heterogeneous. 
There were 2 de novo presentations of AIH in association with pregnancy, 5 were 
cirrhotic with burnt out disease, 6 were in biochemical and histological remission and had 
subsequently had treatment discontinued and the remaining 7 had their medication stopped 
either due to personal wishes or on medical advice with regard to their wish to become 
pregnant. Moreover, the frequency of blood monitoring during the gestational and post-partum 
period varied widely throughout the cohort. In light of this a generalised statement suggesting 
lack of immunosuppressive therapy is associated with a disease flare, although correct is limited 
due to heterogenous group and varied monitoring schedules.  
 Pregnancy was also self-reported by patients and had to be recorded in the medical 
notes to be captured by our data search. This means that whilst we are likely to have captured 
all pregnancies that resulted in a delivery, it is also likely that many early miscarriages were not 
captured. This is likely due to a combination of factors, the first being that in women with 
advanced liver disease, menstrual patterns can become erratic and consequently, early 
pregnancy loss in patients with more advanced cirrhosis would be missed and hence, under-
reported. Secondly many early losses may not have been reported to us or not documented in 
the medical notes by the reviewing physician. This again means any statements regarding 
association of liver disease and pregnancy loss may be under-recognised due to the likelihood 
that early pregnancy losses are under-represented in this retrospective data set.  
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  King’s College Hospital in itself represents a further source of bias. It represents both a 
tertiary hepatology referral centre and a large volume transplant centre. This is likely to mean 
that an ascertainment bias exist towards women with more severe disease. Certainly, in chapter 
4, the women transferred to the liver intensive care unit had already been pre-selected by 
referring centres as those women who potentially might require either hepatobiliary surgical 
intervention or liver transplantation. This therefore needs to be recognised when interpreting 
the high incidence of bleeding complications, length of ITU stay, mortality and need for liver 
transplantation in this study. The incidences reported are thus not transferrable to all women 
with pregnancy associated liver dysfunction who require intensive care support. 
 Finally, pre-conception parameters associated with adverse pregnancy outcomes were 
identified using univariate analysis due to the relatively small numbers in each cohort of 
patients and it needs to be noted that identified parameters may not be individually associated 
on multivariate analysis. 
 Although the retrospective nature of this thesis means that results should be 
interpreted with this in mind, the frequency of pregnancy in women with liver disease or 
women requiring intensive care for pregnancy associated liver injury is such, that no single 
centre could generate a prospective study with adequate recruitment numbers. Furthermore 
the data collected in this thesis is the largest report of outcomes in women with liver disease 









10.3 Unmet needs and future work 
 The data and results generated from this thesis has added significantly to the published 
literature and our knowledge and understanding of what adverse outcomes women with liver 
disease may encounter and how such adverse outcomes may be identified pre-conception. This 
body of work will hopefully result in better individualised education of women with liver disease 
wanting to consider pregnancy and reduce maternal and foetal adverse outcomes. It has 
however highlighted several unmet needs, areas for potential ongoing research and the need 
for multicentre collaboration. Achieving this will ultimately improve preconception counselling, 
the assessment and management of such women during pregnancy and in the post-partum 
period and define need for liver transplantation in women with severe pregnancy associated 
liver failure. Achieving this will hopefully transfer to a reduction in morbidity and mortality for 
women with liver disease. 
 A large unmet need in women of child bearing age with liver disease or those post LT is 
their ability to access good advice regarding contraception and education about their fertility. 
For example this thesis highlights a termination of pregnancy post LT is associated with an 
adverse event in 25% of cases with complications including severe haemorrhage, precipitation 
of ACR and sepsis necessitating auxiliary graft removal. Moreover in our cohort of 9 patients 
with cirrhosis who underwent medical termination, one patient had a deterioration of hepatic 
function and needed transplantation. Therefore a TOP should not be considered as a “routine” 
procedure in this cohort and preventing an unwanted or unsafe pregnancy with counselling and 
education on appropriate and safe contraception should become normal practice. Education of 
women with liver disease who are of child bearing age regarding contraceptive use, their 
fertility and risks of pregnancy should become routine.  Delivery of this advice is the challenge. 
General practitioners are unlikely to be confident in advising women with liver disease about 
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contraception, pregnancy and its associated risks, especially as the advice will be specific to that 
individual and the severity of their underlying liver disease. Therefor the responsibility lies with 
the individual patient and their hepatologist. Education about contraception, fertility and 
pregnancy should be discussed with all women of a child bearing age and they should be 
informed that should they have the desire to become pregnant a detailed discussion with their 
physician prior to trying to conceive is warranted. This way women can have their medications 
reviewed, be educated regarding the outcomes and associated risks and make a fully informed 
decision if pregnancy is something they wish to pursue. 
 The outcomes of pregnancy documented in this thesis in women with liver disease and 
pregnancy along with the pre-conception markers of adverse outcome have all been derived 
from a single, large volume, tertiary liver centre. Ideally these findings should be validated by 
other centres. The data for this thesis was generated from over 20 years of records and patient 
attendances at the hospital and a potential criticism would still be the relatively small numbers, 
along with now historic data and hence repeating this work at another single centre is likely to 
add very little. Ultimately the next step should be a national review of patients with pregnancy 
and liver disease, their outcomes and a prospective validation of the findings suggested by this 
thesis.  
Additionally, this body of work has postulated that how a liver “reacts” to the stress or 
immunological changes in pregnancy, may provide valuable prognostic information about that 
individuals liver disease. For example, women with an episode of ACR in association with 
pregnancy had higher risk of graft loss over time and those women with hepatic 
decompensation in pregnancy had significantly reduced long term survival from what their 
prognostic scores would suggest. Whilst these associations appear reasonable, it is critical to 
understand mechanistically and immunologically why a liver transplant patient who has an 
episode of rejection in pregnancy might have an increased risk of graft loss from rejection. This 
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may in turn help us to develop an enhanced understanding of immune tolerance and result in 
an altered immunosuppression strategy for such women to try and prevent graft loss.  
In women with cirrhosis that decompensate in the context of pregnancy the data from 
this thesis suggest a 50% 2 year survival. This also raises the question as to whether patients 
that decompensate during pregnancy should be considered for transplantation post-delivery 
even if their synthetic function recovers. Similarly, it suggests that although the prognostic 
scores such as MELD or UKELD are significantly lower than those at which transplantation would 
ordinarily be considered, patients that decompensate during pregnancy represent a group that 
lack functional hepatic reserve and therefore may benefit from earlier transplantation or much 
closer clinical monitoring in the first year following delivery. Due to the small number of 
patients involved, a national or international study group needs to be created to facilitate 
appropriate case acquisition and allow the answering of such important questions. 
Finally, and perhaps of greatest concern from the data generated from this work is the 
suggestion that no apparent increment in survival has occurred in women who present with  
severe pregnancy associated liver disease over the last 2 decades. This is in contrast to 
outcomes for ALF secondary to other aetiologies, although, again, an ascertainment bias may be 
in-part responsible for these results. (234) Moreover, the multi-system nature of organ 
dysfunction in these conditions may also reflect the severity of disease and the extreme 
phenotypic presentation of this type of case. For AFLP and the hypertensive liver disorders, 
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